{"text": "The report summarizes the discussion on basic and clinical research in this field ... .Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations .", "label": "", "metadata": {}, "score": "28.281986"}
{"text": "Without large head - to - head trials , there has been no clear answer to this question .But a study published in this week 's NEJM , sponsored by the makers of tiotropium , compared this anticholinergic to the \u03b2 2 -agonist salmeterol and found that tiotropium may be more effective in preventing exacerbations .", "label": "", "metadata": {}, "score": "29.10857"}
{"text": "PubMed View Article .van Noord JA , Aumann JL , Janssens E , Smeets JJ , Mueller A , Cornelissen P : Combination therapy of tiotropium plus salmeterol superior to single agent therapy in terms of dyspnea improvement in COPD [ abstract].", "label": "", "metadata": {}, "score": "31.240158"}
{"text": "PubMed View Article .Donohue JF , van Noord JA , Bateman ED , Langley SJ , Lee A , Witek TJ Jr , Kesten S , Towse L : A 6-month , placebo - controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol .", "label": "", "metadata": {}, "score": "31.893167"}
{"text": "Balint B , Watz H , Amos C , et al .Onset of action of indacaterol in patients with COPD : Comparison with salbutamol and salmeterol - fluticasone .", "label": "", "metadata": {}, "score": "32.482605"}
{"text": "Claus Vogelmeier Hospital of the Universities of Giessen and Marburg , Marburg , Germany N Engl J Med 364:1093 - 1103 .We investigated whether the anticholinergic drug tiotropium is superior to the \u03b2(2)-agonist salmeterol in preventing exacerbations of COPD ... .", "label": "", "metadata": {}, "score": "33.837303"}
{"text": "View Article PubMed .Briggs DD Jr , Covelli H , Lapidus R , Bhattycharya S , Kesten S , Cassino C : Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD .", "label": "", "metadata": {}, "score": "34.948242"}
{"text": "Vogelmeier C et al .Efficacy and safety of once - daily QVA149 compared with twice - daily salmeterol / fluticasone in patients with COPD ( ILLUMINATE ) : a randomised , double - blind , parallel group study .", "label": "", "metadata": {}, "score": "35.4927"}
{"text": "27 A randomised trial comparing tiotropium with salmeterol in combination with fluticasone reported increased cardiac adverse events with tiotropium .28 An observational study reported increased risk of mortality with tiotropium compared with LABA .", "label": "", "metadata": {}, "score": "35.690033"}
{"text": "[ Accessed 3 September 2013 ] .Vogelmeier C et al .Once - daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes versus placebo , indacaterol , glycopyrronium , tiotropium and salmeterol / fluticasone in patients with COPD .", "label": "", "metadata": {}, "score": "35.76648"}
{"text": "To date , tiotropium has not clearly demonstrated an important effect on QALYs nor generated large cost savings by avoiding COPD related events in comparison to standard treatment ( real world situation ) or in comparison with salmeterol .", "label": "", "metadata": {}, "score": "35.78588"}
{"text": "PubMed View Article .Hanrahan JP , Grogan DR , Baumgartner RA , Wilson A , Cheng H , Zimetbaum PJ , Morganroth J : Arrhythmias in patients with chronic obstructive pulmonary disease ( COPD ) : occurrence frequency and the effect of treatment with the inhaled long - acting beta2-agonists arformoterol and salmeterol .", "label": "", "metadata": {}, "score": "37.196857"}
{"text": "PubMed .Ayers ML , Mejia R , Ward J , Lentine T , Mahler DA : Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD .", "label": "", "metadata": {}, "score": "37.210915"}
{"text": "PubMed View Article .Vogelmeier C , Kardos P , Harari S , Gans SJ , Stenglein S , Thirlwell J : Formoterol mono- and combination therapy with tiotropium in patients with COPD : a 6-month study .", "label": "", "metadata": {}, "score": "37.525826"}
{"text": "One study compared combination therapy ( salmeterol plus fluticasone ) with monotherapy ( tiotropium ) for 2 years in 1323 patients with a mean FEV 1 of 39 % predicted ( 30 ) .", "label": "", "metadata": {}, "score": "37.804153"}
{"text": "A 6-month , placebo - controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol .James F Donohue Division of Pulmonary Medicine , University of North Carolina , Chapel Hill , NC 27599 7020 , USA Chest 122:47 - 55 .", "label": "", "metadata": {}, "score": "37.896843"}
{"text": "Compared to salmeterol , tiotropium delayed time to first exacerbation ( 187 vs 145 days in the first quartile of patients ) and reduced the number of moderate and severe exacerbations that year ( 0.64 vs 0.72 ) .", "label": "", "metadata": {}, "score": "37.9149"}
{"text": "PubMed View Article .Rennard SI , Anderson W , ZuWallack R , Broughton J , Bailey W , Friedman M , Wisniewski M , Rickard K : Use of a long - acting inhaled beta2-adrenergic agonist , salmeterol xinafoate , in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "38.090153"}
{"text": "There is no evidence that the long - term course of the disease is altered by using tiotropium in comparison with its relevant comparators , such as salmeterol .", "label": "", "metadata": {}, "score": "38.1111"}
{"text": "PubMed View Article .Stockley RA , Chopra N , Rice L : Addition of salmeterol to existing treatment in patients with COPD : a 12 month study .", "label": "", "metadata": {}, "score": "38.31897"}
{"text": "These outcomes are rather difficult to interpret by decision makers , e.g. being not comparable with results of studies in other indications .Four studies compared tiotropium with salmeterol [ 11 - 13 , 20 ] .", "label": "", "metadata": {}, "score": "39.00714"}
{"text": "PubMed View Article .Lombardi D , Cuenoud B , Kr\u00e4mer SD : Lipid membrane interactions of indacaterol and salmeterol : do they influence their pharmacology properties ?", "label": "", "metadata": {}, "score": "39.081505"}
{"text": "PubMed View Article .Patakas D , Andreadis D , Mavrofridis E , Argyropoulou P : Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "39.298798"}
{"text": "Cazzola M , Imperatore F , Salzillo A , Di Perna F , Calderaro F , Imperatore A , Matera MG : Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia .", "label": "", "metadata": {}, "score": "39.433285"}
{"text": "Nelson HS , Weiss ST , Bleecker ER , Yancey SW , Dorinsky PM , the SMART Study Group :The Salmeterol Multicenter Asthma Research Trial : a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol .", "label": "", "metadata": {}, "score": "39.53171"}
{"text": "Theophylline may be useful as adjunctive therapy in combination with long - acting beta 2 agonists in carefully selected patients .One trial comparing salmeterol , oral theophylline , and a combination of both in patients with moderate to severe COPD showed that the combination was more effective than either drug alone and that salmeterol was more effective than theophylline alone .", "label": "", "metadata": {}, "score": "40.110954"}
{"text": "Tiotropium in combination with placebo , salmeterol , or fluticasone - salmeterol for treatment of chronic obstructive pulmonary disease : a randomized trial .Ann Intern Med .", "label": "", "metadata": {}, "score": "40.456013"}
{"text": "Tiotropium in combination with placebo , salmeterol , or fluticasone - salmeterol for treatment of chronic obstructive pulmonary disease : a randomized trial .Ann Intern Med .", "label": "", "metadata": {}, "score": "40.456013"}
{"text": "View Article .Vincken W , van Noord JA , Greefhorst APM , Bantje ThA , Kesten S , Korducki L , Cornelissen PJG : Improved health outcomes in patients with COPD during 1 yr 's treatment with tiotropium .", "label": "", "metadata": {}, "score": "40.4842"}
{"text": "PubMed View Article .Matera MG , Cazzola M , Vinciguerra A , Di Perna F , Calderaro F , Caputi M , Rossi F : A comparison of the bronchodilating effects of salmeterol , salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "40.492756"}
{"text": "PubMed View Article .Benhamou D , Cuvelier A , Muir JF , Leclerc V , Le Gros V , Kottakis J , Bourdeix I : Rapid onset of bronchodilation in COPD : a placebo - controlled study comparing formoterol ( Foradil Aerolizer ) with salbutamol ( Ventodisk ) .", "label": "", "metadata": {}, "score": "40.558563"}
{"text": "In a meta - analysis of 14 randomized clinical trials involving more than 6,400 patients , LABAs ( salmeterol or formoterol ) significantly reduced exacerbations requiring study withdrawal or hospitalization compared with placebo , with a relative risk of 0.78 ( 95 % CI , 0.67 - 0.91 ) [ 73 ] .", "label": "", "metadata": {}, "score": "41.183193"}
{"text": "Mark R Dowling Novartis Institutes for BioMedical Research , Wimblehurst Road , Horsham , West Sussex RH12 5AB Br J Pharmacol 148:927 - 37 .Comparative cost - effectiveness of a fluticasone - propionate / salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "41.27162"}
{"text": "PubMed View Article .Stockley RA , Whitehead PJ , Williams MK : Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo / usual therapy : results of a meta - analysis .", "label": "", "metadata": {}, "score": "41.33411"}
{"text": "Kornmann O , Dahl R , Centanni S , et al .Once - daily indacaterol vs twice - daily salmeterol for COPD : a placebo - controlled comparison .", "label": "", "metadata": {}, "score": "41.604225"}
{"text": "ILLUMINATE compared QVA149 110/50 mcg to the twice - daily LABA / ICS salmeterol / fluticasone 50/500 mcg head - to - head over 26 weeks in patients with COPD [ 2 ] .", "label": "", "metadata": {}, "score": "41.683296"}
{"text": "From a medical point of view , tiotropium earns its place in the treatment of COPD .As shown in a systematic review of the literature , tiotropium was found to have statistically significant effects compared to placebo and ipratropium , but not compared to salmeterol [ 2 ] .", "label": "", "metadata": {}, "score": "42.029453"}
{"text": "View Article .Boyd G , Morice AH , Pounsford JC , Siebert M , Peslis N , Crawford C : An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "42.081028"}
{"text": "Nonetheless , the transition probability to go to the more severe disease states was modelled to be higher for salmeterol and ipratropium .As a result , this model implicated an implicit effect on mortality .", "label": "", "metadata": {}, "score": "42.3332"}
{"text": "PubMed .Jenkins CR , Jones PW , Calverley PM , Celli B , Anderson JA , Ferguson GT , et al .Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease : analysis from the randomised , placebo - controlled TORCH study .", "label": "", "metadata": {}, "score": "42.385178"}
{"text": "PubMed .Jenkins CR , Jones PW , Calverley PM , Celli B , Anderson JA , Ferguson GT , et al .Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease : analysis from the randomised , placebo - controlled TORCH study .", "label": "", "metadata": {}, "score": "42.385178"}
{"text": "27 When used as a nebulized treatment , this combination was not associated with the improvements seen in the metered - dose inhaler study .28 The use of the long - acting beta 2 agonist salmeterol in combination with ipratropium compared with salmeterol alone only improved FEV 1 ; there were no significant improvements in patient - oriented outcomes .", "label": "", "metadata": {}, "score": "42.480362"}
{"text": "Vogelmeier C et al .Once - daily QVA149 significantly improves lung function and symptoms compared to twice - daily fluticasone / salmeterol in COPD patients : The ILLUMINATE study .", "label": "", "metadata": {}, "score": "42.54213"}
{"text": "PubMed View Article .Mahler DA , Donohue JF , Barbee RA , Goldman MD , Gross NJ , Wisniewski ME , Yancey SW , Zakes BA , Rickard KA , Anderson WH : Efficacy of salmeterol xinafoate in the treatment of COPD .", "label": "", "metadata": {}, "score": "42.713684"}
{"text": "The authors note that no differences between treatments ( tiotropium , salmeterol or ipratropium ) in terms of mortality risk were assumed .Also the costs per disease severity state and per severe or non - severe exacerbation were mentioned to be equal across treatment groups .", "label": "", "metadata": {}, "score": "42.75296"}
{"text": "PubMed View Article PubMed Central .Drugs 2008 , 68 : 1975 - 2000 .PubMed View Article .van Noord JA , de Munck DR , Bantje TA , Hop WC , Akveld ML , Bommer AM : Long - term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium .", "label": "", "metadata": {}, "score": "42.91877"}
{"text": "Studies comparing tiotropium with salmeterol relied on the trial results published by Brusasco et al [ 23 ] .At that time , results of the UPLIFT trial were not published yet .", "label": "", "metadata": {}, "score": "43.10711"}
{"text": "N Engl J Med .PubMed .Brusasco V , Hodder R , Miravitlles M , Korducki L , Towse L , Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD .", "label": "", "metadata": {}, "score": "43.517384"}
{"text": "N Engl J Med .PubMed .Brusasco V , Hodder R , Miravitlles M , Korducki L , Towse L , Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD .", "label": "", "metadata": {}, "score": "43.517384"}
{"text": "Delivered By The Respimat Inhaler In Patients With Chronic Obstructive Pulmonary Disease Boehringer Ingelheim Trial Results .QVA149 demonstrated superior bronchodilation compared to indacaterol 150 mcg , glycopyrronium 50 mcg , salmeterol / fluticasone 50/500 mcg BID , OL tiotropium 18 mcg and placebo [ 1,2 ] .", "label": "", "metadata": {}, "score": "43.70616"}
{"text": "ClinicalTrials.gov , n.d .A 26-week Treatment Randomized , Double - blind , Double Dummy , Parallel - group Study to Assess the Efficacy , Safety and Tolerability of QVA149 ( Indacaterol / Glycopyrronium Bromide )", "label": "", "metadata": {}, "score": "43.754704"}
{"text": "PubMed View Article .Welte T , Miravitlles M , Hernandez P , Erikkson G , Peterson S , Polanowski T , Kessler R : Efficacy and tolerability of budesonide / formoterol added to tiotropium in COPD patients .", "label": "", "metadata": {}, "score": "43.77548"}
{"text": "However , there are few data for treatment in the early stages of the disease .We examined the effect of tiotropium on outcomes in a large subgroup of patients with moderate COPD ... .", "label": "", "metadata": {}, "score": "43.937515"}
{"text": "A combination of both drugs q.d .was most effective and provided an additive effect throughout the 24-h dosing interval ... .Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD .", "label": "", "metadata": {}, "score": "44.136223"}
{"text": "PubMed View Article .Breekveldt - Postmaa NS , Koerselman J , Erkens JA , Lammers J - WJ , Herings RMC : Enhanced persistence with tiotropium compared with other respiratory drugs in COPD .", "label": "", "metadata": {}, "score": "44.151886"}
{"text": "Tsagaraki V , Amfilochiou A , Markantonis SL : Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients .Int J Clin Pract 2006 , 60 : 415 - 21 .", "label": "", "metadata": {}, "score": "44.175842"}
{"text": "Detailed Description .This was a multicentre , randomised , double blind , parallel group , placebo - controlled , one year study .It was designed to determine the effect of inhaled tiotropium treatment on airflow obstruction ( PEFR ) , incidence and severity of exacerbations in patients with COPD .", "label": "", "metadata": {}, "score": "44.29003"}
{"text": "The decreased risk of mortality observed in this study with tiotropium is in agreement with the results reported in the Uplift 23 and POET 33 studies , but not in the ipratropium Lung Health Study 18 or several large tiotropium trials using the Respimat device .", "label": "", "metadata": {}, "score": "44.296722"}
{"text": "TRial of Inhaled STeroids ANd long - acting beta2 agonists study group .Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial .", "label": "", "metadata": {}, "score": "44.400696"}
{"text": "TRial of Inhaled STeroids ANd long - acting beta2 agonists study group .Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease : a randomised controlled trial .", "label": "", "metadata": {}, "score": "44.400696"}
{"text": "Dahl R , Chung KF , Buhl R , et al .Efficacy of a new once - daily long - acting inhaled beta 2 -agonist indacaterol versus twice - daily formoterol in COPD .", "label": "", "metadata": {}, "score": "44.64235"}
{"text": "Respir Med 2008 , 102 : 479 - 87 .PubMed View Article .Tashkin D , Pearle J , Iezzoni D , Verghese ST : Treatment with formoterol plus tiotropium is more effective than treatment with tiotropium alone in patients with stable chronic obstructive pulmonary disease : findings from a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "44.72003"}
{"text": "Drug Saf 2007 , 30 : 1151 - 60 .PubMed View Article .Donohue JF , Hanania NA , Sciarappa KA , Goodwin E , Grogan DR , Baumgartner RA , Hanrahan JP : Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease : a one year evaluation of safety and tolerance .", "label": "", "metadata": {}, "score": "44.869293"}
{"text": "PubMed View Article .Broseghini C , Testi R , Polese G , Tosatto R , Rossi A : A comparison between inhaled salmeterol and theophylline in the short - term treatment of stable chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "44.935863"}
{"text": "PubMed View Article .Ferguson GT , Funck - Brentano C , Fischer T , Darken P , Reisner C : Cardiovascular safety of salmeterol in COPD .", "label": "", "metadata": {}, "score": "44.99765"}
{"text": "[ 3 ] .The second pooled analysis assessed the efficacy of once - daily glycopyrronium 50 mcg versus placebo and once - daily OL tiotropium 18 mcg at reducing COPD exacerbations , symptoms and improving health status over 26 to 52 weeks in 1,854 patients from clinical trials ( GLOW1 and GLOW2 )", "label": "", "metadata": {}, "score": "45.034405"}
{"text": "Ann Intern Med 2007 , 146 : 545 - 55 .PubMed .Singh D , Brooks J , Hagan G , Cahn A , O'Connor BJ : Superiority of \" triple \" therapy with salmeterol / fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD .", "label": "", "metadata": {}, "score": "45.120987"}
{"text": "PubMed View Article .Kaushik ML , Kashyap S , Bansal SK , Sharma A : Effectiveness of salmeterol in stable COPD .Indian J Chest Dis Allied Sci 1999 , 41 : 207 - 12 .", "label": "", "metadata": {}, "score": "45.141052"}
{"text": "View Article PubMed .Brusasco V , Hodder R , Miravitlles M , Korducki L , Towse L , Kesten S : Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD .", "label": "", "metadata": {}, "score": "45.28378"}
{"text": "However , studies specifically investigating safety have demonstrated that formoterol and salmeterol have good cardiovascular safety profiles [ 101 , 102 ] .Further , studies with formoterol found a similar profile irrespective of device or formulation [ 103 , 104 ] .", "label": "", "metadata": {}, "score": "45.288322"}
{"text": "PubMed View Article .Kanniess F , Make BJ , Petruzzelli S : Acute effect of carmoterol , a long - acting beta2-agonist , in patients with COPD [ abstract].", "label": "", "metadata": {}, "score": "45.650383"}
{"text": "Meta - analysis : anticholinergics , but not beta - agonists , reduce severe exacerbations and respiratory mortality in COPD [ Published correction appears in J Gen Intern Med 2006;21:1131].", "label": "", "metadata": {}, "score": "45.72459"}
{"text": "This study demonstrated that concurrent treatment with FORM + TIO results in greater therapeutic benefits than TIO alone ... .Combination of formoterol and tiotropium in the treatment of COPD : effects on lung function .", "label": "", "metadata": {}, "score": "45.745262"}
{"text": "[Online].[ Accessed 3 September 2013 ] .ClinicalTrial.gov , n.d .A 52-week Treatment , Multi - center , Randomized , Double - blind , Double Dummy , Parallel - group , Active Controlled Study to Compare the Effect of QVA149 ( Indacaterol Maleate / Glycopyrronium Bromide )", "label": "", "metadata": {}, "score": "45.919296"}
{"text": "PubMed View Article .Hanrahan JP , Hanania NA , Calhoun WJ , Sahn SA , Sciarappa K , Baumgartner RA : Effect of nebulized arformoterol on airway function in COPD : results from two randomized trials .", "label": "", "metadata": {}, "score": "45.980797"}
{"text": "Tashkin DP , Littner M , Andrews CP , Tomlinson L , Rinehart M , Denis - Mize K : Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD :", "label": "", "metadata": {}, "score": "46.2115"}
{"text": "Benefits of adding fluticasone propionate / salmeterol to tiotropium in moderate to severe COPD .Nicola A Hanania Section of Pulmonary and Critical Care Medicine , Baylor College of Medicine , Houston , TX , USA Respir Med 106:91 - 101 .", "label": "", "metadata": {}, "score": "46.29709"}
{"text": "Patients with chronic obstructive pulmonary disease ( COPD ) frequently develop exacerbations , leading to major clinical and health resource use ramifications ... .Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide ; a randomized , double - blind , placebo - controlled , cross - over study in healthy subjects .", "label": "", "metadata": {}, "score": "46.457466"}
{"text": "PubMed View Article .Jones PW , Bosh TK : Quality of life changes in COPD patients treated with salmeterol .Am J Respir Crit Care Med 1997 , 155 : 1283 - 89 .", "label": "", "metadata": {}, "score": "46.528915"}
{"text": "PubMed .Shrewsbury S , Pyke S , Britton M : Meta - analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma ( MIASMA ) .", "label": "", "metadata": {}, "score": "46.795296"}
{"text": "Am J Respir Crit Care Med 2001 ; 163 : 1256 - 76 . . .Inspire Investigators .The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide .", "label": "", "metadata": {}, "score": "46.8491"}
{"text": "PubMed View Article .Troosters T , Celli B , Lystig T , Kesten S , Mehra S , Tashkin DP , Decramer M , on behalf of the UPLIFT investigators : Tiotropium as a first maintenance drug in COPD : secondary analysis of the UPLIFT trial .", "label": "", "metadata": {}, "score": "47.121796"}
{"text": "Eur Respir J. 2002 ; 19:209 - 16 .PubMed .Calverley P , Celli B , Anderson J , et al .The TORCH ( Towards a Revolution in COPD Health ) study : salmeterol / fluticasone propionate ( SFC ) improves survival in COPD over three years .", "label": "", "metadata": {}, "score": "47.169006"}
{"text": "Eur Respir J. 2002 ; 19:209 - 16 .PubMed .Calverley P , Celli B , Anderson J , et al .The TORCH ( Towards a Revolution in COPD Health ) study : salmeterol / fluticasone propionate ( SFC ) improves survival in COPD over three years .", "label": "", "metadata": {}, "score": "47.169006"}
{"text": "Current position in management guidelines .SABAs such as salbutamol ( albuterol ) , terbutaline , pirbuterol or fenoterol and/or short - acting muscarinic antagonists ( SAMAs ) such as ipratropium bromide or oxitropium bromide are recommended as rescue medication for all severities of COPD to relieve acute symptoms of bronchospasm .", "label": "", "metadata": {}, "score": "47.188885"}
{"text": "Fabbri LM , van de Maele B , Lemmens B , Martin C , Horton R , Dolker M , Overend T : Cardiovascular safety of QVA149 , a novel combination of indacaterol and glycopyrronium compared with indacaterol and placebo in patients with COPD [ abstract].", "label": "", "metadata": {}, "score": "47.368774"}
{"text": "Blinded 12-week comparison of once - daily indacaterol and tiotropium in COPD .R Buhl Pulmonary Department , Mainz University Hospital , Langenbeckstrasse 1 , Mainz , D 55131 , Germany Eur Respir J 38:797 - 803 .", "label": "", "metadata": {}, "score": "47.69728"}
{"text": "PubMed View Article PubMed Central .Hanania NA , Darken P , Horstman D , Reisner C , Lee B , Davis S , Shah T : The efficacy and safety of fluticasone propionate ( 250 microg)/salmeterol ( 50 microg ) combined in the Diskus inhaler for the treatment of COPD .", "label": "", "metadata": {}, "score": "47.761765"}
{"text": "Perhaps the most relevant study is the recent ' POET ' study , the largest tiotropium randomised trial conducted to date , with 7376 COPD patients .", "label": "", "metadata": {}, "score": "47.806004"}
{"text": "Nevertheless , it is possible that tiotropium patients had more severe COPD than LABA patients despite our efforts to control for baseline risk factors .More severe COPD might account for higher rates of cardiovascular events , although the decreased mortality in the tiotropium group is inconsistent with this hypothesis .", "label": "", "metadata": {}, "score": "47.84665"}
{"text": "Tiotropium versus salmeterol for the prevention of exacerbations of COPD .Claus Vogelmeier Hospital of the Universities of Giessen and Marburg , Marburg , Germany N Engl J Med 364:1093 - 1103 .", "label": "", "metadata": {}, "score": "47.84838"}
{"text": "Symptom control .Improvements in symptoms were generally similar [ 26 , 27 , 46 ] or greater [ 29 , 59 ] with formoterol and salmeterol than with ipratropium bromide and theophylline .", "label": "", "metadata": {}, "score": "47.888695"}
{"text": "In summary , evidence to date suggests that both formoterol and salmeterol provide significant improvements in lung function , symptoms including dyspnea , and health - related quality of life .", "label": "", "metadata": {}, "score": "47.957672"}
{"text": "View Article PubMed .Maniadakis N , Tzanakis N , Fragoulakis V , Hatzikou M , Siafakas N : Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease ( COPD ) in Greece .", "label": "", "metadata": {}, "score": "48.049164"}
{"text": "Only 2.2 % had two or more COPD - related hospitalisations prior to tiotropium treatment .Table 2 .IC , IE and ICERs depending on the initial number of hospitalisations and exacerbations .", "label": "", "metadata": {}, "score": "48.078087"}
{"text": "PubMed View Article .Naline E , Trifilieff A , Fairhurst RA , Advenier C , Molimard M : Effect of indacaterol , a novel long - acting \u00e2 2 -agonist , on isolated human bronchi .", "label": "", "metadata": {}, "score": "48.09195"}
{"text": "6 , 7 Similar studies of tiotropium have shown that it improves symptom control and reduces exacerbations , rescue inhaler use , and hospitalizations .Several trials compared tiotropium with ipratropium and demonstrated that fewer exacerbations occurred in those receiving tiotropium .", "label": "", "metadata": {}, "score": "48.269478"}
{"text": "Based on our large observational database , 89 % of the patients ( i.e. 50 156 patients ) was not hospitalised for COPD in the year before the first tiotropium delivery .", "label": "", "metadata": {}, "score": "48.466595"}
{"text": "Characteristics of medical history prior to study entry are shown in table 2 .A high proportion of patients in both groups had spirometry testing ( 89 % of tiotropium patients and 84 % of LABA patients ) and a diagnosis of COPD ( 89 % of tiotropium patients and 88 % of LABA patients ) .", "label": "", "metadata": {}, "score": "48.527767"}
{"text": "Formoterol and tiotropium compared with tiotropium alone for treatment of COPD .Donald P Tashkin David Geffen School of Medicine at UCLA , University of California Los Angeles , 10833 Le Conte Avenue , Los Angeles , CA 90095 , USA COPD 6:17 - 25 . .04 ) were seen at endpoint with combination FORM + TIO versus TIO monotherapy .", "label": "", "metadata": {}, "score": "48.552055"}
{"text": "Bateman E et al .Benefits of dual bronchodilation with QVA149 once daily versus placebo , indacaterol , NVA237 and tiotropium in patients with COPD : the SHINE study .", "label": "", "metadata": {}, "score": "48.616375"}
{"text": "PubMed .Wedzicha JA , Calverley PM , Seemungal TA , Hagan G , Ansari Z , Stockley RA , INSPIRE Investigators .The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide .", "label": "", "metadata": {}, "score": "48.754677"}
{"text": "PubMed .Wedzicha JA , Calverley PM , Seemungal TA , Hagan G , Ansari Z , Stockley RA , INSPIRE Investigators .The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide .", "label": "", "metadata": {}, "score": "48.754677"}
{"text": "PubMed View Article .Am J Respir Crit Care Med 2010 , 182 : 155 - 162 .PubMed View Article .Kornmann O , Dahl R , Centanni S , Dogra A , Owen R , Lassen C , Kramer B : Once - daily indacaterol vs twice - daily salmeterol for COPD : a placebo - controlled comparison .", "label": "", "metadata": {}, "score": "48.756996"}
{"text": "PubMed View Article .Wadbo M , L\u00f6fdahl CG , Larsson K , Skoogh BE , Tornling G , Arwestr\u00f6m E , Bengtsson T , Str\u00f6m K , Swedish Society of Respiratory Medicine : Effects of formoterol and ipratropium bromide in COPD : a 3-month placebo - controlled study .", "label": "", "metadata": {}, "score": "48.81756"}
{"text": "PubMed View Article .Donohue JF , Menjoge S , Kesten S : Tolerance to bronchodilating effects of salmeterol in COPD .Respir Med 2003 , 97 : 1014 - 20 .", "label": "", "metadata": {}, "score": "48.846046"}
{"text": "Indacaterol provides 24-hour bronchodilation in COPD : a placebo - controlled blinded comparison with tiotropium .Claus Vogelmeier Novartis Pharmaceuticals Inc , One Health Plaza , East Hanover , NJ 07936 1080 , USA Respir Res 11:135 .", "label": "", "metadata": {}, "score": "48.90175"}
{"text": "Salpeter SR , Buckley NS , Salpeter EE .Meta - analysis : anticholinergics , but not beta - agonists , reduce severe exacerbations and respiratory mortality in COPD .", "label": "", "metadata": {}, "score": "48.923553"}
{"text": "Salpeter SR , Buckley NS , Salpeter EE .Meta - analysis : anticholinergics , but not beta - agonists , reduce severe exacerbations and respiratory mortality in COPD .", "label": "", "metadata": {}, "score": "48.923553"}
{"text": "The two treatments were well tolerated with similar adverse event profiles .Compared with tiotropium , indacaterol provided significantly greater improvements in clinical outcomes ... .", "label": "", "metadata": {}, "score": "48.970688"}
{"text": "Improvement in self - reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients .Steven Kesten Boehringer Ingelheim GmbH , Ingelheim , Germany 2Harbor UCLA Medical Center , Torrance , CA , USA Int J Chron Obstruct Pulmon Dis 3:127 - 36 .", "label": "", "metadata": {}, "score": "49.069916"}
{"text": "PubMed View Article .Baumgartner RA , Hanania NA , Calhoun WJ , Sahn SA , Sciarappa K , Hanrahan JP : Nebulized arformoterol in patients with COPD : a 12-week , multicenter , randomized , double - blind , double - dummy , placebo- and active - controlled trial .", "label": "", "metadata": {}, "score": "49.105568"}
{"text": "Rennard SI , Serby CW , Ghafaouri M , Johnson PA , Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD .", "label": "", "metadata": {}, "score": "49.141304"}
{"text": "2000;161(4 pt 1):1136 - 42 .Casaburi R , Briggs DD Jr , Donohue JF , Serby CW , Menjoge SS , Witek TJ Jr.The spirometric efficacy of once - daily dosing with tiotropium in stable COPD : a 13-week multicenter trial .", "label": "", "metadata": {}, "score": "49.158485"}
{"text": "View Article PubMed .Najafzadeh M , Marra CA , Sadatsafavi M , Aaron SD , Sullivan SD , Vandemheen KL , Jones PW , Fitzgerald JM : Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD .", "label": "", "metadata": {}, "score": "49.168495"}
{"text": "Results were most sensitive to the treatment effect on hospitalisations .Based on our large observational database , up to 89 % of the patients were not hospitalised for COPD in the year before the first tiotropium delivery .", "label": "", "metadata": {}, "score": "49.174805"}
{"text": "For the selected patients , all MCD - HBD hospital stay data from 2002 to 2005 were obtained .As such , observational data one year before and after the first delivery of tiotropium was gathered .", "label": "", "metadata": {}, "score": "49.38967"}
{"text": "Niewoehner DE , Rice K , Cote C , Paulson D , Cooper JA Jr , Korducki L , et al .Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium , a once - daily inhaled anticholinergic bronchodilator : a randomized trial .", "label": "", "metadata": {}, "score": "49.41809"}
{"text": "PubMed View Article .Tashkin DP , Donohue JF , Mahler DA , Huang H , Goodwin E , Schaefer K , Hanrahan JP , Andrews WT : Effects of arformoterol twice daily , tiotropium once daily , and their combination in patients with COPD .", "label": "", "metadata": {}, "score": "49.447742"}
{"text": "PubMed View Article .Rennard SI , Tashkin DP , McElhattan J , Goldman M , Ramachandran S , Martin UF , Silkoff PE : One - year evaluation of the efficacy and tolerability of budesonide / formoterol in one hydrofluoroalkane pressurized metered - dose inhaler in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "49.45258"}
{"text": "2002;(4):CD001495 .Calverley P , Pauwels R , Vestbo J , Jones P , Pride N , Gulsvik A , et al . , for the TRial of Inhaled STeroids ANd Long - acting Beta 2 Agonists Study Group .", "label": "", "metadata": {}, "score": "49.499588"}
{"text": "Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD .Thomas Meyer Inamed GmbH , Robert Koch Allee 29 , 82131 Gauting , Germany Respir Med 105:900 - 6 .", "label": "", "metadata": {}, "score": "49.515938"}
{"text": "Annual rates of exacerbations with salmeterol and fluticasone were statistically significantly lower than with placebo ( 31 ) .However , ipratropium , a short acting anticholinergic , was not superior to placebo ( RR , 0.95 [ CI , 0.78 to 1.15 ] ) ( 6 ) .", "label": "", "metadata": {}, "score": "49.63407"}
{"text": "Chest 2008 , 134 : 255 - 62 .PubMed View Article .van Noord JA , Buhl R , LaForce C , Martin C , Jones F , Dolker M , Overend T : QVA149 , a novel combination of indacaterol and glycoprronium , demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD [ abstract].", "label": "", "metadata": {}, "score": "49.636433"}
{"text": "PubMed View Article .van Noord JA , Aumann JL , Janssens E , Smeets JJ , Verhaert J , Disse B , Mueller A , Cornelissen PJ : Comparison of tiotropium once daily , formoterol twice daily and both combined once daily in patients with COPD .", "label": "", "metadata": {}, "score": "49.65962"}
{"text": "In this very large trial , 2987 and 3006 patients were randomly assigned to the tiotropium and placebo group , respectively [ 8 ] .In the tiotropium study database , it was observed that there was no reduction in the use of other medication after the first delivery of tiotropium .", "label": "", "metadata": {}, "score": "49.666718"}
{"text": "J Biol Chem 2008 , 283 : 24659 - 72 .PubMed View Article PubMed Central .Feldman G , Siler T , Pasad N , Jack D , Piggott S , Owen R , Higgins M , Kramer B , for the INLIGHT 1 Study Group : Efficacy and safety of indacaterol 150 mcg once - daily in COPD : a double - blind , randomised , 12-week study .", "label": "", "metadata": {}, "score": "49.739243"}
{"text": "View Article .Oostenbrink JB , Rutten - van Molken M , Al MJ , Van Noord JA , Vincken W : One - year cost - effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "49.821518"}
{"text": "Eur Respir J 2008 , 31 : 742 - 50 .PubMed View Article .Salpeter SR , Buckley NS , Salpeter EE : Meta - analysis : anticholinergics , but not beta - agonists , reduce severe exacerbations and respiratory mortality in COPD .", "label": "", "metadata": {}, "score": "49.862823"}
{"text": "Treatment effect .In October 2008 , results of the UPLIFT trial have been published .In this randomized , double - blind trial , 4 years of tiotropium treatment was compared with placebo in patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic drugs .", "label": "", "metadata": {}, "score": "50.079746"}
{"text": "PubMed View Article .Sturton RG , Trifilieff A , Nicholson AG , Barnes PJ : Pharmacological characterisation of indacaterol a novel once daily inhaled \u03b2 2 adrenoceptor agonist , on small airways in human and rat precision cut lung slices .", "label": "", "metadata": {}, "score": "50.265358"}
{"text": "PubMed View Article .Grove A , Lipworth BJ , Reid P , Smith RP , Ramage L , Ingram CG , Jenkins RJ , Winter JH , Dhillon DP : Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease .", "label": "", "metadata": {}, "score": "50.289635"}
{"text": "PubMed View Article .Tashkin DP , Celli B , Senn S , Burkhart D , Kesten S , Menjoge S , Decramer M , for the UPLIFT study investigators : A 4-year trial of tiotropium in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "50.32794"}
{"text": "A review on the efficacy / effectiveness of tiotropium showed no impact of tiotropium on survival [ 2 ] .However , avoiding exacerbations and exacerbation - related hospitalisation may influence quality of life ( QoL ) .", "label": "", "metadata": {}, "score": "50.389797"}
{"text": "Methods .Strengths of both observational and RCT data were combined in a model .A large longitudinal ( 2002 - 2006 ) observational dataset of regular tiotropium users ( 56 321 patients ) was analysed to retrieve the baseline risk for exacerbations and exacerbation - related hospitalisations the year before the first delivery of tiotropium .", "label": "", "metadata": {}, "score": "50.412437"}
{"text": "In studies of up to one year , indacaterol was well tolerated with an acceptable safety profile , including cardiovascular safety , similar to placebo , and comparable to tiotropium and formoterol [ 55 , 127 , 128 ] .", "label": "", "metadata": {}, "score": "50.443153"}
{"text": "However , a recently published RCT ( outside our inclusion criteria ) that included 252 patients with moderate to severe COPD who were monitored over 8 weeks compared outpatient hospital - based pulmonary rehabilitation with home - based pulmonary rehabilitation ( 51 ) .", "label": "", "metadata": {}, "score": "50.53254"}
{"text": "Efficacy and safety of nebulized formoterol as add - on therapy in COPD patients receiving maintenance tiotropium bromide : Results from a 6-week , randomized , placebo - controlled , clinical trial .", "label": "", "metadata": {}, "score": "50.545242"}
{"text": "PubMed .Niewoehner DE , Rice K , Cote C , Paulson D , Cooper JA Jr , Korducki L. et al .Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium , a once - daily inhaled anticholinergic bronchodilator : a randomized trial .", "label": "", "metadata": {}, "score": "50.65744"}
{"text": "PubMed .Niewoehner DE , Rice K , Cote C , Paulson D , Cooper JA Jr , Korducki L. et al .Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium , a once - daily inhaled anticholinergic bronchodilator : a randomized trial .", "label": "", "metadata": {}, "score": "50.65744"}
{"text": "Details on hospitalizations due to COPD exacerbations were recorded in a special hospitalization booklet .Study Hypothesis : .The objectives of this study were to evaluate the effect of a one - year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function , incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "50.715828"}
{"text": "Furthermore , even if the relative treatment effect would be higher in a specific subgroup , than still the absolute gain ( which determines the cost - effectiveness ) would be limited due to the low baseline risk for events without tiotropium treatment occurring in our real - world population .", "label": "", "metadata": {}, "score": "50.728683"}
{"text": "A summary is provided in Table 2 [ 1 , 25 - 31 ] .Table 2 .Summary of clinical efficacy for currently available \u03b2 2 -agonists in COPD .", "label": "", "metadata": {}, "score": "50.86786"}
{"text": "Man WD , Mustfa N , Nikoletou D , Kaul S , Hart N , Rafferty GF , Donaldson N , Polkey MI , Moxham J : Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD .", "label": "", "metadata": {}, "score": "50.936367"}
{"text": "We wondered whether tiotropium also increased physical activities outside of pulmonary rehabilitation ... .The spirometric efficacy of once - daily dosing with tiotropium in stable COPD : a 13-week multicenter trial .", "label": "", "metadata": {}, "score": "50.949566"}
{"text": "The objectives of this study were to evaluate the effect of a one - year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function , incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "51.074043"}
{"text": "Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease : a randomized trial .Ann Intern Med .PubMed .", "label": "", "metadata": {}, "score": "51.300667"}
{"text": "Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease : a randomized trial .Ann Intern Med .PubMed .", "label": "", "metadata": {}, "score": "51.300667"}
{"text": "PubMed View Article .Aalbers R , Ayres J , Backer V , Decramer M , Lier PA , Magyar P , Malolepszy J , Ruffin R , Sybrecht GW : Formoterol in patients with chronic obstructive pulmonary disease : a randomized , controlled , 3-month trial .", "label": "", "metadata": {}, "score": "51.30829"}
{"text": "PubMed View Article .Bouyssou T , Hoenke C , Rudolf K , Lustenberger P , Pestel S , Sieger P , Lotz R , Heine C , B\u00fcttner FH , Schnapp A , Konetzki I : Discovery of olodaterol , a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy .", "label": "", "metadata": {}, "score": "51.317528"}
{"text": "( Additional file ) .QALY : quality - adjusted life year .Scenario analyses .In the scenario with 100 % compliant tiotropium users which stopped taking salmeterol , the incremental cost decreases to \u20ac 341 ( 95 % CI 246 - 445 ) .", "label": "", "metadata": {}, "score": "51.414986"}
{"text": "PubMed View Article .O'Donnell DE , Voduc N , Fitzpatrick M , Webb KA : Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "51.524887"}
{"text": "The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD : a pilot study .Mario Cazzola Department of Respiratory Medicine , Unit of Pneumology and Allergology , A Cardarelli Hospital , Naples , Italy Respir Med 101:957 - 62 .", "label": "", "metadata": {}, "score": "51.548042"}
{"text": "2006;(3):CD001104 .Szafranski W , Cukier A , Ramirez A , Menga G , Sansores R , Nahabedian S , et al .Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease [ Published correction appears in Eur Respir J 2003;21:912].", "label": "", "metadata": {}, "score": "51.71675"}
{"text": "The combination of short - acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented , but data on combination of long - acting agents are lacking ... .", "label": "", "metadata": {}, "score": "51.912773"}
{"text": "Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD .D D Briggs University of Alabama at Birmingham , 459 Boshell Diabetes Building , 1808 7th Avenue South , Birmingham , AL , USA Pulm Pharmacol Ther 18:397 - 404 .", "label": "", "metadata": {}, "score": "51.98895"}
{"text": "Thus , the results of clinical studies must be interpreted with caution .To date , clinical studies have not been specifically designed to investigate the effect of formoterol on exacerbations , and no significant benefit on moderate to severe exacerbations has been demonstrated [ 23 , 30 , 31 , 78 ] .", "label": "", "metadata": {}, "score": "52.0313"}
{"text": "Rossing TH , Make BJ , Heyman ER : Carmoterol does not induce tolerance in COPD [ abstract].Am J Respir Crit Care Med 2008 , 177 ( Abstracts ) : A962 .", "label": "", "metadata": {}, "score": "52.081383"}
{"text": "PubMed View Article .Chest 2002 , 121 : 1058 - 69 .PubMed View Article .Schultze - Werninghaus G : Multicenter 1-year trial on formoterol , a new long - acting beta 2-agonist , in chronic obstructive airway disease .", "label": "", "metadata": {}, "score": "52.12938"}
{"text": "PubMed View Article .Szafranski W , Cukier A , Ramirez A , Menga G , Sansores R , Nahabedian S , Peterson S , Olsson H : Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "52.3245"}
{"text": "PubMed View Article .J Pharmacol Exp Ther 2006 , 317 : 762 - 70 .PubMed View Article .Bauwens O , Ninane V , Van de Maele B , Firth R , Dong F , Owen R , Higgins M : 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD : comparison with placebo and formoterol .", "label": "", "metadata": {}, "score": "52.484695"}
{"text": "This study received ethical approval from the UK Department of Health Multicentre Research Ethics Committee .Results .The study population included 4767 tiotropium patients and 6073 LABA patients who contributed 2775 person - years of exposure to tiotropium and 2303 person - years of exposure to a single - ingredient LABA ( table 1 ) .", "label": "", "metadata": {}, "score": "52.495686"}
{"text": "Eur Respir J 2009 , 34 ( Suppl 53 ) : E4346 .Linberg SE , Heyman ER , Nandeuil MA , Kottakis I , Maison - Blance P : Cardiac safety of the novel very long - acting beta2-agonist carmoterol following single rising doses in healthy volunteers [ abstract].", "label": "", "metadata": {}, "score": "52.49617"}
{"text": "Footnotes .To cite : Jara M , Wentworth C , Lanes S. A new user cohort study comparing the safety of long - acting inhaled bronchodilators in COPD .", "label": "", "metadata": {}, "score": "52.57032"}
{"text": "N Engl J Med .PubMed .Burge PS , Calverley PM , Jones PW , Spencer S , Anderson JA , Maslen TK .Randomised , double blind , placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease : the ISOLDE trial .", "label": "", "metadata": {}, "score": "52.586845"}
{"text": "N Engl J Med .PubMed .Burge PS , Calverley PM , Jones PW , Spencer S , Anderson JA , Maslen TK .Randomised , double blind , placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease : the ISOLDE trial .", "label": "", "metadata": {}, "score": "52.586845"}
{"text": "Value Health 2005 , 8 : 32 - 46 .View Article PubMed .Rutten - van Molken M , Oostenbrink JB , Miravitlles M , Monz BU : Modelling the 5-year cost effectiveness of tiotropium , salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain .", "label": "", "metadata": {}, "score": "52.63666"}
{"text": "The addition of nebulized formoterol to tiotropium in maintenance treatment of COPD provided clinically meaningful , statistically significant and sustained improvements in pulmonary function without additional adverse effects ... .", "label": "", "metadata": {}, "score": "52.712402"}
{"text": "There are multiple individual and combined treatment regimens , with options including anticholinergics , beta 2 agonists , smoking cessation , and steroids .This article reviews the recommendations and evidence for the pharmacologic management of stable COPD , highlighting the effect of medications on patient - oriented outcomes , such as mortality , symptoms , and hospitalization , where data exist .", "label": "", "metadata": {}, "score": "52.77996"}
{"text": "Formoterol and salmeterol have acceptable benefit : risk profiles in the treatment of COPD ; however , both have their limitations .For example , both formoterol and salmeterol have 12-hour durations of action and are approved for twice - daily dosing .", "label": "", "metadata": {}, "score": "52.79965"}
{"text": "Nevertheless , reimbursement modalities remained unchanged after this revision .Since then , results of the large UPLIFT ( Understanding Potential Long - term Impacts on Function with Tiotropium ) trial have been published , which are taken into account in this economic evaluation .", "label": "", "metadata": {}, "score": "52.800407"}
{"text": "A number of placebo- and active - controlled Phase III studies in COPD have been completed or are ongoing [ 55 , 124 - 129 ] .", "label": "", "metadata": {}, "score": "52.801178"}
{"text": "Objective To investigate a possible increased risk observed in tiotropium clinical trials of stroke and other adverse events .Design New users of long - acting anticholinergic therapy ( tiotropium HandiHaler \u00ae ) were compared with new users of long - acting \u03b2 - agonist ( LABA ) monotherapy , and propensity scores were used to control confounding .", "label": "", "metadata": {}, "score": "52.8534"}
{"text": "PubMed View Article .Akkoca Yildiz O , Onen ZP , Demir G , Eri\u015f G\u00fclbay B , Saryal S , Karabiyiko\u011flu G : Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients ?", "label": "", "metadata": {}, "score": "53.071842"}
{"text": "Inhaled long - acting \u03b2 2 -agonists ( LABAs ) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol .", "label": "", "metadata": {}, "score": "53.09826"}
{"text": "PubMed .Decramer M , Celli B , Kesten S , Lystig T , Mehra S , Tashkin DP , UPLIFT investigators .Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease ( UPLIFT ) : a prespecified subgroup analysis of a randomised controlled trial .", "label": "", "metadata": {}, "score": "53.141697"}
{"text": "PubMed .Decramer M , Celli B , Kesten S , Lystig T , Mehra S , Tashkin DP , UPLIFT investigators .Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease ( UPLIFT ) : a prespecified subgroup analysis of a randomised controlled trial .", "label": "", "metadata": {}, "score": "53.141697"}
{"text": "A Dutch study found that steroids combined with an antibiotic were prescribed in 23 % of exacerbations [ 6 ] .This factor was taken into account in our model resulting in 0.8 exacerbations on average per patient during one year , which was in line with the yearly exacerbation frequency in the UPLIFT trial ( 0.85 in the placebo group ) .", "label": "", "metadata": {}, "score": "53.275116"}
{"text": "PubMed View Article .Pulm Pharmacol Ther 2007 , 20 : 740 - 9 .PubMed View Article .Beier J , Beeh KM , Brookman L , Peachey G , Hmissi A , Pascoe S : Bronchodilator effects of indacaterol and formoterol in patients with COPD .", "label": "", "metadata": {}, "score": "53.383503"}
{"text": "Chest .Martin RJ , Bartelson BL , Smith P , Hudgel DW , Lewis D , Pohl G , et al .Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD .", "label": "", "metadata": {}, "score": "53.394787"}
{"text": "Onukwugha E , Mullins CD , DeLisle S : Using cost - effectiveness analysis to sharpen formulary decision - making : The example of tiotropium at the veterans affairs health care system .", "label": "", "metadata": {}, "score": "53.437645"}
{"text": "A dose - ranging study of indacaterol in obstructive airways disease , with a tiotropium comparison .Stephen Rennard University of Nebraska Medical Center , Pulmonary and Critical Care Medicine , Omaha , Nebraska 68198 5885 , USA Respir Med 102:1033 - 44 .", "label": "", "metadata": {}, "score": "53.455116"}
{"text": "Mahler DA , Wire P , Horstman D , Chang CN , Yates J , Fischer T , Shah T : Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "53.4966"}
{"text": "Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea .[ ERS abstract 850630 ; Session 245 ; Date : September 03 , 2012 Time : 12:50 - 14:40 .", "label": "", "metadata": {}, "score": "53.51629"}
{"text": "Evidence is inadequate to predict in which patients inhaled therapies will have the greatest effect on long - term decline in lung function .Another trial of long - acting \u03b2 - agonist plus inhaled corticosteroid compared with tiotropium alone showed no statistically significant mean change in FEV 1 decline over 2 years ( 30 ) .", "label": "", "metadata": {}, "score": "53.55997"}
{"text": "Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease ( UPLIFT ) : a prespecified subgroup analysis of a randomised controlled trial .", "label": "", "metadata": {}, "score": "53.573444"}
{"text": "The role of anticholinergics in chronic obstructive pulmonary disease .Peter J Barnes Department of Thoracic Medicine , National Heart and Lung Institute , Imperial College , London , United Kingdom Am J Med 117:24S-32S. Once - daily administration of tiotropium is well tolerated and has shown significant advantages over ipratropium bromide , given 4 times daily , in the control of COPD ... .", "label": "", "metadata": {}, "score": "53.66454"}
{"text": "PubMed .Calverley PM , Anderson JA , Celli B , Ferguson GT , Jenkins C , Jones PW , Yates JC , Vestbo J , TORCH investigators : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "53.746315"}
{"text": "Data with active comparators are limited , but small studies have found similar improvements in exercise endurance and dyspnea ratings during submaximal or progressive exercise tests between twice - daily LABAs and ipratropium bromide [ 68 - 70 ] .", "label": "", "metadata": {}, "score": "53.80359"}
{"text": "Barr RG , Bourbeau J , Camargo CA , Ram FS .Inhaled tiotropium for stable chronic obstructive pulmonary disease .Cochrane Database Syst Rev .", "label": "", "metadata": {}, "score": "53.84592"}
{"text": "In a post - hoc analysis , the authors found that the benefits of tiotropium held whether or not the patients were on concurrent ICS therapy .", "label": "", "metadata": {}, "score": "53.87924"}
{"text": "R Buhl Pulmonary Department , Mainz University Hospital , Langenbeckstrasse 1 , Mainz , D 55131 , Germany Eur Respir J 38:797 - 803 .Efficacy of once - daily indacaterol 75 \u03bcg relative to alternative bronchodilators in COPD : a study level and a patient level network meta - analysis .", "label": "", "metadata": {}, "score": "53.9475"}
{"text": "In conclusion , tiotropium 5 and 10 microg daily , delivered via Respimat SMI , significantly improved lung function compared with ipratropium pMDI and placebo ... .", "label": "", "metadata": {}, "score": "53.95324"}
{"text": "PubMed View Article PubMed Central .Barnes PJ , Pocock SJ , Magnussen H , Iqbal A , Kramer B , Higgins M , Lawrence D : Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design .", "label": "", "metadata": {}, "score": "53.963383"}
{"text": "ClinicalTrials.gov , n.d .Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components , QAB149 and NVA237 , in Patients With Chronic Obstructive Pulmonary Disease ( COPD ) ( BEACON ) .", "label": "", "metadata": {}, "score": "53.972523"}
{"text": "A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD .T Voshaar Medizinische Klinik III , Stiftung Krankenhaus Bethanien f\u00fcr die , Grafschaft Moers , Bethanienstr 21 , D 47441 Moers , Germany Respir Med 102:32 - 41 .", "label": "", "metadata": {}, "score": "53.973633"}
{"text": "Neyt M , Van den Bruel A , Gailly J , Thiry N , Devriese S : Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease : Health Technology Assessment .", "label": "", "metadata": {}, "score": "54.02057"}
{"text": "PubMed View Article .Randell J , Saarinen A , Walamies M , Vahteristo M , Silvasti M , L\u00e4helm\u00e4 S : Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer .", "label": "", "metadata": {}, "score": "54.047375"}
{"text": "However , it is interesting to note that the use of ICS was not associated with a further risk reduction [ 73 ] .A LABA - ICS combination tended to reduce the risk of an exacerbation more than a LABA alone , although this did not reach statistical significance ( OR 0.90 ; 95 % CI , 0.80 - 1.01 ) .", "label": "", "metadata": {}, "score": "54.08255"}
{"text": "At present , no clear insight into this phenomenon is available ... .The effect of tiotropium on exacerbations and airflow in patients with COPD .", "label": "", "metadata": {}, "score": "54.08769"}
{"text": "Combining these medications may provide additional benefits ... .Comparison of tiotropium once daily , formoterol twice daily and both combined once daily in patients with COPD .", "label": "", "metadata": {}, "score": "54.1295"}
{"text": "PubMed View Article .Dahl R , Greefhorst LA , Nowak D , Nonikov V , Byrne AM , Thomson MH , Till D , Della Cioppa G , the Formoterol in Chronic Obstructive Pulmonary Disease I Study Group : Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "54.24105"}
{"text": "We found that more LABA patients than tiotropium patients had an asthma diagnosis in addition to their COPD diagnosis .The decreased risk of asthma exacerbations in the tiotropium group is consistent with a greater proportion of patients in the LABA group having an asthma component to their COPD .", "label": "", "metadata": {}, "score": "54.33387"}
{"text": "Philip M Short Asthma and Allergy Research Group , University of Dundee , Dundee , DD1 9SY , Scotland Chest 141:81 - 6 .It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids ( ICSs ) plus long - acting \u03b2 - agonists ( LABAs ) ... .", "label": "", "metadata": {}, "score": "54.48384"}
{"text": "Clinical studies have demonstrated that both formoterol and salmeterol are well tolerated , over periods of at least a year [ 28 , 30 , 31 , 36 , 48 , 78 ] .", "label": "", "metadata": {}, "score": "54.52005"}
{"text": "Anand A Dalal GlaxoSmithKline , Research Triangle Park , NC , USA J Med Econ 12:339 - 47 .Tiotropium improves FEV1 in patients with COPD irrespective of smoking status .", "label": "", "metadata": {}, "score": "54.667664"}
{"text": "Effects of arformoterol twice daily , tiotropium once daily , and their combination in patients with COPD .D P Tashkin David Geffen School of Medicine UCLA , Los Angeles , CA 90095 1690 , USA Respir Med 103:516 - 24 .", "label": "", "metadata": {}, "score": "54.70155"}
{"text": "Li GL , MacIntyre F , Surujbally B , Chong CL , Davis J : Safety and toleration of PF-00610355 , a novel inhaled long acting \u03b2 2 adrenoreceptor agonist [ abstract].", "label": "", "metadata": {}, "score": "54.715973"}
{"text": "We also added recommendations on when to consider pharmacotherapy in patients with stable COPD , clarified how to select among various monotherapies , reaffirmed our 2007 recommendations on when to use spirometry , and expanded on our recommendation for pulmonary rehabilitation .", "label": "", "metadata": {}, "score": "54.74579"}
{"text": "Littner MR , Ilowite JS , Tashkin DP , Friedman M , Serby CW , Menjoge SS , et al .Long - acting bronchodilation with once - daily dosing of tiotropium ( Spiriva ) in stable chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "54.769768"}
{"text": "D'Urzo A , et al .Efficacy and safety of once - daily NVA237 in patients with moderate - to - severe COPD : the GLOW1 trial .", "label": "", "metadata": {}, "score": "54.823452"}
{"text": "ILLUMINATE was a 26 week , multi - center , randomized , double - blind , double dummy , parallel - group study to assess the efficacy , safety and tolerability of once - daily QVA149 compared to twice - daily fixed dose combination of salmeterol / fluticasone 50/500 mcg in patients with moderate - to - severe stable COPD [ 2 ] .", "label": "", "metadata": {}, "score": "54.825302"}
{"text": "Clinical recommendation .Evidence rating .References .Comments .Extended therapy with short- or long - acting inhaled anticholinergics should be used to improve symptom control and reduce exacerbations and mortality risk in patients with COPD .", "label": "", "metadata": {}, "score": "54.850166"}
{"text": "[ PMID : 19566934 ] .Welsh EJ , Cates CJ , Poole P. Combination inhaled steroid and long - acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "54.94033"}
{"text": "[ PMID : 19566934 ] .Welsh EJ , Cates CJ , Poole P. Combination inhaled steroid and long - acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "54.94033"}
{"text": "18 Observational studies have reported associations between ipratropium and stroke , 19 cardiovascular hospitalisation 20 and death .Tiotropium has a similar mechanism of action to ipratropium , and in 2008 , the FDA issued an early communication after a pooled analysis of placebo - controlled clinical trials revealed an excess risk of stroke with tiotropium .", "label": "", "metadata": {}, "score": "55.223473"}
{"text": "PubMed View Article .Campbell M , Eliraz A , Johansson G , Tornling G , Nihl\u00e9n U , Bengtsson T , Rabe KF : Formoterol for maintenance and as - needed treatment of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "55.259846"}
{"text": "7 Furthermore , among patients with sinus node dysfunction , asymptomatic atrial tachyarrhythmias increase the risk of stroke and death .We conducted this epidemiologic study to examine the possible association between tiotropium ( HandiHaler \u00ae powder formulation ) and risk of stroke and other cardiovascular adverse events , including angina and myocardial infarction ( MI ) .", "label": "", "metadata": {}, "score": "55.27679"}
{"text": "One of the strengths of our evaluation is that it considers patients that use tiotropium in their everyday life .In contrast , populations considered in previous analyses were more selective .", "label": "", "metadata": {}, "score": "55.39322"}
{"text": "A 4-year trial of tiotropium in chronic obstructive pulmonary disease .The New England journal of medicine 2008 , 359 : 1543 - 1554 .", "label": "", "metadata": {}, "score": "55.427494"}
{"text": "Salpeter SR , Ormiston TM , Salpeter EE .Cardiovascular effects of beta - agonists in patients with asthma and COPD : a meta - analysis .", "label": "", "metadata": {}, "score": "55.563114"}
{"text": "[ 99 , 100 ] indicates a strong trend towards a dose - response relationship of increased hospitalization and death , due to heart failure in patients with underlying heart failure who received increasing amounts of \u03b2 2 -agonist .", "label": "", "metadata": {}, "score": "55.575592"}
{"text": "Monotherapy trials reported absolute decreases in the annual rate of FEV 1 decline associated with use of tiotropium ( 40 mL / y ) , inhaled corticosteroids ( 44 mL / y ) , and long - acting \u03b2 - agonists ( 42 mL / y ) .", "label": "", "metadata": {}, "score": "55.585293"}
{"text": "Eur Respir J .Oostenbrink JB , Rutten - van Molken MP , Al MJ , van Noord JA , Vincken W. One - year cost - effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "55.610924"}
{"text": "One study found tiotropium to be dominant , [ 20 ] however , this result was determined deterministically not including uncertainty around the treatment effect .", "label": "", "metadata": {}, "score": "55.699387"}
{"text": "Conclusions .Long - acting bronchodilators are fundamental to the management of COPD ; however , many patients remain symptomatic despite their use .Twice - daily LABAs salmeterol and formoterol provide some improvements in clinical outcomes compared with placebo and , although there are known class effects , have a favorable safety profile .", "label": "", "metadata": {}, "score": "55.760857"}
{"text": "PubMed View Article .Keene ON , Calverley PMA , Jones PW , Vestbo J , Anderson JA : Statistical analysis of exacerbation rates in COPD :", "label": "", "metadata": {}, "score": "55.784653"}
{"text": "Lapperre and colleagues ( 40 ) found that use of inhaled corticosteroids alone or in combination with a long - acting \u03b2 - agonist was associated with a small , non - clinically significant improvement over baseline dyspnea compared with placebo ( change in Medical Research Council dyspnea score of approximately 0.2 to 0.3 ) .", "label": "", "metadata": {}, "score": "55.787346"}
{"text": "Alsaeedi A , Sin DD , McAlister FA .The effects of inhaled corticosteroids in chronic obstructive pulmonary disease : a systematic review of randomized placebo - controlled trials .", "label": "", "metadata": {}, "score": "55.799786"}
{"text": "PubMed View Article .Rennard S , Bantje T , Centanni S , Chanez P , Chuchalin A , D'Urzo A , Kornmann O , Perry S , Jack D , Owen R , Higgins M : A dose - ranging study of indacaterol in obstructive airways disease , with a tiotropium comparison .", "label": "", "metadata": {}, "score": "55.830326"}
{"text": "PubMed View Article .Minakata Y , Iijima H , Takahashi T , Miura M , Ogawa H , Kimura K , Koga T , Kinoshita M , Tsuda T , Aizawa H , Ichinose M : Efficacy and safety of formoterol in Japanese patients with COPD .", "label": "", "metadata": {}, "score": "55.929626"}
{"text": "Make BJ , Kanniess F , Bateman ED , Linberg SE : Efficacy of 3 different doses of carmoterol , a long - acting beta2-agonist in patients with COPD [ abstract].", "label": "", "metadata": {}, "score": "55.961605"}
{"text": "Rennard SI , Chapman KR , Luthra A , Swales J , Lassen C , Owen R , Kramer B : Once - daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease [ abstract].", "label": "", "metadata": {}, "score": "55.967648"}
{"text": "QVA149 is an investigational inhaled , once - daily , fixed - dose combination of indacaterol maleate and glycopyrronium bromide .QVA149 is being investigated for the treatment of COPD in the Phase III IGNITE clinical trial program .", "label": "", "metadata": {}, "score": "56.19126"}
{"text": "The purpose of this study is to calculate tiotropium 's cost - effectiveness under real - world conditions ... .Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro .", "label": "", "metadata": {}, "score": "56.203987"}
{"text": "PubMed View Article .Cazzola M , Matera MG , L\u00f6tvall J : Ultra long - acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "56.211723"}
{"text": "The combination of inhaled steroids and long - acting beta 2 agonists reduces exacerbations , improves quality of life , and improves lung function in patients with moderate to severe COPD .", "label": "", "metadata": {}, "score": "56.271683"}
{"text": "About the IGNITE clinical trial program In the Phase III IGNITE clinical trial program , investigational QVA149 is being investigated for the treatment of COPD patients as an inhaled FDC of indacaterol maleate and glycopyrronium bromide .", "label": "", "metadata": {}, "score": "56.302277"}
{"text": "Carmoterol has demonstrated long duration of activity in patients with COPD [ 132 , 133 ] , with no tolerance observed over two weeks of treatment [ 134 ] .", "label": "", "metadata": {}, "score": "56.332485"}
{"text": "Therefore , both because of its size and because it seems to correspond to what happens in reality , the treatment effects and the surrounding uncertainty from the UPLIFT trial are taken into account to calculate the real - world cost - effectiveness of tiotropium .", "label": "", "metadata": {}, "score": "56.3543"}
{"text": "The evaluated evidence showed that combination therapies do not consistently demonstrate benefits over monotherapy .This guideline update reprises the analysis of the 2007 ACP guideline by focusing on 9 trials of at least 2 years ' duration .", "label": "", "metadata": {}, "score": "56.423164"}
{"text": "However , the annual hospitalization rate was 18 % lower in the salmeterol group than the placebo group ( 31 ) .In this guideline update , no new studies were identified during our initial search time frame that evaluated the effect of inhaled monotherapies ( anticholinergics , long - acting \u03b2 - agonists , or corticosteroids ) on exacerbations , hospitalizations , or mortality .", "label": "", "metadata": {}, "score": "56.48965"}
{"text": "PubMed View Article .Pontier SM , Percherancier Y , Galandrin S , Breit A , Gale C , Bouvier M : Cholesterol - dependent separation of the \u03b2 2 -adrenergic receptor from its partners determines signalling efficacy .", "label": "", "metadata": {}, "score": "56.507214"}
{"text": "N Engl J Med .PubMed .Vestbo J , S\u00f8rensen T , Lange P , Brix A , Torre P , Viskum K. Long - term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease : a randomised controlled trial .", "label": "", "metadata": {}, "score": "56.715057"}
{"text": "N Engl J Med .PubMed .Vestbo J , S\u00f8rensen T , Lange P , Brix A , Torre P , Viskum K. Long - term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease : a randomised controlled trial .", "label": "", "metadata": {}, "score": "56.715057"}
{"text": "Long - acting inhaled anticholinergics are probably more beneficial than short - acting formulations .Use of inhaled corticosteroids might benefit patients with mild COPD who have an inflammatory component or significant reversibility on spirometry .", "label": "", "metadata": {}, "score": "56.79033"}
{"text": "Because tiotropium is available only in a single - ingredient preparation , whereas LABAs are also available in combination with inhaled corticosteroids , the LABA group was restricted to patients prescribed single - ingredient LABAs .", "label": "", "metadata": {}, "score": "56.838314"}
{"text": "The cost - effectiveness of tiotropium was unfavourable due to the low average of hospitalisations with standard care but without tiotropium treatment ( almost 90 % did not experience an exacerbation - related hospitalisation ) .", "label": "", "metadata": {}, "score": "56.861828"}
{"text": "The relationship between exacerbations and patient - related clinical outcomes is not clearly understood ... .Cardiovascular safety of tiotropium in patients with COPD .Bartolome Celli Carita St Elizabeth s Medical Center , Boston , MA , USA Chest 137:20 - 30 .", "label": "", "metadata": {}, "score": "56.863228"}
{"text": "A systematic review of studies comparing oral mucolytics with placebo for three to six months showed a small decrease in exacerbations from a baseline of 2.7 exacerbations per year to 2.0 exacerbations per year with treatment .", "label": "", "metadata": {}, "score": "56.902435"}
{"text": "These methods have not been compared for their ability to assess long- and short - acting anticholinergic agents .We therefore performed a double - blind , placebo - controlled , four - way cross - over study in 30 healthy subjects ... .", "label": "", "metadata": {}, "score": "56.91284"}
{"text": "Discussion .This study found small increased risks of stroke , MI and angina along with a decreased risk of mortality with tiotropium .Individual studies are often too small to identify with certainty associations between specific medications and rare adverse events , and these findings should be considered in context with other evidence .", "label": "", "metadata": {}, "score": "56.92269"}
{"text": "Introduction .Inhaled anticholinergic medications , including short - acting ipratropium bromide ( ipratropium ) and long - acting tiotropium bromide ( tiotropium ) , are mainstays for the treatment of symptoms of chronic obstructive pulmonary disease ( COPD ) .", "label": "", "metadata": {}, "score": "57.01928"}
{"text": "Thorax 2010 , 65 : 473 - 479 .PubMed View Article .Hanania NA , Kalberg C , Yates J , Emmett A , Horstman D , Knobil K : The bronchodilator response to salmeterol is maintained with regular , long - term use in patients with COPD .", "label": "", "metadata": {}, "score": "57.032913"}
{"text": "As COPD progresses , patients with frequent exacerbations may require ' triple therapy ' with a LAMA , LABA and an ICS .Evidence to date indicates that ICS / LABA in combination with tiotropium improves lung function , symptoms and health status , and reduces the risk of hospitalizations compared with tiotropium alone in patients with COPD [ 149 - 151 ] .", "label": "", "metadata": {}, "score": "57.075546"}
{"text": "Efficacy of aclidinium bromide 400 \u03bcg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD .Rainard Fuhr Early Phase Clinical Unit Berlin , PAREXEL International GmbH , Berlin , Germany Chest 141:745 - 52 .", "label": "", "metadata": {}, "score": "57.275246"}
{"text": "PubMed .Gross NJ , Nelson HS , Lapidus RJ , Dunn L , Lynn L , Rinehart M , Denis - Mize K , the Formoterol Study Group : Efficacy and safety of formoterol fumarate delivered by nebulisation to COPD patients .", "label": "", "metadata": {}, "score": "57.28888"}
{"text": "A dose - ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients .Denis Caillaud CHU Clermont Ferrand , Pulmonary Department , Hopital G Montpied , Clermont Ferrand , France Int J Chron Obstruct Pulmon Dis 2:559 - 65 .", "label": "", "metadata": {}, "score": "57.335007"}
{"text": "Efficacy and safety of oxitropium bromide , theophylline and their combination in COPD patients : a double - blind , randomized , multicentre study ( BREATH Trial ) .", "label": "", "metadata": {}, "score": "57.44285"}
{"text": "Finally , tiotropium HandiHaler is available in one dose , and this study was unable to evaluate dose - response .However , among patients using therapy for at least 6 months , the associations with angina , MI and stroke became stronger , while the association with mortality became weaker .", "label": "", "metadata": {}, "score": "57.563766"}
{"text": "LABA monotherapy in COPD is not associated with increased risk of respiratory mortality .A meta - analysis performed in 2006 [ 90 ] , suggested that \u03b2 2 -agonists were associated with an increased rate of respiratory deaths compared with placebo , and a 2-fold greater risk of severe exacerbations compared with muscarinic antagonists .", "label": "", "metadata": {}, "score": "57.63144"}
{"text": "Tiotropium 5microg via Respimat and 18microg via HandiHaler ; efficacy and safety in Japanese COPD patients .M Ichinose Third Department of Internal Medicine , Wakayama Medical University , Kimiidera , Wakayama , Japan Respir Med 104:228 - 36 .", "label": "", "metadata": {}, "score": "57.68141"}
{"text": "Effect of add - on therapy of tiotropium in COPD treated with theophylline .Tomotaka Kawayama Department of Medicine , Kurume University School of Medicine , Kurume , Japan Int J Chron Obstruct Pulmon Dis 3:137 - 47 .", "label": "", "metadata": {}, "score": "57.768997"}
{"text": "View Article PubMed .Oostenbrink JB , Rutten - van Molken M , Monz BU , FitzGerald JM : Probabilistic Markov model to assess the cost - effectiveness of bronchodilator therapy in COPD patients in different countries .", "label": "", "metadata": {}, "score": "57.88797"}
{"text": "Effects of tiotropium on lung hyperinflation , dyspnoea and exercise tolerance in COPD .D E O'Donnell Respiratory Investigation Unit , Dept of Medicine , Queen s University , Kingston , Ontario , Canada Eur Respir J 23:832 - 40 .", "label": "", "metadata": {}, "score": "57.91667"}
{"text": "Dahl et al .QVA administered once daily provides significant improvements in lung function over 1 year in patients with COPD :The ENLIGHTEN study .", "label": "", "metadata": {}, "score": "57.921127"}
{"text": "Moreover , there appears to be a partial decline in the integrated 12-hour improvement in FEV 1 following the morning dose of formoterol 24 \u03bcg from 3 to 12 months of twice - daily therapy [ 46 ] .", "label": "", "metadata": {}, "score": "57.948105"}
{"text": "All tiotropium effect estimates in this study are relative to effects of LABA .A valid effect estimate indicating a higher rate with tiotropium means that tiotropium increases risk more than LABA but both drugs could be either increasing or decreasing risk .", "label": "", "metadata": {}, "score": "57.985325"}
{"text": "View Article PubMed .Schramm W , Haake D , Brandt A : Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "58.04258"}
{"text": "Formoterol and salmeterol have both demonstrated significant improvements in lung function [ 12 , 26 , 27 , 29 - 51 ] .Improvements in pre - bronchodilator forced expiratory volume in 1 second ( FEV 1 ) ranged from 50 - 90 mL compared with placebo [ 26 , 30 , 36 , 40 , 49 ] .", "label": "", "metadata": {}, "score": "58.070522"}
{"text": "Incorporating tiotropium into a respiratory therapist - directed bronchodilator protocol for managing in - patients with COPD exacerbations decreases bronchodilator costs .Gail S Drescher Pulmonary Services Department , Washington Hospital Center , 110 Irving Street NW , Washington , DC 20010 , USA Respir Care 53:1678 - 84 .", "label": "", "metadata": {}, "score": "58.11313"}
{"text": "PubMed View Article .Donohue JF , Hanania NA , Fogarty C , Campbell SC , Rinehart M , Denis - Mize K : Long - term safety of nebulized formoterol : results of a twelve - month open - label clinical trial .", "label": "", "metadata": {}, "score": "58.147587"}
{"text": "Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents .Reem Alzayer Curtin University of Technology , Perth , Australia Qual Prim Care 18:189 - 99 .", "label": "", "metadata": {}, "score": "58.19864"}
{"text": "In some [ 29 , 30 , 48 , 71 ] , but not all [ 23 , 28 , 31 , 33 , 36 ] studies , improvements compared with placebo exceeded the MCID of 4 units for the SGRQ [ 72 ] .", "label": "", "metadata": {}, "score": "58.461147"}
{"text": "A single dose of PF-00610355 450 \u03bcg had a superior duration of action as measured by specific airway conductance ( sGAW ) compared with placebo ( 16.4 hours longer ) and salmeterol ( 9.8 hours longer ) [ 140 ] .", "label": "", "metadata": {}, "score": "58.52675"}
{"text": "Scenario analysis .Next to the base case , two scenarios are elaborated .A first scenario incorporated the theoretical yearly cost for tiotropium ( \u20ac 621 ) and excluded the observed expenditures for salmeterol ( on average \u20ac 225.46 ) , reflecting 100 % tiotropium compliant users that did not take salmeterol anymore .", "label": "", "metadata": {}, "score": "58.550213"}
{"text": "Together , these benefits could lead to improved overall clinical outcomes in COPD patients [ 6 ] , and might help compliance with GOLD guidelines .", "label": "", "metadata": {}, "score": "58.65663"}
{"text": "US National Institutes of Health .Effect of Inhalation Of Tiotropium Once Daily 18 mcg Versus Salmeterol Twice Daily 50 mcg On Time To First Exacerbation in COPD Patients ( A Randomised , Double - Blind , Double - Dummy , Parallel Group , One - Year Study ) .", "label": "", "metadata": {}, "score": "58.698704"}
{"text": "Treatment with oral mucolytics such as n -acetylcysteine ( Mucomyst ; brand not available in the United States ) may result in a small reduction in acute exacerbations and in the total number of days of disability for patients with moderate to severe COPD .", "label": "", "metadata": {}, "score": "58.743828"}
{"text": "Eur Respir J 2008 , 32 : 17 - 24 .PubMed View Article .Liu D , Menjoge S : Statistical analysis of COPD exacerbations ( letter ) .", "label": "", "metadata": {}, "score": "58.812405"}
{"text": "The present review focuses on the role and future of long - acting \u03b2 2 -agonists ( LABAs ) in the management of COPD , updating previously published reviews [ 6 ] .", "label": "", "metadata": {}, "score": "58.838413"}
{"text": "Thus , we reaffirm our 2007 guideline , which recommends against treating asymptomatic individuals with or without spirometric evidence of airflow obstruction , regardless of the presence or absence of risk factors for airflow obstruction .", "label": "", "metadata": {}, "score": "58.84291"}
{"text": "The pharmacodynamic effects of single inhaled doses of formoterol , tiotropium and their combination in patients with COPD .Mario Cazzola Unit of Pneumology and Allergology , Department of Respiratory Medicine , A Cardarelli Hospital , Via del Parco Margherita 24 , Naples 80121 , Italy Pulm Pharmacol Ther 17:35 - 9 .", "label": "", "metadata": {}, "score": "58.908146"}
{"text": "No study evaluated the use of periodic spirometry after initiation of therapy to monitor ongoing disease status or modify therapy .Recommendation 2 : For stable COPD patients with respiratory symptoms and FEV 1 between 60 % and 80 % predicted , ACP , ACCP , ATS , and ERS suggest that treatment with inhaled bronchodilators may be used ( Grade : weak recommendation , low - quality evidence ) .", "label": "", "metadata": {}, "score": "58.917786"}
{"text": "GLOW1 and GLOW2 were multicenter , randomized , double - blind , placebo controlled , parallel group studies in patients with moderate - to - severe COPD .", "label": "", "metadata": {}, "score": "58.948112"}
{"text": "For patients with stable COPD , there is an associated improvement in FEV 1 .The regular short - term use of long - acting beta 2 agonists did not improve breathlessness or other health - related quality - of - life measures in eight RCTs , although a small improvement in FEV 1 was found .", "label": "", "metadata": {}, "score": "58.958054"}
{"text": "This is followed by the authors ' views on the ideal criteria for a new LABA for COPD , and a discussion of the extent to which novel LABAs , currently being developed , may meet these criteria .", "label": "", "metadata": {}, "score": "59.111435"}
{"text": "Roede BM , Bindels PJ , Brouwer HJ , Bresser P , de Borgie CA , Prins JM : Antibiotics and steroids for exacerbations of COPD in primary care : compliance with Dutch guidelines .", "label": "", "metadata": {}, "score": "59.296402"}
{"text": "Ninety - five per cent of LABA prescriptions were for salmeterol .The proportion of current smokers was slightly higher in tiotropium users than in LABA users ( 37 % compared with 30 % ) .", "label": "", "metadata": {}, "score": "59.42421"}
{"text": "In our guideline update , there is no new evidence to support the use of routine periodic spirometry after initiation of therapy to monitor disease status or to modify therapy in symptomatic patients .", "label": "", "metadata": {}, "score": "59.43229"}
{"text": "Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long - term Treatment in Patients With Moderately Severe Copd .Impact on Severity and Incidence of Exacerbations .", "label": "", "metadata": {}, "score": "59.45582"}
{"text": "In conclusion , tiotropium reduced exacerbations and associated health resource use , and improved airflow over 1 yr in chronic obstructive pulmonary disease patients ... .", "label": "", "metadata": {}, "score": "59.522514"}
{"text": "Similarly , nebulized arformoterol ( the active ( R , R)-enantiomer of formoterol ) 25 \u03bcg and 50 \u03bcg but not 15 \u03bcg twice daily significantly improved TDI ( 1.08 and 1.04 units vs placebo respectively ) [ 33 ] .", "label": "", "metadata": {}, "score": "59.631416"}
{"text": "One month of tiotropium costs \u20ac51.75 per patient , whereas e.g. salmeterol , i.e. another long - acting bronchodilator , costs \u20ac31.24 per month .", "label": "", "metadata": {}, "score": "59.641273"}
{"text": "19 , 20 Rescue inhaler use was decreased by four uses per week with tiotropium ; improved quality - of - life scores and fewer unscheduled office visits also were noted .", "label": "", "metadata": {}, "score": "59.738327"}
{"text": "GLOW2 was a 52 week study with patients randomized to receive once - daily glycopyrronium 50 mcg or placebo , and included an exploratory arm to compare the effects of once - daily OL tiotropium 18 mcg versus placebo [ 3,4 ] .", "label": "", "metadata": {}, "score": "59.85656"}
{"text": "These symptomatic improvements included shortness of breath , exercise tolerance , rescue medication use and health - related quality of life 5,6,8,18 .In clinical studies , investigational QVA149 demonstrated an acceptable safety profile with no meaningful differences between the treatment groups in the incidence of adverse and serious adverse events 5,6,7,8,19 .", "label": "", "metadata": {}, "score": "60.03076"}
{"text": "Treatment guidelines for COPD consider long - acting bronchodilators as a class and make no distinction between anticholinergic drugs and long - acting \u03b2 agonists ( LABAs ) , resulting in clinical equipoise .", "label": "", "metadata": {}, "score": "60.10701"}
{"text": "This paper focuses on the current and future role of LABAs in COPD management .The efficacy and safety of currently available LABAs is reviewed , and their limitations considered .", "label": "", "metadata": {}, "score": "60.13021"}
{"text": "Health Technology Assessment KCE reports 108C ; 2009 . D'AgostinoRB Jr , D'Agostino RB Sr : Estimating treatment effects using observational data .JAMA : the journal of the American Medical Association 2007 , 297 : 314 - 316 .", "label": "", "metadata": {}, "score": "60.245834"}
{"text": "Improvements in lung function were sustained over 24 hours .Vilanterol trifenatate was well tolerated at all doses and the frequency of adverse events was comparable to placebo [ 139 ] .", "label": "", "metadata": {}, "score": "60.27433"}
{"text": "There were no differences in lung function or adverse effects .One recent RCT assessing n -acetylcysteine ( 600 mg twice daily for three years ) found no difference in exacerbation rates or FEV 1 . 31 Of the studied medications , only n - acetylcysteine is available in the United States ; there are no RCTs available for guaifenesin ( Humibid ) in COPD .", "label": "", "metadata": {}, "score": "60.40738"}
{"text": "Bouyssou T , Casarosa P , Naline E , Pestel S , Konetzki I , Devillier P , Schnapp A : Pharmacological characterization of olodaterol , a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour - long duration of action in preclinical models .", "label": "", "metadata": {}, "score": "60.50787"}
{"text": "There is also increasing evidence that metalloproteinases ( MMPs ) may contribute to the pathogenesis of COPD , but the influence of agents that used for the treatment of COPD is not well understood ... .", "label": "", "metadata": {}, "score": "60.597034"}
{"text": "While formoterol has an onset of action similar to salbutamol , salmeterol may not produce a significant increase in bronchodilation for as long as 2 hours following the dose .", "label": "", "metadata": {}, "score": "60.68502"}
{"text": "The COMBIVENT Inhalation Solution Study Group .Routine nebulized ipratropium and albuterol together are better than either alone in COPD .Chest .van Noord JA , de Munck DR , Bantje TA , Hop WC , Akveld ML , Bommer AM .", "label": "", "metadata": {}, "score": "60.71026"}
{"text": "Spirometry is useful to identify symptomatic patients with airflow obstruction who may benefit from pharmacotherapy .The evidence supports the initiation of inhaled bronchodilator treatment ( anticholinergics , long - acting \u03b2 - agonists , or corticosteroids ) in patients who have respiratory symptoms and FEV 1 less than 60 % predicted .", "label": "", "metadata": {}, "score": "60.774246"}
{"text": "Among non - cardiovascular and non - respiratory end points , results showed an increased risk of dry mouth with tiotropium , but not for other anticholinergic end points including constipation and urinary retention .", "label": "", "metadata": {}, "score": "60.79564"}
{"text": "This resulted in a rate of 0.14 ( SD 0.46 ) hospitalisations per year ( Table 1 ) , comparable to the 0.16 rate in the placebo arm of the UPLIFT trial .", "label": "", "metadata": {}, "score": "60.8101"}
{"text": "View Article PubMed .Brookes ST , Whitely E , Egger M , Smith GD , Mulheran PA , Peters TJ : Subgroup analyses in randomized trials : risks of subgroup - specific analyses ; power and sample size for the interaction test .", "label": "", "metadata": {}, "score": "60.81711"}
{"text": "Banerji D et al .Dual bronchodilation with once - daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD : the IGNITE trials .", "label": "", "metadata": {}, "score": "60.829964"}
{"text": "In one RCT involving patients with COPD who were dependent on steroids , there were no differences in disease exacerbation , quality of life , or spirometric measures when the patients switched from oral to inhaled therapy .", "label": "", "metadata": {}, "score": "60.92778"}
{"text": "The structure of the model is shown in figure 1 .The disease course of COPD is more complex than this model shows .However , to calculate an intervention 's cost - effectiveness , only the difference in ( i.e. incremental ) costs and effects are of importance .", "label": "", "metadata": {}, "score": "60.936172"}
{"text": "To systematically review the risk of mortality associated with long term use of tiotropium delivered using a mist inhaler for symptomatic improvement in chronic obstructive pulmonary disease ... .", "label": "", "metadata": {}, "score": "60.944576"}
{"text": "PubMed View Article .Janssens W , Van den Brande P , Hardeman E , De Langhe E , Philps T , Troosters T , Decramer M : Inspiratory flow rates at different levels of resistance in elderly COPD patients .", "label": "", "metadata": {}, "score": "61.02327"}
{"text": "A recent meta - analysis of 12 RCTs assessing inhaled corticosteroids demonstrated one fewer exacerbation for every 12 patients with moderate to severe disease who were treated for 18 months . 13 As in earlier studies , there was no effect on mortality , and the effectiveness was not significant in patients with mild disease .", "label": "", "metadata": {}, "score": "61.058113"}
{"text": "Enhanced persistence with tiotropium compared with other respiratory drugs in COPD .Nancy S Breekveldt - Postma PHARMO Institute , Utrecht , The Netherlands Respir Med 101:1398 - 405 .", "label": "", "metadata": {}, "score": "61.0793"}
{"text": "Sestini P , Renzoni E , Robinson S , Poole P , Ram FS .Short - acting beta 2 agonists for stable chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "61.107628"}
{"text": "Although the generalizability of these data to patients with less severe airflow obstruction is less clear , evidence reviewed in this guideline update suggests that patients with moderate COPD also experience benefit ( 49 ) .", "label": "", "metadata": {}, "score": "61.15896"}
{"text": "This guideline does not address all components of management of a patient with COPD and is limited to pharmacologic management , pulmonary rehabilitation , and oxygen therapy .", "label": "", "metadata": {}, "score": "61.175438"}
{"text": "Information on baseline risks for exacerbations and exacerbation - related hospitalisations without tiotropium is based on the year before the first tiotropium delivery .Details on the costs for tiotropium were based on the first year after the first delivery .", "label": "", "metadata": {}, "score": "61.179768"}
{"text": "Tiotropium as a first maintenance drug in COPD : secondary analysis of the UPLIFT trial .T Troosters Respiratory Division and Pulmonary Rehabilitation , UZ Gasthuisberg , Herestraat 49 , B3000 Leuven , Belgium Eur Respir J 36:65 - 73 .", "label": "", "metadata": {}, "score": "61.20002"}
{"text": "R Casaburi Harbor UCLA Research and Education Institute , Torrance , CA 90502 , USA Eur Respir J 19:217 - 24 .This suggests that tiotropium will make an important contribution to chronic obstructive pulmonary disease therapy ... .", "label": "", "metadata": {}, "score": "61.235153"}
{"text": "PubMed .Casaburi R , Mahler DA , Jones PW , Wanner A , San PG , ZuWallack RL . et al .A long - term evaluation of once - daily inhaled tiotropium in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "61.256794"}
{"text": "PubMed .Casaburi R , Mahler DA , Jones PW , Wanner A , San PG , ZuWallack RL . et al .A long - term evaluation of once - daily inhaled tiotropium in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "61.256794"}
{"text": "JAMA .PubMed .Buffels J , Degryse J , Decramer M , Heyrman J. Spirometry and smoking cessation advice in general practice : a randomised clinical trial .", "label": "", "metadata": {}, "score": "61.364365"}
{"text": "JAMA .PubMed .Buffels J , Degryse J , Decramer M , Heyrman J. Spirometry and smoking cessation advice in general practice : a randomised clinical trial .", "label": "", "metadata": {}, "score": "61.364365"}
{"text": "PubMed .Shaker SB , Dirksen A , Ulrik CS , Hestad M , Stavngaard T , Laursen LC . et al .The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography .", "label": "", "metadata": {}, "score": "61.384655"}
{"text": "PubMed .Shaker SB , Dirksen A , Ulrik CS , Hestad M , Stavngaard T , Laursen LC . et al .The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography .", "label": "", "metadata": {}, "score": "61.384655"}
{"text": "In some studies , combination therapy with various inhaled agents ( anticholinergics , long - acting \u03b2 - agonists , or corticosteroids ) was shown to reduce exacerbations , hospitalizations , mortality , and improve health - related quality of life compared with monotherapy .", "label": "", "metadata": {}, "score": "61.545807"}
{"text": "PubMed .Salpeter SR , Ormiston TM , Salpeter EE .Cardiovascular effects of beta - agonists in patients with asthma and COPD : a meta - analysis .", "label": "", "metadata": {}, "score": "61.57289"}
{"text": "PubMed .Salpeter SR , Ormiston TM , Salpeter EE .Cardiovascular effects of beta - agonists in patients with asthma and COPD : a meta - analysis .", "label": "", "metadata": {}, "score": "61.57289"}
{"text": "Two recent meta - analyses published after the 2007 review reported on adverse effects ( 44 - 45 ) .One meta - analysis of 11 RCTs of greater than 6 months ' duration did not identify increased risks for pneumonia , 1-year mortality , or fracture associated with inhaled corticosteroids as monotherapy ( 44 ) .", "label": "", "metadata": {}, "score": "61.6933"}
{"text": "J A Van Noord Department of Respiratory Diseases , Atrium Medisch Centrum , Heerlen , The Netherlands Respir Med 103:22 - 9 .The Respimat Soft Mist Inhaler ( SMI ) , a novel , propellant - free inhaler , has been developed and proposed as an alternative delivery device for use with tiotropium ... .", "label": "", "metadata": {}, "score": "61.712128"}
{"text": "Another systematic review showed that inspiratory muscle training with targeted hyperventilation increases muscle strength and endurance , and it improves exercise capacity and decreases dyspnea for adults with stable COPD ( 55 ) .", "label": "", "metadata": {}, "score": "61.864784"}
{"text": "The studies are designed to investigate the efficacy , safety and tolerability , lung function , exercise endurance , exacerbations , shortness of breath and quality of life in patients treated with investigational QVA149 .", "label": "", "metadata": {}, "score": "62.109436"}
{"text": "Recent editorials have recommended that physicians should continue to use LABAs to treat asthma , but only when combined with appropriate doses of inhaled corticosteroids [ 82 , 83 ] .", "label": "", "metadata": {}, "score": "62.15155"}
{"text": "Combination therapy ( salmeterol plus fluticasone ) reduced the annual rate of exacerbations compared with monotherapy ( salmeterol alone , fluticasone alone , or placebo ) ( 31 ) .", "label": "", "metadata": {}, "score": "62.190163"}
{"text": "Efficacy in COPD has traditionally been assessed primarily through impact on lung function measured by spirometry .However , to adequately understand the impact of a medication , outcomes of importance to the patient including symptoms and quality of life must also be taken into account [ 24 ] .", "label": "", "metadata": {}, "score": "62.195305"}
{"text": "The UPLIFT study included 5993 patients and compared tiotropium plus any other nonanticholinergic respiratory medications with placebo plus any other nonanticholinergic respiratory medications over 4 years .", "label": "", "metadata": {}, "score": "62.2121"}
{"text": "Tiotropium HandiHaler in the treatment of COPD : a safety review .Steven Kesten Boehringer Ingelheim Pharmaceuticals , Ridgefield , CT 06877 0368 , USA Int J Chron Obstruct Pulmon Dis 4:397 - 409 .", "label": "", "metadata": {}, "score": "62.309605"}
{"text": "Efficacy and tolerability of budesonide / formoterol added to tiotropium in patients with chronic obstructive pulmonary disease .Tobias Welte Department of Respiratory Medicine , Hannover Medical School , Hannover , Germany Am J Respir Crit Care Med 180:741 - 50 .", "label": "", "metadata": {}, "score": "62.312294"}
{"text": "PubMed View Article .Campbell SC , Criner GJ , Levine BE , Simon SJ , Smith JS , Orevillo CJ , Ziehmer BA : Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "62.315487"}
{"text": "Rodrigo GJ , Nannini LJ , Rodr\u00edguez - Roisin R : Safety of long - acting \u03b2 - agonists in stable COPD .Chest 2008 , 133 : 1079 - 87 .", "label": "", "metadata": {}, "score": "62.35948"}
{"text": "Article summary .Article focus .This study investigated whether there are possible increased risks of stroke and other adverse events , including angina and myocardial infarction , with tiotropium use in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "62.423595"}
{"text": "In addition , we found no evidence to support the use of routine periodic spirometry after initiation of therapy in order to monitor disease status or guide therapy modification .", "label": "", "metadata": {}, "score": "62.431877"}
{"text": "SORT : KEY RECOMMENDATIONS FOR PRACTICE .Clinical recommendation .Extended therapy with short- or long - acting inhaled anticholinergics should be used to improve symptom control and reduce exacerbations and mortality risk in patients with COPD .", "label": "", "metadata": {}, "score": "62.551254"}
{"text": "The results were comparable in patients treated with OL tiotropium 18 mcg .The results were similar to OL tiotropium 18 mcg compared to placebo [ 4 ] .", "label": "", "metadata": {}, "score": "62.576237"}
{"text": "PubMed View Article .Calverley PM : Long - acting inhaled bronchodilators in COPD : how many drugs do we need ?Eur Respir J 2005 , 26 : 190 - 1 .", "label": "", "metadata": {}, "score": "62.581383"}
{"text": "NCT , 2011 .BMJ 2011 ; 342 : d3215 .Boehringer Ingelheim International .A Randomized Double - Blind , Placebo - Controlled , Parallel - Group Study To Assess Long Term ( One - Year )", "label": "", "metadata": {}, "score": "62.637268"}
{"text": "Other LABAs with a 24-hour duration of bronchodilation include carmoterol , vilanterol trifenatate and oldaterol , with early results indicating potential for once - daily dosing in humans .", "label": "", "metadata": {}, "score": "62.647568"}
{"text": "Cost to the patient will be higher , depending on prescription filling fee .Inhaled short- and long - acting anticholinergics improve symptoms and quality of life in patients with COPD .", "label": "", "metadata": {}, "score": "62.653652"}
{"text": "Bateman ED , Make BJ , Nandeuil MA : Safety and tolerability of a long - acting beta2-agonist in patients with COPD [ abstract].", "label": "", "metadata": {}, "score": "62.66629"}
{"text": "Outpatient management of severe COPD .N Engl J Med 2010 , 362 : 1407 - 16 .PubMed View Article .Hasegawa M , Makita H , Nasuhara Y , Odajima N , Nagai K , Ito Y , Betsuyaku T , Nishimura M : Relationship between improved airflow limitation and changes in airway caliber induced by inhaled anticholinergics in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "62.67913"}
{"text": "PubMed View Article PubMed Central .Neder JA , Fuld JP , Overend T , Thirlwell J , Carter R , Stevenson R , Ward SA : Effects of formoterol on exercise tolerance in severely disabled patients with COPD .", "label": "", "metadata": {}, "score": "62.7681"}
{"text": "No cardiac safety concerns were reported at doses less than 16 \u03bcg in healthy volunteers [ 136 ] , while in patients with COPD initial data also suggests it has a good safety profile and is well tolerated [ 137 ] .", "label": "", "metadata": {}, "score": "62.791862"}
{"text": "PubMed .Calverley PM , Boonsawat W , Cseke Z , Zhong N , Peterson S , Olsson H : Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "62.79715"}
{"text": "Preclinical and Phase II studies indicated that indacaterol has a 24-hour duration of bronchodilation with fast onset of action , a good cardiovascular safety profile and no antagonism of the effect of rescue medication [ 22 , 116 - 121 ] .", "label": "", "metadata": {}, "score": "62.82911"}
{"text": "Mahler D et al .Superior lung function with once - daily QVA149 translates into improvements in patient reported breathlessness compared with placebo and tiotropium in COPD patients : the BLAZE study .", "label": "", "metadata": {}, "score": "62.943615"}
{"text": "Evidence was inconclusive regarding the effect of inhaled agents ( anticholinergics and long - acting \u03b2 - agonists ) on mortality , hospitalizations , and dyspnea .", "label": "", "metadata": {}, "score": "62.981598"}
{"text": "PubMed View Article .Au DH , Udris EM , Curtis JR , McDonell MB , Fihn SD : Association between chronic heart failure and inhaled \u03b2-2-adrenoceptor agonist .", "label": "", "metadata": {}, "score": "63.167"}
{"text": "PubMed View Article .Lancet 2003 , 361 : 449 - 56 .PubMed View Article .Chhabra SK , Vijayan VK , Vasu T : Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "63.185997"}
{"text": "One study of patients with FEV 1 between 50 % and 80 % predicted who were treated with the combination of a long - acting \u03b2 - agonist and inhaled corticosteroid showed little improvement in exacerbations , mortality , or health - related quality of life compared with placebo recipients ( 48 ) .", "label": "", "metadata": {}, "score": "63.19279"}
{"text": "Other challenges in designing exacerbation trials such as differential discontinuation and follow - up of discontinued patients are discussed ... .Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium , a once - daily inhaled anticholinergic bronchodilator : a randomized trial .", "label": "", "metadata": {}, "score": "63.20891"}
{"text": "On the basis of 2 RCTs , the incidence of fracture over 3 years was similar with inhaled corticosteroids and placebo ( 1.4 % vs. 2.0 % , respectively ) ( 24 , 26 ) .", "label": "", "metadata": {}, "score": "63.219822"}
{"text": "On the other hand , it also showed that this is only a minority of the population taking tiotropium on a regular basis .The largest group of patients did not experience any exacerbation or hospitalisation .", "label": "", "metadata": {}, "score": "63.27118"}
{"text": "In our view , to abandon the use of spirometry in asymptomatic smokers will certainly promote ( if not worsen ) the continued under - diagnosis ( and under resourcing ) of COPD .", "label": "", "metadata": {}, "score": "63.275124"}
{"text": "On the other hand they may have been a bit too reductionist in choosing to characterize COPD solely on the basis of a single spirometric measurement .", "label": "", "metadata": {}, "score": "63.303497"}
{"text": "TORCH found no increased risk of mortality with salmeterol monotherapy .Further , a recent meta - analysis of 27 studies found no significant difference between LABA and placebo in terms of risk of respiratory death ( relative risk 1.09 [ 95 % , CI 0.45 - 2.64 ] ) [ 73 ] .", "label": "", "metadata": {}, "score": "63.31639"}
{"text": "Condition ICMJE .Pulmonary Disease , Chronic Obstructive .Intervention ICMJE .Drug : Tiotropium .Study Arm ( s ) .Not Provided .Not Provided .", "label": "", "metadata": {}, "score": "63.38308"}
{"text": "Safety , tolerability and risk benefit analysis of tiotropium in COPD .Yuji Oba University of Missouri , School of Medicine , Division of Pulmonary , Critical Care and Environmental Medicine , Columbia , MO 65212 , USA Int J Chron Obstruct Pulmon Dis 3:575 - 84 .", "label": "", "metadata": {}, "score": "63.452206"}
{"text": "Cardiovascular side effects are also possible in susceptible patients [ 93 ] , and there is some risk associated with the use of \u03b2 2 -agonists in patients with COPD and concomitant cardiac diseases , particularly chronic heart failure [ 94 , 95 ] .", "label": "", "metadata": {}, "score": "63.4917"}
{"text": "Phase III data from the GLOW 1 , 2 and 3 studies demonstrated that glycopyrronium increased patients ' lung function over a 24-hour period compared to placebo with a fast onset of action at first dose , and improved exercise endurance versus placebo [ 12 - 14 ] .", "label": "", "metadata": {}, "score": "63.49421"}
{"text": "However , evidence from large datasets such as TORCH and pooled analyses reviewed above support a relatively modest reduction in the rate of moderate and severe exacerbations [ 28 , 73 , 79 ] .", "label": "", "metadata": {}, "score": "63.50102"}
{"text": "GLOW pooled analyses demonstrated that investigational glycopyrronium increased lung function , improved patient outcomes compared to placebo [ 3,4 ] .Results of the first pooled analysis of GLOW1 and GLOW2 data demonstrated that patients on glycopyrronium 50 mcg experienced rapid , sustained and clinically meaningful bronchodilation over 52 weeks [ 3 ] .", "label": "", "metadata": {}, "score": "63.521233"}
{"text": "Recommendation 2 : For stable COPD patients with respiratory symptoms and FEV 1 between 60 % and 80 % predicted , ACP , ACCP , ATS , and ERS suggest that treatment with inhaled bronchodilators may be used ( Grade : weak recommendation , low - quality evidence ) .", "label": "", "metadata": {}, "score": "63.531525"}
{"text": "Withdrawal of chronic systemic corticosteroids in patients with COPD : a randomized trial .Am J Respir Crit Care Med .Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base .", "label": "", "metadata": {}, "score": "63.590603"}
{"text": "Decision model of tiotropium for the treatment of COPD .( Additional file ) .exac .: exacerbation .Items shown in grey are not taken into account .", "label": "", "metadata": {}, "score": "63.62258"}
{"text": "Dr. Criner : Consultancy : Uptake Medical , PortAero , Pulmonx ; Grants / grants pending ( money to institution ) : Aeris Therapeutics , Emphysas Medica .", "label": "", "metadata": {}, "score": "63.734406"}
{"text": "The Lung Health Study ( trials 1 and 2 ) found no statistically significant differences in hospitalizations per 100 person - years of exposure between ipratropium and placebo or between inhaled corticosteroids and placebo ( 19 , 25 ) .", "label": "", "metadata": {}, "score": "63.739784"}
{"text": "PubMed .Vincken W , van Noord JA , Greefhorst AP , Bantje TA , Kesten S , Korducki L , et al .Dutch / Belgian Tiotropium Study Group .", "label": "", "metadata": {}, "score": "63.799126"}
{"text": "PubMed .Vincken W , van Noord JA , Greefhorst AP , Bantje TA , Kesten S , Korducki L , et al .Dutch / Belgian Tiotropium Study Group .", "label": "", "metadata": {}, "score": "63.799126"}
{"text": "Thus , there is still an unmet need , particularly to improve symptoms , in many COPD patients .A range of features can be identified that could be considered to be criteria for a new LABA to fulfil .", "label": "", "metadata": {}, "score": "63.80665"}
{"text": "Eur Respir J .Wouters EF , Postma DS , Fokkens B , Hop WC , Prins J , Kuipers AF , et al . , for the COSMIC ( COPD and Seretide : a Multi - center Intervention and Characterization ) Study Group .", "label": "", "metadata": {}, "score": "64.03883"}
{"text": "2004;(3):CD003794 .Poole PJ , Black PN .Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease .Cochrane Database Syst Rev .2006;(3):CD001287 .", "label": "", "metadata": {}, "score": "64.10403"}
{"text": "Oxitropium bromide in combination with theophylline provided a greater improvement in evening post - dosing PEFR .Oxitropium bromide alone or in combination with theophylline improved the quality of life better than theophylline alone ... .", "label": "", "metadata": {}, "score": "64.15233"}
{"text": "Walters JA , Walters EH , Wood - Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease .Cochrane Database Syst Rev .2005;(3):CD005374 .", "label": "", "metadata": {}, "score": "64.21448"}
{"text": "PubMed .Stratelis G , Mo\u0308lstad S , Jakobsson P , Zetterstro\u0308m O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD .", "label": "", "metadata": {}, "score": "64.24352"}
{"text": "PubMed .Stratelis G , Mo\u0308lstad S , Jakobsson P , Zetterstro\u0308m O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD .", "label": "", "metadata": {}, "score": "64.24352"}
{"text": "Once - daily LABAs used both alone and in combination with long - acting muscarinic antagonists represent a promising advance in the treatment of COPD , and are likely to further improve outcomes for patients .", "label": "", "metadata": {}, "score": "64.39024"}
{"text": "Discussion .A disadvantage of our database is that no parameter was present indicating the COPD stage .As a result , no subgroup analyses could be made according to these stages .", "label": "", "metadata": {}, "score": "64.409065"}
{"text": "A number of novel LABAs with once - daily profiles are in development which may be judged against these criteria .Indacaterol , a LABA with a 24-hour duration of bronchodilation and fast onset of action , is the most advanced of these .", "label": "", "metadata": {}, "score": "64.44291"}
{"text": "The routine use of spirometry in asymptomatic patients in primary care settings may potentially lead to unnecessary testing , increased costs and resource utilization , unnecessary disease labeling , and the harms of long - term treatment with no known preventive effect on avoiding future symptoms .", "label": "", "metadata": {}, "score": "64.44629"}
{"text": "PubMed .Vogelmeier C , Hederer B , Glaab T , Schmidt H , Rutten - vanMo\u0308lken MP , Beeh KM , et al .POET - COPD Investigators .", "label": "", "metadata": {}, "score": "64.572266"}
{"text": "PubMed .Vogelmeier C , Hederer B , Glaab T , Schmidt H , Rutten - vanMo\u0308lken MP , Beeh KM , et al .POET - COPD Investigators .", "label": "", "metadata": {}, "score": "64.572266"}
{"text": "Appleton S , Poole P , Smith B , Veale A , Bara A. Long - acting beta 2 -agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation .", "label": "", "metadata": {}, "score": "64.58469"}
{"text": "Pauwels RA , Lo\u0308fdahl CG , Laitinen LA , Schouten JP , Postma DS , Pride NB . et al .Long - term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking .", "label": "", "metadata": {}, "score": "64.62106"}
{"text": "Pauwels RA , Lo\u0308fdahl CG , Laitinen LA , Schouten JP , Postma DS , Pride NB . et al .Long - term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking .", "label": "", "metadata": {}, "score": "64.62106"}
{"text": "Aclidinium bromide , a novel long - acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile .Amadeu Gavald\u00e1 Almirall S A , Biology Department , Sant Feliu de Llobregat , Barcelona , Spain Life Sci 90:301 - 5 .", "label": "", "metadata": {}, "score": "64.62324"}
{"text": "\u03b2 2 -adrenergic receptor agonists may also attenuate cholinergic neurotransmission due to stimulation of \u03b2 2 -adrenergic receptors on parasympathetic ganglia [ 9 , 10 ] .", "label": "", "metadata": {}, "score": "64.640945"}
{"text": "Donohue JF , Fogarty C , L\u00f6tvall J , et al .Once - daily bronchodilators for chronic obstructive pulmonary disease : Indacaterol versus tiotropium .", "label": "", "metadata": {}, "score": "64.650856"}
{"text": "PubMed View Article .Mahler DA , Weinberg DH , Wells CK , Feinstein AR : The measurement of dyspnea : contents , interobserver agreement , and physiologic correlates of two new clinical indexes .", "label": "", "metadata": {}, "score": "64.793976"}
{"text": "PubMed View Article .Make B , Casaburi R , Kline Leidy N : Interpreting results from clinical trials : understanding minimal clinically important differences in COPD outcomes .", "label": "", "metadata": {}, "score": "64.82738"}
{"text": "Nevertheless , the population in trials often does not reflect a real - world population .An approach to measure the cost - effectiveness for this population is to apply the relative treatment effect found in RCTs to the baseline risk for an event calculated from observational data .", "label": "", "metadata": {}, "score": "64.95094"}
{"text": "Tiotropium bromide , a new , once - daily inhaled anticholinergic bronchodilator for chronic - obstructive pulmonary disease .Alicia R ZuWallack St Francis Hospital and Medical Center , Hartford , CT 06105 , USA Expert Opin Pharmacother 5:1827 - 35 .", "label": "", "metadata": {}, "score": "64.95844"}
{"text": "Nevertheless , with regard to safety of inhaled anticholinergic drugs , the FDA recently concluded that ' data from Uplift adequately addressed the potential safety signal of stroke and adverse cardiovascular outcomes . '", "label": "", "metadata": {}, "score": "64.99901"}
{"text": "J Med Chem 2010 , 53 ( 11 ) : 4522 - 30 .PubMed View Article .Macintyre F , Jones I , Surujbally B : A randomised , double - blind study to determine the duration of action of lung pharmacodynamics by plethysmography ( sGaw ) of a \u03b2 2 adrenoreceptor agonist , PF-00610355 [ abstract].", "label": "", "metadata": {}, "score": "65.08483"}
{"text": "41 42 The Uplift study , for instance , describes higher rates of serious angina and ischaemic stroke with tiotropium than placebo 24 and so can hardly provide reassurance about the absence of such risks .", "label": "", "metadata": {}, "score": "65.13865"}
{"text": "Vincken W , van Noord JA , Greefhorst AP , Bantje TA , Kesten S , Korducki L , et al . , for the Dutch / Belgian Tiotropium Study Group .", "label": "", "metadata": {}, "score": "65.23156"}
{"text": "Comparison(s ) : .Tiotropium 18 mcg once daily vs Placebo .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .", "label": "", "metadata": {}, "score": "65.23256"}
{"text": "Treatment with theophylline may cause a small improvement in FEV 1 ; however , it is poorly tolerated , requires monitoring , and does not improve patient - oriented outcomes such as breathlessness .", "label": "", "metadata": {}, "score": "65.24279"}
{"text": "Inhaled corticosteroids should be used instead .Use of the oral mucolytic n -acetylcysteine ( Mucomyst ; brand not available in the United States ) provides a small reduction in exacerbations in patients with severe COPD who are not taking inhaled steroids .", "label": "", "metadata": {}, "score": "65.24582"}
{"text": "Inhaled corticosteroids should be used instead .Use of the oral mucolytic n -acetylcysteine ( Mucomyst ; brand not available in the United States ) provides a small reduction in exacerbations in patients with severe COPD who are not taking inhaled steroids .", "label": "", "metadata": {}, "score": "65.24582"}
{"text": "A bout NVA237/QVA149 .NVA237 ( glycopyrronium bromide - Seebri \u00ae Breezhaler \u00ae ) was licensed to Novartis in April 2005 by Sosei and its co - development partner , Vectura .", "label": "", "metadata": {}, "score": "65.24977"}
{"text": "Recently , safety concerns have been raised about increased mortality with the mist inhaler formulation of tiotropium ( Respimat \u00ae ) , which is available in several countries but which was not approved for marketing in the USA .", "label": "", "metadata": {}, "score": "65.32783"}
{"text": "Potential impact of ultra - LABAs on COPD management as monotherapy and in combination .It could be hypothesized that a longer duration of bronchodilation with an ultra - LABA may be associated with superior and more consistent efficacy over a range of endpoints than is achieved with a twice - daily LABA .", "label": "", "metadata": {}, "score": "65.42157"}
{"text": "In constructing the logistic models used to calculate the propensity scores , all available variables described above were entered into the model .Multivariate analysis was performed using Cox ' proportional hazard model with adjustment for indicators of propensity score quintile to estimate adjusted HRs and corresponding 95 % CIs .", "label": "", "metadata": {}, "score": "65.50554"}
{"text": "PubMed View Article .Drazen JM , O'Byrne PM : Risks of long - acting beta - agonists in achieving asthma control .New Eng J Med 2009 , 360 : 1671 - 2 .", "label": "", "metadata": {}, "score": "65.549255"}
{"text": "This avoided an impact on hospitalisation cost of interventions unrelated to COPD in the same stay in other hospital wards .The cost was calculated as the sum of all expenditures available in the MFG data for the selected stay .", "label": "", "metadata": {}, "score": "65.56299"}
{"text": "In the 2007 ACP guideline , we did not find any high - quality evidence that the use of spirometry or the communication of spirometry results to patients improved smoking cessation .", "label": "", "metadata": {}, "score": "65.57955"}
{"text": "Tiotropium for treatment of stable COPD : a meta - analysis of clinically relevant outcomes .Abebaw Mengistu Yohannes Department of Health Professions , Manchester Metropolitan University , Manchester , United Kingdom , UK Respir Care 56:477 - 87 .", "label": "", "metadata": {}, "score": "65.6517"}
{"text": "Comparative safety of long - acting inhaled bronchodilators : a cohort study using the UK THIN primary care database .Michele Jara Boehringer Ingelheim Pharmaceuticals Inc , Ridgefield , CT 06877 0368 , USA Drug Saf 30:1151 - 60 .", "label": "", "metadata": {}, "score": "65.65489"}
{"text": "SHINE was a 26 week , multicenter , randomized , double - blind , parallel - group , placebo and active controlled pivotal trial of 2,144 patients with moderate - to - severe COPD to assess efficacy in terms of trough FEV 1 [ 1 ] .", "label": "", "metadata": {}, "score": "65.81117"}
{"text": "PubMed .Celli BR , Thomas NE , Anderson JA , Ferguson GT , Jenkins CR , Jones PW . et al .Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease : results from the TORCH study .", "label": "", "metadata": {}, "score": "65.837326"}
{"text": "PubMed .Celli BR , Thomas NE , Anderson JA , Ferguson GT , Jenkins CR , Jones PW . et al .Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease : results from the TORCH study .", "label": "", "metadata": {}, "score": "65.837326"}
{"text": "ClinicalTrials.gov , n.d .Comparison of Long - term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation ( RADIATE ) .", "label": "", "metadata": {}, "score": "65.89483"}
{"text": "A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease .Charles K N Chan University Health Network , Toronto General Hospital , Toronto , Canada Can Respir J 14:465 - 72 .", "label": "", "metadata": {}, "score": "66.046776"}
{"text": "We did not update the search to evaluate the utility of long - term oxygen therapy .Recommendation 1 : ACP , ACCP , ATS , and ERS recommend that spirometry should be obtained to diagnose airflow obstruction in patients with respiratory symptoms ( Grade : strong recommendation , moderate - quality evidence ) .", "label": "", "metadata": {}, "score": "66.07828"}
{"text": "\" But it means that for a physician treating a patient with COPD , they are essentially therapeutically equivalent ; the combination of cost , availability and side effects will dictate which is the right drug for a given patient .", "label": "", "metadata": {}, "score": "66.18555"}
{"text": "Environ Health .Silva GE , Sherrill DL , Guerra S , Barbee RA .Asthma as a risk factor for COPD in a longitudinal study .", "label": "", "metadata": {}, "score": "66.30011"}
{"text": "The target audience for this guideline includes all clinicians caring for patients with COPD , and the target patient population is comprised of patients with stable COPD .", "label": "", "metadata": {}, "score": "66.33769"}
{"text": "Andrea S Gershon Institute for Clinical Evaluative Sciences , Toronto , Ontario , Canada COPD 5:229 - 34 .This result suggests that tiotropium might also be associated with decreased mortality compared to no treatment at all .", "label": "", "metadata": {}, "score": "66.36675"}
{"text": "In some studies , combination therapy has been associated with a modest increase in the risk for adverse events , whereas other studies have not found this .", "label": "", "metadata": {}, "score": "66.39166"}
{"text": "IGNITE data demonstrated the efficacy of the dual - bronchodilator QVA149 ( indacaterol maleate / glycopyrronium bromide ) and showed a superior effect on lung function and patient - reported outcomes versus comparators [ 1,2,6 ] .", "label": "", "metadata": {}, "score": "66.40379"}
{"text": "One recent meta - analysis of inhaled anticholinergics found modest reductions in exacerbations , hospitalizations , and death with the use of this agent .16", "label": "", "metadata": {}, "score": "66.42424"}
{"text": "PubMed View Article .Hochrainer D , Holz H , Kreher C , Scaffidi L , Spallek M , Wachtel H : Comparison if the aerosol velocity and spray duration of Respimat \u00ae Soft Mist \u2122 Inhaler and pressurized metered dose inhalers .", "label": "", "metadata": {}, "score": "66.443954"}
{"text": "Studies to date with twice - daily LABAs indicate that a minority of patients achieve clinically relevant improvements in dyspnea or health - related quality of life , based on current validated thresholds [ 21 , 73 ] .", "label": "", "metadata": {}, "score": "66.46442"}
{"text": "Exercise tolerance .There are fewer studies investigating the effect of LABAs on exercise tolerance .Two 12-week studies found no significant difference in distance covered in the incremental shuttle walking test with formoterol 18 \u03bcg twice daily via Turbuhaler compared with placebo [ 32 , 51 ] .", "label": "", "metadata": {}, "score": "66.5099"}
{"text": "We read with disappointment the first recommendation of these recently published guidelines which state \" Spirometry should not be used to screen for airflow obstruction in individuals without respiratory symptoms \" ( 1 ) .", "label": "", "metadata": {}, "score": "66.545746"}
{"text": "Tiotropium 's cost - effectiveness for the treatment of COPD : a cost - utility analysis under real - world conditions .Mattias Neyt Belgian Health Care Knowledge Centre KCE , Brussels , Belgium BMC Pulm Med 10:47 .", "label": "", "metadata": {}, "score": "66.65262"}
{"text": "In our study the cost for an exacerbation not requiring hospitalisation was on average \u20ac 52.72 and the COPD - related hospitalisation cost was \u20ac 5617 .", "label": "", "metadata": {}, "score": "66.67647"}
{"text": "The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease .C Verkindre Centre Hospitalier Germon et Gauthier , Bethune , France Respiration 73:420 - 7 .", "label": "", "metadata": {}, "score": "66.732895"}
{"text": "In addition , we did not update the search for the utility of supplemental oxygen for patients with COPD who have awake , resting hypoxemia because widespread consensus remains on this issue .", "label": "", "metadata": {}, "score": "66.744125"}
{"text": "Recommendation 1 : ACP , ACCP , ATS , and ERS recommend that spirometry should be obtained to diagnose airflow obstruction in patients with respiratory symptoms ( Grade : strong recommendation , moderate - quality evidence ) .", "label": "", "metadata": {}, "score": "66.77795"}
{"text": "PubMed View Article PubMed Central .La Vecchia C , Fabbri LM : Prevention of death in COPD ( letter ) .New Engl J Med 2007 , 356 : 2211 - 2 .", "label": "", "metadata": {}, "score": "66.78885"}
{"text": "Primary and secondary outcome measures Incidence rates of total stroke , myocardial infarction , angina and other adverse events .Conclusion Small increased risks of serious ischaemic cardiovascular events have been reported with inhaled anticholinergic medication from randomised and nonrandomized studies of ipratropium , tiotropium HandiHaler \u00ae and tiotropium Respimat \u00ae .", "label": "", "metadata": {}, "score": "66.80107"}
{"text": "The evidence reviewed for the 2007 ACP guideline showed no beneficial effect of treatment of asymptomatic persons , with or without risk factors for airflow obstruction , to prevent future respiratory symptoms or reduce subsequent decline in lung function .", "label": "", "metadata": {}, "score": "66.87714"}
{"text": "Further , initial data from a single study suggests LABA / LAMA combinations may provide superior bronchodilator efficacy compared with LABA / ICS , at least in moderate COPD [ 146 ] ; however , this was a short - term ( 6 weeks ) study and did not assess possible differences in patient - reported outcomes .", "label": "", "metadata": {}, "score": "67.020035"}
{"text": "Targeted use of spirometry for diagnosis of airflow obstruction is beneficial for patients with respiratory symptoms , particularly dyspnea .Existing evidence does not support the use of spirometry to screen for airflow obstruction in individuals without respiratory symptoms , including those with current or past exposure to risk factors for COPD .", "label": "", "metadata": {}, "score": "67.16944"}
{"text": "PubMed .Anthonisen NR , Connett JE , Kiley JP , Altose MD , Bailey WC , Buist AS . et al .Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 .", "label": "", "metadata": {}, "score": "67.44438"}
{"text": "PubMed .Anthonisen NR , Connett JE , Kiley JP , Altose MD , Bailey WC , Buist AS . et al .Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 .", "label": "", "metadata": {}, "score": "67.44438"}
{"text": "PubMed .Pardee NE , Winterbauer RH , Morgan EH , Allen JD , Olson DE .Combinations of four physical signs as indicators of ventilatory abnormality in obstructive pulmonary syndromes .", "label": "", "metadata": {}, "score": "67.44705"}
{"text": "PubMed .Pardee NE , Winterbauer RH , Morgan EH , Allen JD , Olson DE .Combinations of four physical signs as indicators of ventilatory abnormality in obstructive pulmonary syndromes .", "label": "", "metadata": {}, "score": "67.44705"}
{"text": "The choice between \u03b22-agonists , anticholinergics , methylxanthines , or combination therapy depends on availability and individual response in terms of symptom relief and side effects .", "label": "", "metadata": {}, "score": "67.5107"}
{"text": "First , we consider the entire body of evidence pertaining to class effects , and we consider each study on its merits .In particular , studies should not be disregarded merely because they are not randomised 19 - 21 29 or they include an another medication as a control group instead of a placebo group .", "label": "", "metadata": {}, "score": "67.6534"}
{"text": "Bronchitis , cough , dyspnea , headache , nausea , pain , URTI .Inhaled corticosteroid / long - acting agonist ( fluticasone / beta 2 salmeterol inhaled [ Advair Diskus ] : 100/50 , 250/50 , or 500/50 mcg per puff ) .", "label": "", "metadata": {}, "score": "67.72006"}
{"text": "Bronchitis , cough , dyspnea , headache , nausea , pain , URTI .Inhaled corticosteroid / long - acting agonist ( fluticasone / beta 2 salmeterol inhaled [ Advair Diskus ] : 100/50 , 250/50 , or 500/50 mcg per puff ) .", "label": "", "metadata": {}, "score": "67.72006"}
{"text": "LABAs are associated with known class effects , the most significant being related to cardiac safety [ 1 ] .Finally , consideration should be given to the delivery of any new molecule , ensuring the inhaler device is appropriate to the COPD patient .", "label": "", "metadata": {}, "score": "67.72249"}
{"text": "Unfortunately , accurate utility ( or disutility ) scores for events on which tiotropium may have an impact , i.e. exacerbations and exacerbation - related hospitalizations , are still lacking .", "label": "", "metadata": {}, "score": "67.81887"}
{"text": "Of course , the impact depends on the combination of the baseline risk for an event , the treatment effect and its costs .Most economic evaluations used a 1-year timeframe and assumed tiotropium had no influence on mortality .", "label": "", "metadata": {}, "score": "67.83952"}
{"text": "Inhaled corticosteroids may be added to bronchodilator treatment in patients with severe COPD and a history of repeated exacerbations .No one long - acting bronchodilator is recommended over another in management guidelines [ 1 ] , because few studies have specifically compared different LABAs [ 19 , 20 ] .", "label": "", "metadata": {}, "score": "67.84197"}
{"text": "View Article PubMed .Yusuf S , Wittes J , Probstfield J , Tyroler HA : Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials .", "label": "", "metadata": {}, "score": "67.91562"}
{"text": "Improvements in symptom - limited exercise performance over 8 h with once - daily tiotropium in patients with COPD .Francois Maltais Centre de Recherche , Hopital Laval , Institut Universitaire de Cardiologie et de Pneumologie de l Universite Laval , 725 Chemin Ste Foy , Quebec , QC , G1V 4G5 , Canada Chest 128:1168 - 78 .", "label": "", "metadata": {}, "score": "68.015854"}
{"text": "Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD .K M C Verhamme Department of Medical Informatics , Erasmus MC , Rotterdam , The Netherlands Pulm Pharmacol Ther 25:19 - 26 .", "label": "", "metadata": {}, "score": "68.038315"}
{"text": "Clinicians should base selection of treatment from among various monotherapies on individual patient preferences , cost , and adverse effect profile .Many symptomatic patients with stable COPD and an FEV 1 less than 60 % predicted may benefit from combination therapy , but when to use combination therapy instead of monotherapy has not been clearly established .", "label": "", "metadata": {}, "score": "68.09374"}
{"text": "\u03b2 2 -agonists are widely used in the management of COPD , either alone or in combination with other bronchodilators , corticosteroids , or both .", "label": "", "metadata": {}, "score": "68.10295"}
{"text": "QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD : the ENLIGHTEN study .[ ERS abstract 853405 ; Session 315 ; Date : September 03 , 2012 Time : 14:45 - 16:45 .", "label": "", "metadata": {}, "score": "68.12193"}
{"text": "Gastrointestinal side effects were more common with theophylline .An additional comparison of theophylline and long - acting beta 2 agonists demonstrated superiority of the long - acting beta 2 agonists over theophylline in patient - oriented outcomes and physiologic measures , and again showed the lack of benefit with theophylline in quality of life and in exacerbation occurrence .", "label": "", "metadata": {}, "score": "68.12757"}
{"text": "PubMed .Tashkin DP , Celli B , Senn S , Burkhart D , Kesten S , Menjoge S , et al .UPLIFT Study Investigators .", "label": "", "metadata": {}, "score": "68.23578"}
{"text": "PubMed .Tashkin DP , Celli B , Senn S , Burkhart D , Kesten S , Menjoge S , et al .UPLIFT Study Investigators .", "label": "", "metadata": {}, "score": "68.23578"}
{"text": "For the latter , assumptions had to be made due to a lack of evidence .Further research on the impact of exacerbations on a patient 's QoL ( measured with a generic instrument useful for economic evaluations ) would be interesting .", "label": "", "metadata": {}, "score": "68.243835"}
{"text": "Please also indicate any funding received in support of this work .The information will be posted with your response .Characterizing COPD Solely on Basis of Single Spirometric Measurement ?", "label": "", "metadata": {}, "score": "68.43477"}
{"text": "R Casaburi Harbor UCLA Research and Education Institute Dr Casaburi , Torrance , CA 90509 , USA Chest 118:1294 - 302 .To compare the bronchodilator efficacy and safety of tiotropium and placebo ... .", "label": "", "metadata": {}, "score": "68.614426"}
{"text": "Table 2 presents the cost - effectiveness of tiotropium depending on the initial number of exacerbations and/or hospitalisations .It shows that the number of hospitalisations in particular determines tiotropium 's cost - effectiveness .", "label": "", "metadata": {}, "score": "68.70331"}
{"text": "Evidence from 1 RCT showed no benefit of spirometry in achieving smoking cessation success at 6 , 12 , or 24 months of follow - up ( 20 ) .", "label": "", "metadata": {}, "score": "68.716644"}
{"text": "Inhaled corticosteroids should be used to reduce the frequency of COPD exacerbations , but they are not useful for symptom control .Systematic review of RCTs There is inconsistent evidence for reduction in FEV 1 with inhaled steroids .", "label": "", "metadata": {}, "score": "68.754364"}
{"text": "Inhaled corticosteroids should be used to reduce the frequency of COPD exacerbations , but they are not useful for symptom control .Systematic review of RCTs There is inconsistent evidence for reduction in FEV 1 with inhaled steroids .", "label": "", "metadata": {}, "score": "68.754364"}
{"text": "Monotherapy with a long - acting inhaled agent ( long - acting anticholinergic , long - acting \u03b2 - agonist , or corticosteroid ) was superior to placebo or short - acting anticholinergic therapy in reducing exacerbations .", "label": "", "metadata": {}, "score": "68.832214"}
{"text": "Therefore , combined ipratropium and albuterol should be used for the treatment of bronchospasm associated with COPD in patients who require more than one bronchodilator .", "label": "", "metadata": {}, "score": "68.83247"}
{"text": "Another lost opportunity would be in identifying smokers most at risk of lung cancer ( 3 ) at a time when CT - based screening for lung cancer appears to show a significant survival benefit ( 4 ) .", "label": "", "metadata": {}, "score": "68.83436"}
{"text": "If we abandon spirometric screening of asymptomatic smokers we will lose this opportunity , as we and others have shown reduced FEV1 confers a 6 fold greater risk of lung cancer compared to smokers with normal lung function ( 5 ) .", "label": "", "metadata": {}, "score": "68.98079"}
{"text": "View Article PubMed .Andersson I , Johansson K , Larsson S , Pehrsson K : Long - term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD .", "label": "", "metadata": {}, "score": "68.99138"}
{"text": "Given the general trend for twice - daily LABAs to provide improved lung function and more consistent symptom control compared with shorter - acting comparators ( Table 2 ) , one could argue that a longer duration of action is desirable in COPD [ 80 ] .", "label": "", "metadata": {}, "score": "69.04739"}
{"text": "Conclusion .This is the first economic evaluation that tries to calculate tiotropium 's cost - effectiveness for a population treated in every - day practice .", "label": "", "metadata": {}, "score": "69.06751"}
{"text": "Improvements in lung function were sustained in studies of 3 months to 3 years ' duration when twice - daily LABAs were used as maintenance therapy [ 28 - 31 , 46 , 48 , 51 , 52 ] .", "label": "", "metadata": {}, "score": "69.07678"}
{"text": "The INSPIRE study : influence of prior use and discontinuation of inhaled corticosteroids .Stephan F Lanes Am J Respir Crit Care Med 178:543 - 4 ; author reply 544 .", "label": "", "metadata": {}, "score": "69.121666"}
{"text": "Welte T et al .QVA149 once daily is safe and well tolerated in patients with COPD : the SHINE study .[ ATS abstract 41616 ; Session A43 ; Date : May 19 , 2013 , 8:15 - 16.30].", "label": "", "metadata": {}, "score": "69.142456"}
{"text": "( February 12 ) .Blogroll .Archives .Novartis continues to build its COPD pipeline and presents new data on investigational once - daily QVA149 at ERS .", "label": "", "metadata": {}, "score": "69.16664"}
{"text": "Clinical safety .There is clear consensus with regard to the central role of inhaled bronchodilators as the standard of care in COPD patients .However , recent concerns have been raised suggesting that LABA use could lead to an increased risk of respiratory death in patients with asthma .", "label": "", "metadata": {}, "score": "69.18558"}
{"text": "Non - randomized studies must always be concerned with possible bias arising from differences in baseline risks between treatment groups .We used propensity scores and multivariate models to control efficiently for available risk factors .", "label": "", "metadata": {}, "score": "69.25821"}
{"text": "However , results of other studies did not support this benefit ; the average change in respiratory symptoms was below a clinically noticeable threshold , and adverse events were increased ( 6 ) .", "label": "", "metadata": {}, "score": "69.352135"}
{"text": "Muscarinic antagonists ( X ) block M 3 receptors to prevent binding of acetylcholine ( ACh ) , indirectly stimulating smooth muscle relaxation via inhibition of bronchoconstriction .", "label": "", "metadata": {}, "score": "69.40614"}
{"text": "Brussels : Belgian Health Care Knowledge Centre ( KCE ) ; 2008 .Assmann SF , Pocock SJ , Enos LE , Kasten LE : Subgroup analysis and other ( mis)uses of baseline data in clinical trials .", "label": "", "metadata": {}, "score": "69.62759"}
{"text": "Many patients find COPD symptoms really tough to cope with - even if they 're already taking treatment , \" said Tim Wright , Global Head of Development , Novartis . \" Novartis is pleased that these new analyses further support the efficacy of dual therapy , which has the potential to make a real difference to peoples ' lives .", "label": "", "metadata": {}, "score": "69.7225"}
{"text": "In addition , analyses were stratified by respiratory diagnostic status ( COPD and asthma , COPD without asthma , other ) , use of oral corticosteroids and history of coronary artery disease .", "label": "", "metadata": {}, "score": "69.78825"}
{"text": "A LABA with a 24-hour duration of action could provide improvements in efficacy , compared with twice - daily LABAs , and the once - daily dosing regimen could help improve compliance .", "label": "", "metadata": {}, "score": "69.82243"}
{"text": "T J Witek Respiratory Development and Operations , Boehringer Ingelheim GmbH Ingelheim am Rhein , Germany Eur Respir J 21:267 - 72 .Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease : systematic review and meta - analysis of randomised controlled trials .", "label": "", "metadata": {}, "score": "69.82898"}
{"text": "( 3 ) Rabe KF . , Hurd S. , Anzueto A et al Global Initiative for Chronic Obstructive Lung Disease .Global Strategy for the diagnosis , management , and prevention of chronic obstructive pulmonary disease : Gols executive summary Am J Respir Crit Care Med 2007;176:532 - 555 .", "label": "", "metadata": {}, "score": "69.95624"}
{"text": "All authors approved the final version .Funding Boehringer Ingelheim Pharmaceuticals .Competing interests Dr MJ is employed by Acorda Therapeutics , Hawthorne , NY .", "label": "", "metadata": {}, "score": "69.9902"}
{"text": "Details of the search strategy are available in the full HTA report [ 2 ] .Eight full economic evaluations of tiotropium were identified , all published after 2004 .", "label": "", "metadata": {}, "score": "70.0391"}
{"text": "COPD sufferers know the symptoms all too well : the phlegmy cough , gasping wheezy breaths , and chest tightness that signal an exacerbation .Guidelines recommend inhaled long - acting bronchodilators - either an anticholinergic or a \u03b2 2 -agonist - to mitigate symptoms and reduce the frequency of these exacerbations in patients with moderate to severe disease .", "label": "", "metadata": {}, "score": "70.10275"}
{"text": "It was hypothesised that the increased risk of deaths , which were mostly cardiac and sudden or unexplained deaths , may be the result of the device delivering a greater dose than the powder formulation .", "label": "", "metadata": {}, "score": "70.14648"}
{"text": "Author details .SGAW : .Specific Airway Conductance .SMART : .Salmeterol Multicentre Asthma Research Trial .SGRQ : .St. George 's Respiratory Questionnaire .", "label": "", "metadata": {}, "score": "70.209854"}
{"text": "d : using the published 95%CI to define our distribution results in the following mean values in the model : 85.85 % instead of 86 % and 93.67 % instead of 94 % .", "label": "", "metadata": {}, "score": "70.22303"}
{"text": "Chest .Liesker JJ , Wijkstra PJ , Ten Hacken NH , Koeter GH , Postma DS , Kerstjens HA .A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD .", "label": "", "metadata": {}, "score": "70.27223"}
{"text": "Symptomatic patients with FEV 1 less than 60 % predicted will benefit from inhaled treatments ( anticholinergics , long - acting \u03b2 - agonists , or corticosteroids ) .", "label": "", "metadata": {}, "score": "70.295586"}
{"text": "Tiotropium may avoid exacerbations and exacerbation - related hospitalisations .Next to changes in costs , this also entails changes in utilities .Therefore , for both exacerbations and exacerbation - related hospitalisations QoL data were gathered .", "label": "", "metadata": {}, "score": "70.34451"}
{"text": "Two studies were trial - based economic evaluations [ 18 , 19 ] .The US studies were deterministic [ 21 ] or probabilistic [ 22 ] simulations using aggregated data depicting a typical COPD patient .", "label": "", "metadata": {}, "score": "70.48487"}
{"text": "PubMed .Drummond MB , Dasenbrook EC , Pitz MW , Murphy DJ , Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "70.75128"}
{"text": "PubMed .Drummond MB , Dasenbrook EC , Pitz MW , Murphy DJ , Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "70.75128"}
{"text": "Absence of electrocardiographic findings and improved function with once - daily tiotropium in patients with chronic obstructive pulmonary disease .Henry Covelli Pulmonary Consultants of North Idaho , Coeur d Alene , Idaho 83814 , USA Pharmacotherapy 25:1708 - 18 .", "label": "", "metadata": {}, "score": "70.87166"}
{"text": "Nevertheless , the referenced papers to support these figures do not mention such data .It would be interesting if researchers try to measure the impact of these events on QoL ( in complement to measuring QoL on pre - specified points in time , since these events may occur in between ) .", "label": "", "metadata": {}, "score": "70.893265"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : January 9 , 2006 ) .Secondary efficacy endpoints were : incidence , severity and duration of exacerbations number of patients with one or more exacerbation rate of PEFR drops number of lost working days number of days of hospitalisation use of rescue medication , etc .", "label": "", "metadata": {}, "score": "70.93292"}
{"text": "Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium .Cristoforo Incorvaia Pulmonary Rehabilitation Unit , ICP Hospital , Milan , Italy Int J Chron Obstruct Pulmon Dis 3:123 - 6 .", "label": "", "metadata": {}, "score": "70.9422"}
{"text": "The decision to prescribe an anticholinergic versus a beta - agonist remains nuanced , notes NEJM editor - in - chief Dr. Jeffrey Drazen .\"", "label": "", "metadata": {}, "score": "70.99469"}
{"text": "PubMed View Article .Casaburi R : Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions .", "label": "", "metadata": {}, "score": "71.02899"}
{"text": "Data showed that investigational QVA149 significantly improved bronchodilation providing a rapid onset within five minutes , and sustained bronchodilation during a 24-hour period which was maintained for up to 26 weeks 19 .", "label": "", "metadata": {}, "score": "71.061325"}
{"text": "Chest .Rossi A , Kristufek P , Levine BE , Thomson MH , Till D , Kottakis J , et al . , for the Formoterol in Chronic Obstructive Pulmonary Disease ( FICOPD ) II Study Group .", "label": "", "metadata": {}, "score": "71.07745"}
{"text": "Results showed that both interventions produced similar improvements in the dyspnea domain of the Chronic Respiratory Questionnaire and total score on St. George 's Respiratory Questionnaire .", "label": "", "metadata": {}, "score": "71.10022"}
{"text": "Does tiotropium lower exacerbation and hospitalization frequency in COPD patients : results of a meta - analysis .Ann Van den Bruel Belgian Health Care Knowledge Centre KCE , Brussels , Belgium BMC Pulm Med 10:50 .", "label": "", "metadata": {}, "score": "71.21299"}
{"text": "Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD .V Brusasco Facolta di Medicina e Chirurgia , Universita di Genova , Genova , Italy Thorax 58:399 - 404 .", "label": "", "metadata": {}, "score": "71.2408"}
{"text": "The choice therefore depends on availability and the response of the individual patient [ 1 ] .Inhaled therapy is preferred to oral therapy , in light of the greater risk of systemic side effects with oral beta - agonists and the unfavorable safety profile of oral methylxanthines .", "label": "", "metadata": {}, "score": "71.25362"}
{"text": "It represents an update of the 2007 ACP clinical practice guideline on diagnosis and management of stable chronic obstructive pulmonary disease ( COPD ) and is intended for clinicians who manage patients with COPD .", "label": "", "metadata": {}, "score": "71.33472"}
{"text": "PubMed View Article .Celli BR , MacNee W , committee members : Standards for the diagnosis and treatment of patients with COPD : a summary of the ATS / ERS position paper .", "label": "", "metadata": {}, "score": "71.34135"}
{"text": "Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease : systematic review with meta - analysis .Gustavo J Rodrigo Departamento de Emergencia , Hospital Central de las Fuerzas Armadas , Av 8 de octubre 3020 , Montevideo 11600 , Uruguay Respir Med 103:1421 - 9 .", "label": "", "metadata": {}, "score": "71.36125"}
{"text": "Several studies made assumptions on the QoL deterioration .A reduction of 15 % in QoL for one month after a ( moderate ) exacerbation and 50 % or 70 % for a severe exacerbation ( requiring hospitalisation ) was assumed , [ 10 - 13 ] or a relative ratio of 3.33 or 4.67 .", "label": "", "metadata": {}, "score": "71.376236"}
{"text": "Cost - utility analysis of indacaterol in Germany : a once - daily maintenance bronchodilator for patients with COPD .David Price Centre of Academic Primary Care , University of Aberdeen , Foresterhill Health Centre , Westburn Road , Aberdeen AB25 2AY , UK Respir Med 105:1635 - 47 .", "label": "", "metadata": {}, "score": "71.46042"}
{"text": "Impact of frequency of COPD exacerbations on pulmonary function , health status and clinical outcomes .A Anzueto Audie L Murphy Division , The University of Texas Health Science Center at San Antonio , Texas , USA Int J Chron Obstruct Pulmon Dis 4:245 - 51 .", "label": "", "metadata": {}, "score": "71.5585"}
{"text": "Improves symptoms and quality of life and decreases exacerbations , hospitalizations , and deaths 6 , 7 .Tiotropium ( Spiriva ) .Angioedema , bronchospasm ( paradoxical ) , glaucoma , hypersensitivity reaction .", "label": "", "metadata": {}, "score": "71.576065"}
{"text": "[ PMID : 19160250 ] .Geddes EL , O'Brien K , Reid WD , Brooks D , Crowe J. Inspiratory muscle training in adults with chronic obstructive pulmonary disease : an update of a systematic review .", "label": "", "metadata": {}, "score": "71.61577"}
{"text": "[ PMID : 19160250 ] .Geddes EL , O'Brien K , Reid WD , Brooks D , Crowe J. Inspiratory muscle training in adults with chronic obstructive pulmonary disease : an update of a systematic review .", "label": "", "metadata": {}, "score": "71.61577"}
{"text": "Nevertheless , these patients are also included in the Belgian reimbursement modalities for tiotropium .This can be very determining for the results of an economic evaluation .", "label": "", "metadata": {}, "score": "71.67083"}
{"text": "New ultra - LABAs have the potential to improve outcomes for COPD patients , both alone ( providing an alternative to the only once - daily muscarinic antagonist bronchodilator currently available ) or in combination .", "label": "", "metadata": {}, "score": "71.69464"}
{"text": "The results for angina , MI and stroke reported here and in other studies of inhaled anticholinergic drugs are usually not statistically significant .The absence of statistical significance in studies that lack the power to detect small effects should be expected and does not indicate the absence of an effect .", "label": "", "metadata": {}, "score": "71.72906"}
{"text": "PubMed View Article .Witek TJ Jr , Mahler DA : Meaningful effect size and patterns of response of the Transition Dyspnea Index .J Clin Epidemiol 2003 , 56 : 248 - 55 .", "label": "", "metadata": {}, "score": "71.74249"}
{"text": "10 11 Both long - acting bronchodilators are indicated for treating symptoms of COPD ; LABAs are also indicated for the treatment of asthma .The source population included patients in the UK enrolled with a general practitioner who contributes to The Health Improvement Network ( THIN ) primary care database .", "label": "", "metadata": {}, "score": "71.81096"}
{"text": "The literature showed that combinations of findings in the history and clinical examination were more helpful than a single finding for predicting the presence or absence of airflow obstruction ( 10 - 15 ) .", "label": "", "metadata": {}, "score": "71.8228"}
{"text": "There were no differences between monotherapy and combination therapy in the overall rates of exacerbations , exacerbations requiring hospitalization , the percentage of patients who had at least 1 exacerbation , or mean change in FEV 1 at 2 years .", "label": "", "metadata": {}, "score": "71.93676"}
{"text": "Soft - mist inhalers are also less technique - dependent than metered - dose inhalers [ 112 ] , and may hold promise for future delivery of LABAs alone or in combination with other agents .", "label": "", "metadata": {}, "score": "72.01407"}
{"text": "In addition , LABAs have an acceptable safety profile , and are not associated with an increased risk of respiratory mortality , although adverse effects such as palpitations and tremor may limit the dose that can be tolerated .", "label": "", "metadata": {}, "score": "72.045944"}
{"text": "The study was funded by Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield , CT .Two of the authors ( MJ and SL ) were employees of Boehringer Ingelheim at the time the study was conducted .", "label": "", "metadata": {}, "score": "72.04912"}
{"text": "32 Similarly , a Cochrane review identified 27 RCTs that showed better endurance and exercise capacity with the use of supplemental oxygen in participants who had moderate to severe COPD .", "label": "", "metadata": {}, "score": "72.075714"}
{"text": "In addition , patient adherence to treatment plans is a major obstacle to successful COPD management , especially since it is likely that patients will also be on a range of medications for comorbidities .", "label": "", "metadata": {}, "score": "72.09111"}
{"text": "PubMed .Eaton T , Garrett JE , Young P , Fergusson W , Kolbe J , Rudkin S. et al .Ambulatory oxygen improves quality of life of COPD patients : a randomised controlled study .", "label": "", "metadata": {}, "score": "72.12979"}
{"text": "PubMed .Eaton T , Garrett JE , Young P , Fergusson W , Kolbe J , Rudkin S. et al .Ambulatory oxygen improves quality of life of COPD patients : a randomised controlled study .", "label": "", "metadata": {}, "score": "72.12979"}
{"text": "12Another study found improvements in post - dose FEV 1 but no improvement in quality of life .There is growing evidence that the use of beta 2 -agonist therapy is not without harm and may be associated with increased cardiovascular events .", "label": "", "metadata": {}, "score": "72.14699"}
{"text": "Beeh et al .QVA149 once daily improves exercise tolerance and lung function in patients with COPD : the BRIGHT study .[ BTS Winter Meeting 2012 ,", "label": "", "metadata": {}, "score": "72.23331"}
{"text": "However , in this analysis , mortality is influenced when comparing the three treatment arms due to different transition probabilities between the disease states for the alternative treatments .", "label": "", "metadata": {}, "score": "72.27588"}
{"text": "Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Measure of the Long Term Influence of SPIRIVA \u00ae in Acute Respiratory Disorders .", "label": "", "metadata": {}, "score": "72.30426"}
{"text": "This deterioration and improvement in QoL was included in our model for exacerbation - related hospitalisations .A correlation of 0.9 was implemented between the value at admission and discharge to avoid increases of more than 1.1584 ( i.e. the maximum difference according to the Flemish EQ-5 D utility scale ) in our probabilistic model .", "label": "", "metadata": {}, "score": "72.309296"}
{"text": "12 The database is derived from the same software as the General Practice Research Database and has been validated for COPD , as well as stroke and MI , and is widely used in epidemiologic research .", "label": "", "metadata": {}, "score": "72.3295"}
{"text": "PubMed View Article PubMed Central .Au DH , Udris EM , Fan VS , Curtis JR , McDonell MB , Fihn SD : Risk of mortality and heart failure exacerbations associated with inhaled \u03b2 - adrenoceptor agonists among patients with known left ventricular systolic dysfunction .", "label": "", "metadata": {}, "score": "72.35065"}
{"text": "Shortness of breath and wheezing can be alleviated with the use of combined ipratropium and albuterol ( Combivent ) administered via a metered - dose inhaler .", "label": "", "metadata": {}, "score": "72.40797"}
{"text": "Currently , evidence does not support the use of spirometry as a screening strategy for airflow obstruction in persons without respiratory symptoms , even in the presence of risk factors .", "label": "", "metadata": {}, "score": "72.44076"}
{"text": "View Article .Bourbeau J , Bartlett SJ : Patient adherence in COPD .Thorax 2008 , 63 : 831 - 8 .PubMed View Article .", "label": "", "metadata": {}, "score": "72.50571"}
{"text": "Studies using the sensitive measure of submaximal exercise testing suggest there is a beneficial effect on exercise tolerance , although data are limited in this area .", "label": "", "metadata": {}, "score": "72.53452"}
{"text": "Preclinical studies with olodaterol suggested a potential for once - daily dosing in humans , along with a rapid onset of action and a favorable safety profile [ 130 , 131 ] .", "label": "", "metadata": {}, "score": "72.58476"}
{"text": "PubMed .Troosters T , Gosselink R , Decramer M. Short- and long - term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease : a randomized trial .", "label": "", "metadata": {}, "score": "72.60668"}
{"text": "PubMed .Troosters T , Gosselink R , Decramer M. Short- and long - term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease : a randomized trial .", "label": "", "metadata": {}, "score": "72.60668"}
{"text": "Methods .The basic idea is to use the strengths of both observational and RCT data .RCTs are the ideal method for measuring treatment effects .", "label": "", "metadata": {}, "score": "72.612946"}
{"text": "Banerji D et al .Once - daily NVA237 improves lung function in COPD patients : pooled results of the GLOW1 and GLOW2 studies .[ ERS abstract 853239 ; Session 245 ; Date : September 03 , 2012 Time : 12:50 - 14:40 .", "label": "", "metadata": {}, "score": "72.6689"}
{"text": "In the absence of published evidence on a difference in relative treatment effect between subgroups , this may be seen as a realistic assumption .Decision model .", "label": "", "metadata": {}, "score": "72.67973"}
{"text": "One study showed no difference at 36-month follow - up among individuals who received annual spirometry results in addition to smoking cessation information and advice and individuals who received spirometry results only at baseline and at year 3 ( 22 ) .", "label": "", "metadata": {}, "score": "72.73428"}
{"text": "IGNITE Phase III clinical trial program , and the glycopyrronium bromide ( Seebri \u00ae Breezhaler \u00ae ) GLOW Phase III clinical trial program .Among the data presented , three new studies from the investigational QVA149 IGNITE Phase III clinical trial program ( SHINE , ILLUMINATE and ENLIGHTEN ) demonstrated that QVA149 significantly improved lung function compared to other COPD therapies [ 1,2,6 ] .", "label": "", "metadata": {}, "score": "72.73529"}
{"text": "The latter shows that the treatment can only be considered cost effective at relatively very high willingness - to - pay values .The results are most sensitive to the treatment effect on hospitalisations ( correlation coefficient 0.671 ) .", "label": "", "metadata": {}, "score": "72.796844"}
{"text": "Small airways ventilation heterogeneity and hyperinflation in COPD : response to tiotropium bromide .Sylvia Verbanck Respiratory Division , University Hospital Brussels , Belgium Int J Chron Obstruct Pulmon Dis 2:625 - 34 .", "label": "", "metadata": {}, "score": "72.800476"}
{"text": "There is no difference in the annual rate of FEV 1 decline or prevention of symptoms in these individuals with treatment .No evidence from RCTs supports treating asymptomatic individuals , with or without risk factors for airflow obstruction , who do not have spirometric evidence of airflow obstruction .", "label": "", "metadata": {}, "score": "72.8009"}
{"text": "PubMed .Chaouat A , Weitzenblum E , Kessler R , Charpentier C , Enrhart M , Schott R. et al .A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients .", "label": "", "metadata": {}, "score": "72.9048"}
{"text": "PubMed .Chaouat A , Weitzenblum E , Kessler R , Charpentier C , Enrhart M , Schott R. et al .A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients .", "label": "", "metadata": {}, "score": "72.9048"}
{"text": "Tiotropium versus placebo for chronic obstructive pulmonary disease .Charlotta Karner Population Health Sciences and Education , St George s , University of London , London , UK Cochrane Database Syst Rev 7:CD009285 .", "label": "", "metadata": {}, "score": "73.11004"}
{"text": "Oba Y : Cost - effectiveness of long - acting bronchodilators for chronic obstructive pulmonary disease .Mayo Clin Proc 2007 , 82 : 575 - 582 .", "label": "", "metadata": {}, "score": "73.1702"}
{"text": "By not screening high risk individuals , such as chronic asymptomatic smokers , we are loosing the opportunity for a teachable moment , which demonstrates to smokers their inherent susceptibility and irreversible \" end - organ damage \" .", "label": "", "metadata": {}, "score": "73.29773"}
{"text": "Ann Intern Med .PubMed . van Wetering CR , Hoogendoorn M , Mol SJ , Rutten - vanMo\u0308lken MP , Schols AM . Short- and long - term efficacy of a community - based COPD management programme in less advanced COPD : a randomised controlled trial .", "label": "", "metadata": {}, "score": "73.35044"}
{"text": "Ann Intern Med .PubMed . van Wetering CR , Hoogendoorn M , Mol SJ , Rutten - vanMo\u0308lken MP , Schols AM . Short- and long - term efficacy of a community - based COPD management programme in less advanced COPD : a randomised controlled trial .", "label": "", "metadata": {}, "score": "73.35044"}
{"text": "PubMed .Lung Health Study Research Group .Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease .N Engl J Med .", "label": "", "metadata": {}, "score": "73.36073"}
{"text": "PubMed .Lung Health Study Research Group .Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease .N Engl J Med .", "label": "", "metadata": {}, "score": "73.36073"}
{"text": "A combination of findings was more helpful for diagnosing airflow obstruction than was any individual sign , symptom , or piece of historical information .The combination of all 3 of the following items - patient - reported smoking history greater than 55 pack - years , wheezing on auscultation , and patient self - reported wheezing - almost assures the presence of airflow obstruction ( LR , 156 ) .", "label": "", "metadata": {}, "score": "73.38329"}
{"text": "Muscarinic receptor signaling in the pathophysiology of asthma and COPD .Reinoud Gosens Department of Molecular Pharmacology , University of Groningen , Groningen , The Netherlands Respir Res 7:73 .", "label": "", "metadata": {}, "score": "73.46626"}
{"text": "Although some patients who were studied had an FEV 1 greater than 60 % predicted , the mean FEV 1 of the included patients has been 60 % predicted or less for most COPD treatment trials .", "label": "", "metadata": {}, "score": "73.51573"}
{"text": "References .( 1)Garcia - Rio F. , Pino JM . , Dorgham A. , Alonso A. , Villamor J Spirometric reference equations for caucasian european women and men aged 65 - 86 years Eur Respir J 2004;24:397 - 405 .", "label": "", "metadata": {}, "score": "73.53482"}
{"text": "A recent study shows , for example , that frequent exacerbations may exist as a separate phenotype over a wide range of severity by spirometric criteria [ 1].", "label": "", "metadata": {}, "score": "73.61973"}
{"text": "One new trial ( 23 ) of at least 2 years ' duration in addition to the 2 trials reviewed for the 2007 guideline ( 24 , 31 ) provided information on respiratory health - related quality of life as measured by the St. George 's Respiratory Questionnaire .", "label": "", "metadata": {}, "score": "73.65955"}
{"text": "PubMed View Article PubMed Central .Am J Respir Crit Care Med 2008 , 178 : 332 - 8 .PubMed View Article .SLMT02 Italian Study Group .", "label": "", "metadata": {}, "score": "73.73974"}
{"text": "Nannini L , Cates CJ , Lasserson TJ , Poole P. Combined corticosteroid and long acting beta - agonist in one inhaler for chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "73.7486"}
{"text": "Key messages .Compared with LABA , tiotropium HandiHaler was associated with increased risks of angina , myocardial infarction and stroke and lower risk of total mortality .", "label": "", "metadata": {}, "score": "73.76707"}
{"text": "For rescue therapy , short - acting beta 2 agonists or combination anticholinergics with a short - acting beta 2 agonist should be used .Inhaled corticosteroids should be considered before initiating a long - acting beta 2 agonist .", "label": "", "metadata": {}, "score": "74.03053"}
{"text": "PubMed View Article .Rutten FH , Cramer MJ , Lammers JW , Grobbee DE , Hoes AW : Heart failure and chronic obstructive pulmonary disease : an ignored combination ?", "label": "", "metadata": {}, "score": "74.084236"}
{"text": "Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease .J A Van Noord Dept of Respiratory Diseases , Atrium Medical Centre , Heerlen , The Netherlands Eur Respir J 19:639 - 44 .", "label": "", "metadata": {}, "score": "74.08711"}
{"text": "Pooled analyses of results from trials of monotherapy show no statistically significant differences in outcomes among various monotherapies .However , some of the large recent trials have shown that different monotherapies may have a greater effect on certain outcomes .", "label": "", "metadata": {}, "score": "74.28053"}
{"text": "Suissa S , Ernst P , Vandemheen KL , Aaron SD : Methodological issues in therapeutic trials of COPD .Eur Respir J 2008 , 31 : 927 - 33 .", "label": "", "metadata": {}, "score": "74.361374"}
{"text": "3 Exposure to tobacco smoke is associated with an increased lifetime risk of developing COPD , 4 and preexisting asthma is associated with a 17-fold increase in that risk .", "label": "", "metadata": {}, "score": "74.37424"}
{"text": "View Article .Rhoden KJ , Meldrum LA , Barnes PJ : Inhibition of cholinergic neurotransmission in human airways by \u03b2 2 -adrenergic receptors .J Appl Physiol 1988 , 65 : 700 - 5 .", "label": "", "metadata": {}, "score": "74.50525"}
{"text": "The patients received treatment daily for 48 weeks ( 336 days ) .PEFR , as well as use of rescue medication and respiratory condition , were self - assessed by patients and recorded every morning on a graphical diary card every morning .", "label": "", "metadata": {}, "score": "74.53806"}
{"text": "This guideline update was developed through a joint collaboration among 4 organizations : the American College of Physicians ( ACP ) , American College of Chest Physicians ( ACCP ) , American Thoracic Society ( ATS ) , and European Respiratory Society ( ERS ) .", "label": "", "metadata": {}, "score": "74.64499"}
{"text": "Shannon Cope Mapi Consultancy , Boston , MA , USA BMC Pulm Med 12:29 .Tiotropium versus placebo for chronic obstructive pulmonary disease .Charlotta Karner Population Health Sciences and Education , St George s , University of London , London , UK Cochrane Database Syst Rev 7:CD009285 .", "label": "", "metadata": {}, "score": "74.76277"}
{"text": "Once - daily or twice - daily formoterol , added to tiotropium , are both better than tiotropium alone , but the published evidence suggests twice - daily formoterol is the best add - on option ... .", "label": "", "metadata": {}, "score": "74.84851"}
{"text": "Young RP , Hopkins R. Lung function predicts lung cancer .Eur Respir J 2010 ; 35 : 1421 - 22 .The National Lung Screening Trial Research Team .", "label": "", "metadata": {}, "score": "74.9134"}
{"text": "The costs , including both the NIHDI reimbursement and patient co - payment , were on average \u20ac 427.71 for tiotropium ( table 1 ) .", "label": "", "metadata": {}, "score": "74.93785"}
{"text": "Initial filings for regulatory approval are expected in Q4 2012 for Europe and Japan .US filing is expected at the end of 2014 .All Novartis COPD portfolio products are being developed for delivery via the Breezhaler \u00ae device , a single - dose dry powder inhaler ( SDDPI ) , which has low air flow resistance , making it suitable for patients with airflow limitation , such as COPD patients .", "label": "", "metadata": {}, "score": "75.000336"}
{"text": "PubMed .Parkes G , Greenhalgh T , Griffin M , Dent R. Effect on smoking quit rate of telling patients their lung age : the Step2quit randomised controlled trial .", "label": "", "metadata": {}, "score": "75.03856"}
{"text": "PubMed .Parkes G , Greenhalgh T , Griffin M , Dent R. Effect on smoking quit rate of telling patients their lung age : the Step2quit randomised controlled trial .", "label": "", "metadata": {}, "score": "75.03856"}
{"text": "The guideline panel evaluated the recommendations on the basis of the evidence .The Minnesota Evidence - based Practice Center performed an updated literature search that included studies from MEDLINE published between March 2007 and December 2009 .", "label": "", "metadata": {}, "score": "75.18989"}
{"text": "Drummond M , Sculpher M , Torrance G , O'Brien B , Stoddart G : Methods for the economic evaluation of health care programmes .Sectoraal Comit\u00e9 van de Sociale Zekerheid en van de Gezondheid - Afdeling Sociale Zekerheid : Beraadslaging nr .", "label": "", "metadata": {}, "score": "75.23298"}
{"text": "As mentioned by Drummond , \" The assumption of constant relative effects being applied to subgroup - specific baseline event rates is common in cost - effectiveness model .", "label": "", "metadata": {}, "score": "75.30046"}
{"text": "In the smoking cessation plus ipratropium group , ipratropium did not prevent the development of symptoms , regardless of the presence of airflow obstruction at baseline .", "label": "", "metadata": {}, "score": "75.31636"}
{"text": "This decision was partly based on the claims that the budget impact for the National Institute for Health and Disability Insurance ( NIHDI ) would be offset by cost savings due to less hospital admissions and less use of antibiotics and oral corticosteroids .", "label": "", "metadata": {}, "score": "75.48998"}
{"text": "Moreover , if we wait for symptoms before spirometry is offered , many smokers will have irreversibly lost as much as 50 % of their lung function ( 2 ) .", "label": "", "metadata": {}, "score": "75.631325"}
{"text": "Patients with end - stage disease and hypoxia should be given long - term oxygen therapy .Some patients have a response with theophylline use , but for most patients the risks outweigh the benefits .", "label": "", "metadata": {}, "score": "75.67252"}
{"text": "PubMed View Article .Eur J Heart Fail 2010 , in press .Cazzola M , Bettoncelli G , Sessa E , Cricelli C , Biscione G : Prevalence of comorbidities in patients with chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "75.73892"}
{"text": "Brichetto L , Song P , Crimi E , Rehder K , Brusasco V : Modulation of cholinergic responsiveness through the \u03b2 2 -adrenergic receptor signal transmission pathway in bovine trachealis .", "label": "", "metadata": {}, "score": "75.78964"}
{"text": "PubMed .Calverley PM , Anderson JA , Celli B , Ferguson GT , Jenkins C , Jones PW , et al .TORCH investigators .", "label": "", "metadata": {}, "score": "75.78995"}
{"text": "PubMed .Calverley PM , Anderson JA , Celli B , Ferguson GT , Jenkins C , Jones PW , et al .TORCH investigators .", "label": "", "metadata": {}, "score": "75.78995"}
{"text": "The guideline panel included representatives from each of the 4 collaborating organizations , and the resulting guideline represents an official and joint clinical practice guideline from those organizations .", "label": "", "metadata": {}, "score": "75.82032"}
{"text": "In this database , the first delivery of tiotropium to a patient can fall between March 1 , 2004 and December 31 , 2005 .As a result , the year before the first delivery can fall between March 1 , 2003 and December 31 , 2005 .", "label": "", "metadata": {}, "score": "75.864716"}
{"text": "Screening for Chronic Obstructive Pulmonary Disease Using Spirometry , Topic Page .March 2008 .U.S. Preventive Services Task Force .Krahn , M and Chapman , KR .", "label": "", "metadata": {}, "score": "76.01155"}
{"text": "Inhaled anticholinergic / short - agonist ( albuterol / acting beta 2 ipratropium [ Combivent ] ) .1 or 2 puffs four times daily as needed .", "label": "", "metadata": {}, "score": "76.01375"}
{"text": "Inhaled anticholinergic / short - agonist ( albuterol / acting beta 2 ipratropium [ Combivent ] ) .1 or 2 puffs four times daily as needed .", "label": "", "metadata": {}, "score": "76.01375"}
{"text": "Heinrich Worth Medical Department I , Klinikum F\u00fcrth , Jakob Henle Str 1 , D 90766 F\u00fcrth , Germany Respir Med 105:571 - 9 .As COPD patients commonly suffer cardio- and cerebrovascular ( CCV ) co - morbidities , our purpose was to establish the CCV safety profile of indacaterol , a novel , inhaled , long - acting \u03b2(2)-agonist for COPD ... .", "label": "", "metadata": {}, "score": "76.03053"}
{"text": "Am J Med .PubMed .Hepper NG , Hyatt RE , Fowler WS .Detection of chronic obstructive lung disease .An evaluation of the medical history and physical examination .", "label": "", "metadata": {}, "score": "76.061"}
{"text": "Am J Med .PubMed .Hepper NG , Hyatt RE , Fowler WS .Detection of chronic obstructive lung disease .An evaluation of the medical history and physical examination .", "label": "", "metadata": {}, "score": "76.061"}
{"text": "A number of novel LABAs with once - daily profiles are in development [ 6 ] .Here , we summarize the data available to date for the most promising of these .", "label": "", "metadata": {}, "score": "76.1193"}
{"text": "PubMed View Article .van der Molen T , Pieters W , Bellamy D , Taylor R : Measuring the success of treatment for chronic obstructive pulmonary disease - patient , physician and healthcare payer perspectives .", "label": "", "metadata": {}, "score": "76.17667"}
{"text": "PubMed .Ventolin Accuhaler : Summary of Product Characteristics .Allen & Hanburys ; 2009 .Bricanyl Turbohaler : Summary of Product Characteristics .Astra Zeneca ; 2009 .", "label": "", "metadata": {}, "score": "76.24485"}
{"text": "Pulm Pharmacol Ther 2009 , 22 : 44 - 9 .PubMed View Article .Partridge MR , Miravitlles M , St\u00e5hl E , Karlsson N , Svensson K , Welte T : Development and validation of the Capacity of Daily Living during the Morning and Global Chest Symptoms Questionnaires in COPD .", "label": "", "metadata": {}, "score": "76.28496"}
{"text": "Based on the ratio of the mean incremental costs to the mean incremental QALYs , they found a cost - effectiveness ratio of \u20ac 4118 per QALY gained [ 13 ] .", "label": "", "metadata": {}, "score": "76.301315"}
{"text": "LABAs with a 12-hour duration of action were subsequently introduced in the late 1990s , following positive experience in asthma [ 11 ] , providing improvements in bronchodilator efficacy and patient outcomes compared with SABAs which have a duration of action of only 4 - 6 hours [ 12 ] .", "label": "", "metadata": {}, "score": "76.348526"}
{"text": "Precision of effect estimates was evaluated from the width of the 95 % CIs .Some end points were rare relative to the number of factors that needed to be controlled , so propensity scores ( derived from logistic regression models ) were used to enhance efficiency of analytic control of confounding .", "label": "", "metadata": {}, "score": "76.42509"}
{"text": "[ PMID : 20464758 ] .Aaron SD , Vandemheen KL , Fergusson D , Maltais F , Bourbeau J , Goldstein R , et al .", "label": "", "metadata": {}, "score": "76.462204"}
{"text": "[ PMID : 20464758 ] .Aaron SD , Vandemheen KL , Fergusson D , Maltais F , Bourbeau J , Goldstein R , et al .", "label": "", "metadata": {}, "score": "76.462204"}
{"text": "An overlap in symptoms , together with the lack of validated discriminatory biomarkers , can make differential diagnosis difficult .The major distinguishing features between the two diseases are clinical : in general , COPD occurs later in life , with slowly progressive symptoms during exercise and is associated with a history of smoking or exposure to noxious gases and particulates .", "label": "", "metadata": {}, "score": "76.4678"}
{"text": "Strengths and limitations of this study .Strengths of this study are the new user design and use of propensity scores to control for available risk factors , including demographic factors , history of respirator , cardiovascular and other illness and respiratory , cardiovascular and other medications .", "label": "", "metadata": {}, "score": "76.5248"}
{"text": "An authorization for the processing and analyses of this database was obtained from the Belgian Privacy Commission [ 5 ] .Population .The initial database of patients with at least one registration of tiotropium included 102 796 patients .", "label": "", "metadata": {}, "score": "76.61479"}
{"text": "Tiotropium ( Spiriva \u00ae , Boehringer - Ingelheim ) is a once - daily inhaled long - acting bronchodilator of the anticholinergic class , used for the maintenance treatment of Chronic Obstructive Pulmonary Disease ( COPD ) .", "label": "", "metadata": {}, "score": "76.70902"}
{"text": "Am J Respir Crit Care Med 1998 , 158 : S146 - 53 .PubMed .Roux E , Molimard M , Savineau JP , Marthan R : Muscarinic stimulation of airway smooth muscle cells .", "label": "", "metadata": {}, "score": "76.81334"}
{"text": "There was no statistically significant difference in overall mortality ( HR , 0.89 [ CI , 0.79 to 1.02 ] ) .Two trials ( 30 - 31 ) of at least 2 years ' duration provided information on health - related quality of life as measured by the St. George 's Respiratory Questionnaire .", "label": "", "metadata": {}, "score": "76.82942"}
{"text": "The principal action of \u03b2 2 -agonists is to relax airway smooth muscle by stimulating \u03b2 2 -adrenergic receptors .This increases the intracellular messenger cyclic AMP that is responsible for the control of smooth muscle tone [ 7 ] .", "label": "", "metadata": {}, "score": "76.95187"}
{"text": "The average age is 68.05 years and 66.39 % are male .These patients should all have been diagnosed with COPD since in Belgium reimbursement of tiotropium is restricted to this indication .", "label": "", "metadata": {}, "score": "77.01449"}
{"text": "Therefore , it is not appropriate as is sometimes done , to refer to COPD patients who exhibit significant reversibility in response to a bronchodilator as having an ' asthmatic ' component or ' mixed disease ' .", "label": "", "metadata": {}, "score": "77.20097"}
{"text": "PubMed .Go\u0301recka D , Gorzelak K , Sliwin\u0301ski P , Tobiasz M , Zielin\u0301ski J. Effect of long - term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia .", "label": "", "metadata": {}, "score": "77.30789"}
{"text": "PubMed .Go\u0301recka D , Gorzelak K , Sliwin\u0301ski P , Tobiasz M , Zielin\u0301ski J. Effect of long - term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia .", "label": "", "metadata": {}, "score": "77.30789"}
{"text": "Patients who benefit the most from inhaled bronchodilators ( anticholinergics or long - acting \u03b2 - agonists ) seem to be those who have respiratory symptoms and airflow obstruction with an FEV 1 less than 60 % predicted .", "label": "", "metadata": {}, "score": "77.31242"}
{"text": "The price for prednisolone was \u20ac31.5 for 20 units of 32 mg , i.e. \u20ac 1.58 per day .With respect to antibiotics , a daily cost of \u20ac 1.13 was taken into account ( amoxicilline ( Docamoxi - 500 mg ) taken 3 times a day ( 1500 mg / day ) costs \u20ac 6.02 for 16 units ) .", "label": "", "metadata": {}, "score": "77.40949"}
{"text": "These improvements were maintained throughout the duration of the trials 1,2 . \"A new treatment option improving lung function and relieving breathlessness around the clock with just one inhalation will be a welcome advance . \"", "label": "", "metadata": {}, "score": "77.44157"}
{"text": "Short - acting rather than long - acting beta 2 agonists should be used to improve symptoms because they have been shown to reduce breathlessness .", "label": "", "metadata": {}, "score": "77.45733"}
{"text": "N Engl J Med .PubMed .Lapperre TS , Snoeck - Stroband JB , Gosman MM , Jansen DF , van Schadewijk A , Thiadens HA , et al .", "label": "", "metadata": {}, "score": "77.52649"}
{"text": "N Engl J Med .PubMed .Lapperre TS , Snoeck - Stroband JB , Gosman MM , Jansen DF , van Schadewijk A , Thiadens HA , et al .", "label": "", "metadata": {}, "score": "77.52649"}
{"text": "Muscarinic antagonists also facilitate bronchodilation but work by competing with acetylcholine for muscarinic receptors [ 8 ] .By inhibiting the action of acetylcholine at receptor sites in the lung , they indirectly inhibit contraction of airway smooth muscle .", "label": "", "metadata": {}, "score": "77.55683"}
{"text": "Contact afpserv@aafp.org for copyright questions and/or permission requests .number of patients with one or more exacerbation [ Time Frame : 50 weeks ] [ Designated as safety issue : No ] . rate of PEFR drops [ Time Frame : 50 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "77.7449"}
{"text": "In patients with COPD , patient education is paramount and should focus on smoking cessation , reduction of occupational and environmental exposures , management of exacerbations , and end - of - life issues .", "label": "", "metadata": {}, "score": "77.84677"}
{"text": "Clinicians should base the choice of specific monotherapy on patient preference , cost , and adverse effect profile .( Grade : weak recommendation , moderate - quality evidence ) .", "label": "", "metadata": {}, "score": "78.06707"}
{"text": "Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada .Vogelmeier C et al .Once - daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes .", "label": "", "metadata": {}, "score": "78.19803"}
{"text": "Clinicians should be careful to avoid attributing symptoms to COPD when common comorbid conditions , such as heart failure , are associated with the same symptoms .", "label": "", "metadata": {}, "score": "78.240326"}
{"text": "Thus , the absence of an increased risk of MI in the Uplift study does not negate increases in risk of MI in the Lung Health Study , 18 POET Study 34 or this study , especially when each of these studies indicates an increased risk of angina .", "label": "", "metadata": {}, "score": "78.30771"}
{"text": "Exacerbations contribute greatly to the increased morbidity and diminished health - related quality of life of COPD patients [ 74 ] .However , there has been a lack of a consistent and widely accepted definition with which to evaluate and compare the efficacy of therapeutic interventions on this outcome [ 75 ] .", "label": "", "metadata": {}, "score": "78.33561"}
{"text": "Individual patients may benefit from the therapy and may show improvement in their respiratory symptoms .However , the duration of maintenance therapy and the frequency of reevaluation once a patient is receiving therapy are unknown because evidence is limited .", "label": "", "metadata": {}, "score": "78.38438"}
{"text": "The combination therapy that has been most studied to date is long - acting inhaled \u03b2 - agonists plus inhaled corticosteroids .( Grade : weak recommendation , moderate - quality evidence ) .", "label": "", "metadata": {}, "score": "78.44069"}
{"text": "In other words , in the real world , tiotropium does not always replace the other long - acting bronchodilators and the comparator is a combination of other drugs .", "label": "", "metadata": {}, "score": "78.464905"}
{"text": "Even if performing spirometry does not in itself modify the underlying risk ( smoking cessation ) or warrant immediate treatment ( use of bronchodilators ) , airflow limitation is a marker of premature death from all causes , in particular heart attack and lung cancer ( 2,3 ) .", "label": "", "metadata": {}, "score": "78.57116"}
{"text": "Wilson JMG , Jungner G. Principles and Practice of Screening for Disease .WHO Chronicle 1968;22(11):473 .Qaseem , A , Snow , V , Shekelle , P , et al .", "label": "", "metadata": {}, "score": "78.63387"}
{"text": "Under - reporting of non - serious AEs could introduce misclassification that would dilute RR estimates for events such as dry mouth and constipation .15 Misclassification could have occurred for more serious end points as well , although we would expect that completeness of the medical record would be better for more serious cardiovascular events .", "label": "", "metadata": {}, "score": "78.64776"}
{"text": "Both comments and pings are currently closed .Get Our Blog Updates Via E - mail !NEJM in the News .The Wall Street Journal referenced the NEJM Brief Report , \" Zika Virus Associated with Microcephaly , \" in an article reporting on WHO 's announcement that possible Zika vaccines are at least 18 months away from broad trials .", "label": "", "metadata": {}, "score": "78.6488"}
{"text": "Pauwels R , Calverley P , Buist AS , Rennard S , Fukuchi Y , Stahl E , L\u00f6fdahl CG : COPD exacerbations : the importance of a standard definition .", "label": "", "metadata": {}, "score": "78.69346"}
{"text": "To reduce confounding by indication , patients who had a recorded diagnosis of asthma as their only respiratory diagnosis were excluded , as were patients less than 40 years old .", "label": "", "metadata": {}, "score": "78.744705"}
{"text": "COPD is a distinct disease from asthma , although there is some degree of overlap , with an estimated 10 - 50 % of COPD patients having concomitant asthma .", "label": "", "metadata": {}, "score": "78.83454"}
{"text": "Pharmacological and clinical evidence , therefore , supports these cardiovascular events as class effects of inhaled anticholinergic drugs .Small increased rates of stroke have been observed fairly consistently across studies , while MI , and cardiovascular death , have been associated in different studies both positively and negatively with anticholinergic medication .", "label": "", "metadata": {}, "score": "78.865875"}
{"text": "Finally , on the basis of studies that showed benefit , it remains unclear when combination therapy is preferred over monotherapy .Pulmonary rehabilitation improves symptoms in patients with an FEV 1 less than 50 % predicted .", "label": "", "metadata": {}, "score": "78.909966"}
{"text": "Evidence to support the use of mucolytics , oral theophylline , and oral corticosteroids is limited .Patients with severe hypoxemia ( i.e. , arterial oxygen pressure less than 55 mm Hg or oxygen saturation less than 88 percent ) should be given continuous oxygen .", "label": "", "metadata": {}, "score": "78.91873"}
{"text": "Follow - up visits , repeated office spirometry , full pulmonary function tests with bronchodilator testing , lung imaging , and drug prescriptions would follow initial primary care - office spirometry in many patients ( 18 ) .", "label": "", "metadata": {}, "score": "78.92624"}
{"text": "COPD exacerbation , cough , dizziness , dry mouth , GI upset , headache , nausea , nervousness , oral irritation , rash , urticaria .", "label": "", "metadata": {}, "score": "78.99191"}
{"text": "O'Reilly JF , Williams AE , Rice L : Health status impairment and costs associated with COPD exacerbation managed in hospital .International journal of clinical practice 2007 , 61 : 1112 - 1120 .", "label": "", "metadata": {}, "score": "79.03874"}
{"text": "Thus , decreased rates of total mortality and total stroke can mask increased rates of cardiovascular mortality 24 or ischaemic stroke .34 Finally , adverse effects do not occur in every patient and may not be apparent in every population or every study .", "label": "", "metadata": {}, "score": "79.07099"}
{"text": "This guideline rates the evidence and recommendations by using the ACP guideline grading system , which is based on the system developed by the GRADE ( Grading of Recommendations , Assessment , Development , and Evaluation ) workgroup ( Table ) .", "label": "", "metadata": {}, "score": "79.14951"}
{"text": "PubMed View Article .Hawkins NM , Petrie MC , Jhund PS , Chalmers GW , Dunn FG , McMurray JJV : Heart failure and chronic obstructive pulmonary disease : diagnostic pitfalls and epidemiology .", "label": "", "metadata": {}, "score": "79.20535"}
{"text": "PubMed .Melbye H , Aaraas I , Hana J , Hensrud A. Improving pulmonary auscultation as a tool in the diagnosis of bronchial obstruction - results of an educational intervention .", "label": "", "metadata": {}, "score": "79.22722"}
{"text": "PubMed .Melbye H , Aaraas I , Hana J , Hensrud A. Improving pulmonary auscultation as a tool in the diagnosis of bronchial obstruction - results of an educational intervention .", "label": "", "metadata": {}, "score": "79.22722"}
{"text": "In addition , studies showed no effect of ambulatory oxygen on respiratory health - related quality of life measures ( 60 - 61 ) .Physiologic indications for the use of long - term oxygen therapy include cor pulmonale or polycythemia with Pa o 2 between 55 and 59 mm Hg ( 62 ) .", "label": "", "metadata": {}, "score": "79.254974"}
{"text": "Due to the central limit theorem , cost parameters retrieved from the large tiotropium study database were sampled from a normal distribution with the appropriate confidence interval around the mean ( table 1 ) .", "label": "", "metadata": {}, "score": "79.38484"}
{"text": "Borg S , Ericsson A , Wedzicha J , Gulsvik A , Lundback B , Donaldson GC , Sullivan SD : A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "79.47627"}
{"text": "Posted on October 5 , 2011 .Amir Qaseem .American College of Physicians .Conflict of Interest : None Declared .We thank Dr. Young and Ms Hopkins for their comments regarding the American College of Physicians ' recent clinical guideline on the diagnosis and management of stable COPD ( 1 ) .", "label": "", "metadata": {}, "score": "79.747574"}
{"text": "On the other hand , caution is needed when drawing conclusions from subgroup findings [ 15 ] .It is generally recognized that subgroup analyses can produce spurious results [ 16 ] .", "label": "", "metadata": {}, "score": "79.754135"}
{"text": "A deterministic ICER is presented if the Latin Hypercube simulations fall in different quadrants of the cost - effectiveness plane [ 14 ] .Results .", "label": "", "metadata": {}, "score": "79.763794"}
{"text": "PubMed View Article PubMed Central .Baker Wl , Baker EL , Coleman CI : Pharmacologic treatments for chronic obstructive pulmonary disease : a mixed treatment comparison meta - analysis .", "label": "", "metadata": {}, "score": "79.77776"}
{"text": "PubMed .Singh S , Loke YK , Furberg CD .Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "79.81144"}
{"text": "PubMed .Singh S , Loke YK , Furberg CD .Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "79.81144"}
{"text": "Moreover , one year appears to be long enough to capture a significant number of important clinical endpoints such as exacerbations and exacerbation - related hospitalisations , and to capture seasonal variations .", "label": "", "metadata": {}, "score": "79.82681"}
{"text": "14 When steroids and long - acting beta 2 agonists were used in combination , withdrawal of the steroids resulted in an increase in exacerbations .", "label": "", "metadata": {}, "score": "79.89461"}
{"text": "Fast onset of action is a significant feature of bronchodilators and may be beneficial for patients with COPD .Rapid relief of symptoms which patients can feel from the first dose provides reassurance of effect , and is likely to improve compliance with the medication [ 108 , 109 ] .", "label": "", "metadata": {}, "score": "79.89732"}
{"text": "Seasonal variation in diagnoses and visits to family physicians .Ann Fam Med .Eisner MD , Balmes J , Katz PP , Trupin L , Yelin EH , Blanc PD .", "label": "", "metadata": {}, "score": "79.929794"}
{"text": "36 ( for 18 g ; around 200 inhalations ) .Angina , angioedema , arrhythmias , bronchospasm ( paradoxical ) , hypertension , hypokalemia , QT - interval prolongation , seizures , urticaria .", "label": "", "metadata": {}, "score": "80.010994"}
{"text": "number of days of hospitalisation [ Time Frame : 50 weeks ] [ Designated as safety issue : No ] .use of rescue medications , type and duration [ Time Frame : 50 weeks ] [ Designated as safety issue : No ] . bacterial and viral characterisation of severe exacerbations [ Time Frame : 50 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "80.03981"}
{"text": "Bradley JM , O'Neill B. Short term ambulatory oxygen for chronic obstructive pulmonary disease .Cochrane Database Syst Rev .2005;(4):CD004356 .Ram FS , Jones PW , Castro AA , De Brito JA , Atallah AN , Lacasse Y , et al .", "label": "", "metadata": {}, "score": "80.07022"}
{"text": "Maltais F , Bourbeau J , Shapiro S , Lacasse Y , Perrault H , Baltzan M , et al .Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network , Fonds de recherche en sante\u0301 du Que\u0301bec .", "label": "", "metadata": {}, "score": "80.14282"}
{"text": "Maltais F , Bourbeau J , Shapiro S , Lacasse Y , Perrault H , Baltzan M , et al .Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network , Fonds de recherche en sante\u0301 du Que\u0301bec .", "label": "", "metadata": {}, "score": "80.14282"}
{"text": "It has long been suggested that older people are especially susceptible to anticholinergic effects , and angina has been described previously as a severe anticholinergic effect secondary to tachyarrhythmias .", "label": "", "metadata": {}, "score": "80.18603"}
{"text": "PubMed .Wilt TJ , Niewoehner D , MacDonald R , Kane RL .Management of stable chronic obstructive pulmonary disease : a systematic review for a clinical practice guideline .", "label": "", "metadata": {}, "score": "80.27471"}
{"text": "PubMed .Wilt TJ , Niewoehner D , MacDonald R , Kane RL .Management of stable chronic obstructive pulmonary disease : a systematic review for a clinical practice guideline .", "label": "", "metadata": {}, "score": "80.27471"}
{"text": "It is therefore important to take into account the uncertainty around these estimations .Both estimates are surrounded by much uncertainty .Furthermore , it should be remarked that a critical review of the literature identified the presence of publication bias [ 2 ] .", "label": "", "metadata": {}, "score": "80.4188"}
{"text": "However , no exact results ( even no mean values ) were provided and results could therefore not be included in a meta - analysis .", "label": "", "metadata": {}, "score": "80.440636"}
{"text": "Chest 1999 , 115 : 966 - 71 .PubMed View Article .Donohue JF : Therapeutic responses in asthma and COPD .Bronchodilators .Chest 2004 , 126 ( 2 Suppl ) : 125S-137S. PubMed View Article .", "label": "", "metadata": {}, "score": "80.62508"}
{"text": "( Grade : strong recommendation , moderate - quality evidence ) .Clinicians should base the choice of specific monotherapy on patient preference , cost , and adverse effect profile .", "label": "", "metadata": {}, "score": "80.71541"}
{"text": "In subgroup analyses , the population was divided depending on the number of hospitalisations related to exacerbations ( i.e. one , two , three or more exacerbation - related hospitalisations ) in combination with the number of exacerbations .", "label": "", "metadata": {}, "score": "80.83834"}
{"text": "Lancet .Gartlehner G , Hansen RA , Carson SS , Lohr KN .Efficacy and safety of inhaled corticosteroids in patients with COPD : a systematic review and meta - analysis of health outcomes .", "label": "", "metadata": {}, "score": "80.86226"}
{"text": "There is an agreed upon criteria that defines when to consider screening ( 2 ) .It includes : 1 ) there should be an accepted treatment available and 2 ) if treatment is started at an early stage , it will be beneficial and change clinical outcomes compared to waiting until patients develop disease signs or symptoms .", "label": "", "metadata": {}, "score": "80.9423"}
{"text": "This leads to enhanced production of cyclic adenosine monophosphate ( cAMP ) which activates protein kinase A ( PKA ) and results in smooth muscle relaxation .", "label": "", "metadata": {}, "score": "81.13241"}
{"text": "Does not improve breathlessness but may decrease exacerbations ( single study ) 12 .Corticosteroids ( inhaled ) .Adrenal suppression , anaphylactoid reactions , angioedema , behavioral disturbances ( children ) , bronchospasm , cataracts , Churg - Strauss syndrome , Cushingoid features , eosinophilia , glaucoma , growth suppression ( children ) , hyperglycemia , osteoporosis , vasculitis .", "label": "", "metadata": {}, "score": "81.16672"}
{"text": "Young RP , Hopkins R , Eaton TE .FEV1 : not just a lung function test but a marker of premature death from all causes .", "label": "", "metadata": {}, "score": "81.17691"}
{"text": "Tashkin DP , Celli B , Senn S , Burkhart D , Kesten S , Menjoge S , Decramer M , Investigators US , Schiavi E , Figueroa Casas JC , Rhodius E , et al .", "label": "", "metadata": {}, "score": "81.34859"}
{"text": "Improves lung function and quality of life and decreases exacerbations in patients with moderate to severe disease 14 .Anaphylaxis , bronchospasm .Bronchospasm , nausea , rash , rhinorrhea , stomatitis , unpleasant odor during administration , urticaria , vomiting .", "label": "", "metadata": {}, "score": "81.65602"}
{"text": "Improves lung function and quality of life and decreases exacerbations in patients with moderate to severe disease 14 .Anaphylaxis , bronchospasm .Bronchospasm , nausea , rash , rhinorrhea , stomatitis , unpleasant odor during administration , urticaria , vomiting .", "label": "", "metadata": {}, "score": "81.65602"}
{"text": "PubMed .Agency for Healthcare Research and Quality .Use of Spirometry for Case Finding , Diagnosis , and Management of Chronic Obstructive Pulmonary Disease .", "label": "", "metadata": {}, "score": "81.73653"}
{"text": "PubMed .Agency for Healthcare Research and Quality .Use of Spirometry for Case Finding , Diagnosis , and Management of Chronic Obstructive Pulmonary Disease .", "label": "", "metadata": {}, "score": "81.73653"}
{"text": "Older individuals were at even higher risk in both studies .Moreover , heart failure may be under - diagnosed in COPD due to diagnostic confusion between the two diseases [ 98 ] .", "label": "", "metadata": {}, "score": "81.768616"}
{"text": "However , combination of all 3 of the following findings in an individual - greater than 55-pack - year history of smoking , wheezing on auscultation , and patient self - reported wheezing - can be considered predictive of airflow obstruction , defined as postbronchodilator FEV 1 -FVC ratio less than 0.70 .", "label": "", "metadata": {}, "score": "81.79357"}
{"text": "CEO of Sosei , Shinichi Tamura commented : .\" We are very encouraged by the substantial body of GLOW and IGNITE data presented at the European Respiratory Society meeting and look forward to the approval of glycopyrronium bromide in Europe and the filing of QVA149 in Europe and Japan .", "label": "", "metadata": {}, "score": "81.849075"}
{"text": "Bronchodilator responsiveness in patients with COPD .D P Tashkin David Geffen School of Medicine , UCLA , 10833 Le Conte Avenue , Los Angeles , CA 90024 , USA Eur Respir J 31:742 - 50 .", "label": "", "metadata": {}, "score": "81.86064"}
{"text": "Improves quality of life and sleep and decreases rescue inhaler use and office visits 8 - 10 .36 ( for 18 g ; around 200 inhalations ) .", "label": "", "metadata": {}, "score": "82.13385"}
{"text": "High - dose oral steroids improve lung function by up to 20 percent in some patients when used for two to four weeks ; however , a systematic review found no significant improvement in patient - oriented outcomes , and long - term use is associated with significant harm .", "label": "", "metadata": {}, "score": "82.14401"}
{"text": "The beta distribution , which is constrained on the interval 0 - 1 , is the ideal distribution for QoL values .Since the study of O'Reilly et al [ 9 ] . provided QoL data during an exacerbation - related hospitalisation with negative values , an adjusted beta distribution with the reported minimum value of -0.59 and a maximum of 1 was applied .", "label": "", "metadata": {}, "score": "82.26679"}
{"text": "The mean FEV 1 was 43 % predicted , and approximately one third of individuals had moderate COPD ( Global Initiative for Chronic Obstructive Lung Disease stage II ) .", "label": "", "metadata": {}, "score": "82.70542"}
{"text": "Qaseem A , Wilt TJ , Weinberger SE , Hanania NA , Criner G , van der Molen T , et al .Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease : A Clinical Practice Guideline Update from the American College of Physicians , American College of Chest Physicians , American Thoracic Society , and European Respiratory Society .", "label": "", "metadata": {}, "score": "82.94642"}
{"text": "Cochrane Database Syst Rev .2002;(4):CD003902 .ZuWallack RL , Mahler DA , Reilly D , Church N , Emmett A , Rickard K , et al .", "label": "", "metadata": {}, "score": "82.96672"}
{"text": "PubMed .Puhan M , Scharplatz M , Troosters T , Walters EH , Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "83.01417"}
{"text": "PubMed .Puhan M , Scharplatz M , Troosters T , Walters EH , Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "83.01417"}
{"text": "N Eng J Med 2011 ; 365 : 395 - 409 .Young RP , Hopkins RJ , Christmas T , Black PN , Metcalf P , Gamble GD .", "label": "", "metadata": {}, "score": "83.05904"}
{"text": "Qaseem A , Wilt TJ , Weinberger SE , Hanania NA , Criner G , van der Molen M , et al .Diagnosis and management of stable chronic obstructive pulmonary disease : A clinical practice guideline update from the American College of Physicians , American College of Chest Physicians , American Thoracic Society , and European Respiratory Society .", "label": "", "metadata": {}, "score": "83.14678"}
{"text": "The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function .Christopher B Cooper Division of Pulmonary and Critical Care Medicine , Department of Medicine , David Geffen School of Medicine at UCLA , University of California Los Angeles , Los Angeles , California 90095 1690 , USA Am J Med 119:21 - 31 .", "label": "", "metadata": {}, "score": "83.1606"}
{"text": "Participants showed clinically significant benefits in St. George 's Respiratory Questionnaire scores at 4 months but not at 12 months ( 52 ) .There were no statistically significant differences in moderate to severe exacerbations ( co - primary outcome with St. George 's Respiratory Questionnaire score ) at 4 or 12 months and no clinically important differences in the 6-minute walk test after 4 months or 2 years .", "label": "", "metadata": {}, "score": "83.19597"}
{"text": "Kerwin E , et al .Eur Resp J 2012 .Published on July 26 , 2012 ( doi:10.1183/09031936.00040712 ) .Beeh KM , et al A .", "label": "", "metadata": {}, "score": "83.19908"}
{"text": "PubMed .McDonald CF , Blyth CM , Lazarus MD , Marschner I , Barter CE .Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia .", "label": "", "metadata": {}, "score": "83.29218"}
{"text": "PubMed .McDonald CF , Blyth CM , Lazarus MD , Marschner I , Barter CE .Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia .", "label": "", "metadata": {}, "score": "83.29218"}
{"text": "Sosei Group Corporation ( \" Sosei \" ; TSE Mothers Index : 4565 ) highlights that further data from the once - daily chronic obstructive pulmonary disease ( COPD ) clinical trial programs were presented today by Novartis at the European Respiratory Society ( ERS ) Congress .", "label": "", "metadata": {}, "score": "83.32602"}
{"text": "Alternative mechanisms for tiotropium .E D Bateman Division of Pulmonology , Department of Medicine , University of Cape Town , Cape Town , South Africa Pulm Pharmacol Ther 22:533 - 42 .", "label": "", "metadata": {}, "score": "83.490364"}
{"text": "Once - daily NVA237 reduces exacerbations and improves symptoms in COPD patients : a pooled analysis , of the GLOW1 and GLOW2 studies .[ ERS abstract 853213 ; Session 314 ; Date : September 03 , 2012 Time : 14:45 - 16:45 .", "label": "", "metadata": {}, "score": "83.5614"}
{"text": "Cochrane review of RCTs There is inconsistent evidence on the benefits of long - acting agents and some inconsistent evidence suggesting a possible increase in mortality .", "label": "", "metadata": {}, "score": "83.64651"}
{"text": "Cochrane review of RCTs There is inconsistent evidence on the benefits of long - acting agents and some inconsistent evidence suggesting a possible increase in mortality .", "label": "", "metadata": {}, "score": "83.64651"}
{"text": "However , only the home - based program reached the minimum clinically important difference at 12 months .The main components of most reported pulmonary rehabilitation programs included endurance and exercise training , education , behavioral modification , and outcome assessment .", "label": "", "metadata": {}, "score": "83.646774"}
{"text": "Thus , they are not intended to over - ride clinicians ' judgment .All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication , or once an update has been issued .", "label": "", "metadata": {}, "score": "83.6743"}
{"text": "A physician 's \" overall clinical impression \" has been evaluated in only 2 studies with a total of 13 physicians .However , the sparseness of the data makes any conclusion about the value of \" overall clinical impression \" premature .", "label": "", "metadata": {}, "score": "83.73605"}
{"text": "The mean incremental cost is \u20ac 373 per patient ( 95 % CI 279 - 475 ) .The UPLIFT non - significant treatment effect on hospitalisations and the significant treatment effect on exacerbations are reflected in these confidence intervals .", "label": "", "metadata": {}, "score": "83.74362"}
{"text": "Will this study change your therapeutic approach for those patients ?This entry was posted on Wednesday , March 23rd , 2011 at 5:00 pm and is filed under Insights .", "label": "", "metadata": {}, "score": "83.947945"}
{"text": "Adrenal suppression , angioedema , arrhythmia ( ventricular ) , asthma exacerbation , bronchospasm ( paradoxical ) , cataracts , Churg - Strauss syndrome , cushingoid features , death ( asthma - related ) , glaucoma , growth suppression ( children ) , hypokalemia ( severe ) , laryngospasm .", "label": "", "metadata": {}, "score": "84.01781"}
{"text": "Adrenal suppression , angioedema , arrhythmia ( ventricular ) , asthma exacerbation , bronchospasm ( paradoxical ) , cataracts , Churg - Strauss syndrome , cushingoid features , death ( asthma - related ) , glaucoma , growth suppression ( children ) , hypokalemia ( severe ) , laryngospasm .", "label": "", "metadata": {}, "score": "84.01781"}
{"text": "Tiotropium for stable chronic obstructive pulmonary disease : A meta - analysis .R G Barr Division of General Medicine , PH 9 East Room 105 , Columbia University Medical Centre , 630 West 168th Street , New York , NY 10032 , USA Thorax 61:854 - 62 .", "label": "", "metadata": {}, "score": "84.173515"}
{"text": "Provenance and peer review Not commissioned ; externally peer reviewed .Data sharing statement Data sets for this study are the property of Boehringer Ingelheim and not currently available . . .", "label": "", "metadata": {}, "score": "84.30165"}
{"text": "Especially the fact of being hospitalised may influence QoL. However , we currently do not know whether further improvements are observed afterwards in real life .", "label": "", "metadata": {}, "score": "84.33"}
{"text": "Reasons for not reporting dyspnea scores include no acceptable and appropriate approach to assess dyspnea in a clinical trial setting and a lack of a uniform method .", "label": "", "metadata": {}, "score": "84.47752"}
{"text": "1 - 5 There has been concern that anticholinergic drugs could induce ischaemia , possibly secondary to tachyarrhythmias , 4 5 and could pose a risk to patients with cardiovascular complications .", "label": "", "metadata": {}, "score": "84.76952"}
{"text": "Diagnosis of COPD according to the European Respiratory Society ( ERS ) ( R95 - 3225 ) and matching the following criteria : .Stable moderate to severe airway obstruction .", "label": "", "metadata": {}, "score": "84.82481"}
{"text": "It was previously remarked that low values reported during the stay in hospital partly constitute an effect of the exacerbation and partly of the hospitalisation .", "label": "", "metadata": {}, "score": "84.882"}
{"text": "Results .After 1000 Latin Hypercube simulations , the incremental benefit expressed as quality - adjusted life years ( QALY ) gained is on average 0.00048 ( 95 % confidence interval ( CI ) 0.00009 - 0.00092 ) .", "label": "", "metadata": {}, "score": "84.96733"}
{"text": "Drafting of the article : A. Qaseem , S.E. Weinberger , N.A. Hanania , G. Criner , T. van der Molen , D.D. Marciniuk , T. Denberg .", "label": "", "metadata": {}, "score": "85.04983"}
{"text": "Paul Shekelle , MD , PhD Greater Los Angeles VA Health Center / RAND 1776 Main Street , Santa Monica , CA 90401 .References .", "label": "", "metadata": {}, "score": "85.29111"}
{"text": "Therefore , these costs were left unchanged in the base case scenario .BCFI : Belgian Centre for Pharmacotherapeutic Information ; LOS : length of stay ; NIHDI : National Institute for Health and Disability Insurance ; QALY : quality - adjusted life year .", "label": "", "metadata": {}, "score": "85.314865"}
{"text": "Arthur F Gelb Pulmonary Division , Department of Medicine , Lakewood Regional Medical Center , Lakewood , CA , USA Pulm Pharmacol Ther 22:237 - 42 .", "label": "", "metadata": {}, "score": "85.32632"}
{"text": "doi:10.7326/0003 - 4819 - 155 - 3 - 201108020 - 00008 .Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease : A Clinical Practice Guideline Update from the American College of Physicians , American College of Chest Physicians , American Thoracic Society , and European Respiratory Society FREE .", "label": "", "metadata": {}, "score": "85.341034"}
{"text": "Manifestations of COPD range from dyspnea , poor exercise tolerance , chronic cough with or without sputum production , and wheezing to respiratory failure or cor pulmonale .", "label": "", "metadata": {}, "score": "85.3452"}
{"text": "[ Time Frame : 50 weeks ] [ Designated as safety issue : No ] . plethysmography ( RV , TLC ) ( optional )[ Time Frame : 50 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "85.35898"}
{"text": "All studies limited their time horizon to one year , with exception of one model - based evaluation using a 5-year time horizon [ 13 ] .", "label": "", "metadata": {}, "score": "85.504196"}
{"text": "Tiotropium ( Spiriva ) .Angioedema , bronchospasm ( paradoxical ) , glaucoma , hypersensitivity reaction .Abdominal pain , blurred vision , candidiasis , chest pain , constipation , dry mouth , dyspepsia , edema , epistaxis , infection , myalgia , pharyngitis , rash , rhinitis , tachycardia , URTI symptoms , urinary hesitancy or retention , UTI , vomiting .", "label": "", "metadata": {}, "score": "85.530136"}
{"text": "Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease .New England Journal of Medicine 2011 ; 363 : 1128 - 1138 .Conflict of Interest : .", "label": "", "metadata": {}, "score": "85.556564"}
{"text": "The goals of treatment are to improve quality of life , exercise tolerance , sleep quality , and survival ; and to reduce dyspnea , nocturnal symptoms , exacerbations , use of rescue medications , and hospitalizations .", "label": "", "metadata": {}, "score": "85.689865"}
{"text": "The best combination to rule out airflow obstruction was absence of a smoking history and no evidence of wheezing on either history or physical examination .", "label": "", "metadata": {}, "score": "85.756"}
{"text": "The dosis of bronchodilators may be increased and oral steroids ( 7 - 10 days 30 - 40 mg prednisolone ) and antibiotics ( 3 - 7 days in case of certain symptoms ) may be prescribed .", "label": "", "metadata": {}, "score": "85.92184"}
{"text": "The introduction of ultra - LABAs is likely to further improve outcomes for patients , when used in combination with a LAMA .Current opinion is that it will be advantageous to develop inhalers containing combinations of two or more classes of once - daily long - acting bronchodilator drugs , in an attempt to simplify treatment regimens as much as possible [ 6 ] .", "label": "", "metadata": {}, "score": "85.938934"}
{"text": "In every cell , the mean value and the lower ( 2.5 % ) and upper ( 97.5 % ) limits of the interval are mentioned .", "label": "", "metadata": {}, "score": "86.05434"}
{"text": "Chest 2008 , 134 : 14 - 9 .PubMed View Article .Dorinsky PM , Reisner C , Ferguson GT , Menjoge SS , Serby CW , Witek TJ , et al .", "label": "", "metadata": {}, "score": "86.08757"}
{"text": "Eur Respir J 2009 ; 34 : 380 - 386 .Conflict of Interest : .RPY , and the funding of his research , has been supported by grants from the University of Auckland , Health Research Council of New Zealand and Synergenz BioSciences Ltd. .", "label": "", "metadata": {}, "score": "86.11545"}
{"text": "Report no .290 - 02 - 0009 .Qaseem A , Snow V , Owens DK , Shekelle P , Clinical Guidelines Committee of the American College of Physicians .", "label": "", "metadata": {}, "score": "86.16319"}
{"text": "Report no .290 - 02 - 0009 .Qaseem A , Snow V , Owens DK , Shekelle P , Clinical Guidelines Committee of the American College of Physicians .", "label": "", "metadata": {}, "score": "86.16319"}
{"text": "In the cost - utility analysis with a 5-year - time horizon , approximately 80 % of the simulations were in the right quadrants of the cost - effectiveness plane .", "label": "", "metadata": {}, "score": "86.18353"}
{"text": "Lancet .Cranston JM , Crockett AJ , Moss JR , Alpers JH .Domiciliary oxygen for chronic obstructive pulmonary disease .Cochrane Database Syst Rev .", "label": "", "metadata": {}, "score": "86.23802"}
{"text": "With this evidence in mind , the there is no net benefit to obtaining spirometry in asymptomatic individuals .Current Addresses of Authors : Amir Qaseem , MD , PhD , MHA American College of Physicians 190 N. Independence Mall West , Philadelphia , PA 19106 .", "label": "", "metadata": {}, "score": "86.30469"}
{"text": "Clinical Efficacy Assessment Subcommittee of the American College of Physicians .Diagnosis and management of stable chronic obstructive pulmonary disease : a clinical practice guideline from the American College of Physicians .", "label": "", "metadata": {}, "score": "86.368286"}
{"text": "Clinical Efficacy Assessment Subcommittee of the American College of Physicians .Diagnosis and management of stable chronic obstructive pulmonary disease : a clinical practice guideline from the American College of Physicians .", "label": "", "metadata": {}, "score": "86.368286"}
{"text": "PubMed .Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema .Report of the Medical Research Council Working Party .", "label": "", "metadata": {}, "score": "86.65257"}
{"text": "PubMed .Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema .Report of the Medical Research Council Working Party .", "label": "", "metadata": {}, "score": "86.65257"}
{"text": "Jones PW : St. George 's Respiratory Questionnaire : MCID .COPD : Journal of Chronic Obstructive Pulmonary Disease 2005 , 2 : 75 - 9 .", "label": "", "metadata": {}, "score": "86.69522"}
{"text": "Results from Cox models and Poisson models were similar , so estimates from Cox models are presented ( table 3 ) .After stratifying by subgroups , results were imprecise and generally similar to the overall results .", "label": "", "metadata": {}, "score": "86.819984"}
{"text": "Sears MR : Safety of long - acting \u03b2 - agonists .Are new data really required ?Chest 2009 , 136 : 604 - 6 .", "label": "", "metadata": {}, "score": "86.841415"}
{"text": "Hawkins NM , Jhund PS , Simpson CR , Petrie MC , Macdonald MR , Dunn FG , Macintyre K , McMurray JJ : Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland .", "label": "", "metadata": {}, "score": "86.94731"}
{"text": "Ann Intern Med .Wilt , TJ , Niewoehner , D , MacDonald , R , Kane , RL .Management of stable chronic obstructive pulmonary disease : A systematic review for a clinical practice guideline .", "label": "", "metadata": {}, "score": "87.03607"}
{"text": "For the analysis of each end point , patients were followed from the date of their first eligible prescription until the earliest of the following : date of treatment end , date of study end point , date of transfer to a new practice , death or January 2007 .", "label": "", "metadata": {}, "score": "87.22873"}
{"text": "Details and results of other scenario analyses can be found in the full HTA report [ 2 ] .Probabilistic modelling .To capture parameter uncertainty , input variables in our model are probabilistic values .", "label": "", "metadata": {}, "score": "87.26969"}
{"text": "PubMed .American Thoracic Society / European Respiratory Society Task Force .Standards for the Diagnosis and Management of Patients with COPD .Version 1.2 .", "label": "", "metadata": {}, "score": "87.376175"}
{"text": "PubMed .American Thoracic Society / European Respiratory Society Task Force .Standards for the Diagnosis and Management of Patients with COPD .Version 1.2 .", "label": "", "metadata": {}, "score": "87.376175"}
{"text": "QVA149 2305 ( BRIGHT ) .Data on file , Novartis Pharma AG .ClinicalTrials.gov identifier : NCT01294787 .QVA149 A2304 ( SPARK ) .Data on file , Novartis Pharma AG .", "label": "", "metadata": {}, "score": "87.44676"}
{"text": "Dr. Shekelle : West Los Angeles Veterans Affairs Medical Center , 11301 Wilshire Boulevard , Los Angeles , CA 90073 .Author Contributions : Conception and design : A. Qaseem , S.E. Weinberger , N.A. Hanania , G. Criner , T. van der Molen , D.D. Marciniuk , H. Schu\u0308nemann .", "label": "", "metadata": {}, "score": "87.4908"}
{"text": "A B Tonnel Centre Hospitalier R\u00e9gional Universitaire CHRU de Lille , Service de Pneumologie et Immuno Allergologie , Lille Cedex , France Int J Chron Obstruct Pulmon Dis 3:301 - 10 .", "label": "", "metadata": {}, "score": "87.532845"}
{"text": "Heterogeneity of results should be considered in light of both causal and non - causal explanations .For composite end points , interpretation often can be clarified by evaluating components , especially cardiovascular deaths .", "label": "", "metadata": {}, "score": "87.672646"}
{"text": "At admission , the mean utility ( -0.077 , SD : 0.397 ) indicated great impairment , with 61 % of patients having a negative utility value representing a health state equivalent to ' worse than death ' .", "label": "", "metadata": {}, "score": "87.67771"}
{"text": "23 As in other studies , the stroke end point was a composite end point that included ischaemic and hemorrhagic stroke , 23 and the incidence of ischaemic stroke in the Uplift study was slightly greater in the tiotropium group than the placebo group .", "label": "", "metadata": {}, "score": "87.7331"}
{"text": "Research Grants 15 .All ten of the original LHS clinical centers plan to participate in this study .To minimize bias , all surviving participants of the LHS will be invited to participate , giving a potential sample size of 5600 .", "label": "", "metadata": {}, "score": "87.797"}
{"text": "Tiotropium , the only once - daily inhaled bronchodilator currently available , is a LAMA that significantly improves lung function , increases exercise capacity and improves effectiveness of pulmonary rehabilitation , improves health status , and reduces exacerbations [ 1 , 79 ] .", "label": "", "metadata": {}, "score": "87.884834"}
{"text": "Guerra S : Overlap of asthma and chronic obstructive pulmonary disease .Curr Opin Pulm Med 2005 , 11 : 7 - 13 .PubMed .", "label": "", "metadata": {}, "score": "87.95578"}
{"text": "I S T Bos Department of Molecular Pharmacology , University of Groningen , Antonius Deusinglaan 1 , 9713 AV , Groningen , The Netherlands Eur Respir J 30:653 - 61 .", "label": "", "metadata": {}, "score": "87.96074"}
{"text": "View Article PubMed .Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) : Global Strategy for the Diagnosis , Management , and Prevention of Chronic Obstructive Pulmonary Disease .", "label": "", "metadata": {}, "score": "87.99694"}
{"text": "In symptomatic patients , spirometry is helpful for determining whether the symptoms are due to respiratory disease or other conditions .Chronic obstructive pulmonary disease is diagnosed when spirometry demonstrates airflow obstruction that is not fully reversible .", "label": "", "metadata": {}, "score": "88.67011"}
{"text": "37In patients with mild disease , the use of short - acting bronchodilators as needed is appropriate .With progression to moderate disease , one or more long - acting bronchodilators should be added .", "label": "", "metadata": {}, "score": "88.87573"}
{"text": "Transition Dyspnea Index .TORCH : .Towards a Revolution in COPD Health .Declarations .Acknowledgements .We thank Mary Sayers of ACUMED who provided medical writing services .", "label": "", "metadata": {}, "score": "88.91857"}
{"text": "It is the combination of this base risk and the relative treatment effect that determines the absolute reduction in events , which determines the intervention 's cost effectiveness .", "label": "", "metadata": {}, "score": "88.95912"}
{"text": "Since no ambulatory clinical data were available , exacerbations are defined on the basis of health care resources use .The proxy used was the delivery of both oral corticosteroids and antibiotics within 7 days .", "label": "", "metadata": {}, "score": "88.974915"}
{"text": "defining airflow obstruction using FEV1/FVC ratio below the 5th percentile .Posted on August 7 , 2011 .oscar , m jolobe .manchester medical society .", "label": "", "metadata": {}, "score": "89.35934"}
{"text": "At the time of writing this article she was an associate program director of the Scott and White Family Medicine Residency Program .She received her medical degree from the University of Manitoba Medical School , Winnipeg , Canada , and completed the Mayo Clinic Family Medicine Residency Program in Rochester , Minn. .", "label": "", "metadata": {}, "score": "89.46411"}
{"text": "Incidence rates of the study end points were calculated as the number of patients experiencing an event divided by the person - years at risk .", "label": "", "metadata": {}, "score": "89.86589"}
{"text": "As a result of these factors , prospective investors are cautioned not to rely on any forward - looking statements .We disclaim any intention or obligation to update or revise any forward - looking statements , whether as a result of new information , future events or otherwise .", "label": "", "metadata": {}, "score": "89.89641"}
{"text": "The percentage of patients who experienced at least 1 exacerbation differed between study groups , although all patients experienced at least 1 exacerbation ( 23 ) .", "label": "", "metadata": {}, "score": "90.051445"}
{"text": "Probabilistic Markov model to assess the cost - effectiveness of bronchodilator therapy in COPD patients in different countries .Jan B Oostenbrink Institute for Medical Technology Assessment , Erasmus MC Rotterdam , PO Box 1738 , 3000 DR Rotterdam , The Netherlands Value Health 8:32 - 46 .", "label": "", "metadata": {}, "score": "90.21109"}
{"text": "17 We also computed effect estimates using Poisson regression .Effect estimates are presented for end points where the event was detected in at least five patients in each treatment group .", "label": "", "metadata": {}, "score": "90.429184"}
{"text": "Administrative , technical , or logistic support : A. Qaseem , R. MacDonald .Collection and assembly of data : A. Qaseem , T.J. Wilt , N.A. Hanania , R. MacDonald .", "label": "", "metadata": {}, "score": "90.53723"}
{"text": "As a result , the price for an exacerbation not requiring hospitalisation was on average \u20ac 52.72 ( Table 1 ) .Exacerbation - related hospitalisations .", "label": "", "metadata": {}, "score": "90.711395"}
{"text": "Final approval of the article : A. Qaseem , S.E. Weinberger , N.A. Hanania , G. Criner , T. van der Molen , D.D. Marciniuk , T. Denberg , H. Schu\u0308nemann , W. Wedzicha , P. Shekelle .", "label": "", "metadata": {}, "score": "90.78134"}
{"text": "Inhaled bronchodilators , such as \u03b2 2 -agonists and muscarinic antagonists , improve lung function by altering airway smooth muscle tone but also act on peripheral airways [ 4 ] .", "label": "", "metadata": {}, "score": "90.80304"}
{"text": "The generalizability of the benefits of pulmonary rehabilitation in patients with less severe airflow obstruction is less clear .Physicians may consider prescribing pulmonary rehabilitation for patients with an FEV 1 greater than 50 % predicted if they remain symptomatic or have exercise limitation despite maximal medical therapy .", "label": "", "metadata": {}, "score": "90.92651"}
{"text": "About COPD .COPD is a progressive disease associated mainly with tobacco smoking , air pollution or occupational exposure , which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness .", "label": "", "metadata": {}, "score": "91.06421"}
{"text": "Diagnosis and management of stable chronic obstructive pulmonary disease : A clinical practice guideline from the American College of Physicians , American College of Chest Physicians , American Thoracic Society , and European Respiratory Society .", "label": "", "metadata": {}, "score": "91.06622"}
{"text": "About COPD COPD is often considered to be a disease of later years , but estimates suggest that 50 % of those with COPD are now less than 65 years old , resulting in increases in absenteeism , premature retirement and reductions in workforce participation 22 .", "label": "", "metadata": {}, "score": "91.22011"}
{"text": "Requests for Single Reprints : Amir Qaseem , MD , PhD , MHA , American College of Physicians , 190 N. Independence Mall West , Philadelphia , PA 19106 : email , aqaseem@acponline.org .", "label": "", "metadata": {}, "score": "91.26353"}
{"text": "Qaseem and Weinberger : American College of Physicians , 190 N. Independence Mall West , Philadelphia , PA 19106 .Dr. Wilt and Mr. MacDonald : Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research , 1 Veterans Drive ( 111 - 0 ) , Minneapolis , MN 55417 .", "label": "", "metadata": {}, "score": "91.30241"}
{"text": "Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) : Global strategy for the diagnosis , management , and prevention of chronic obstructive pulmonary disease .", "label": "", "metadata": {}, "score": "91.35739"}
{"text": "Clinicians should be alert , however , that some patients may deny limitation on exertion because they have knowingly or unknowingly restricted their activities to those that do not cause symptoms .", "label": "", "metadata": {}, "score": "91.36914"}
{"text": "A major part is covered through fixed monthly hospital payments but these are not registered in the MFG data .Additional remuneration consists of a lump sum billed per admission and a lump sum billed per day of hospital stay , both included in the MFG data .", "label": "", "metadata": {}, "score": "91.52346"}
{"text": "Abstract .Background .Tiotropium is reimbursed since March 2004 in Belgium for the treatment of Chronic Obstructive Pulmonary Disease ( COPD ) .Questions however remain on this product 's value for money .", "label": "", "metadata": {}, "score": "91.63228"}
{"text": "The information provided in order to email this topic will not be used to send unsolicited email , nor will it be furnished to third parties .", "label": "", "metadata": {}, "score": "91.7329"}
{"text": "There also is evidence for improvement in endurance and exercise capacity with supplemental oxygen .There is no improvement in mortality when oxygen is used for patients with mild hypoxemia or nocturnal hypoxemia alone .", "label": "", "metadata": {}, "score": "91.783966"}
{"text": "Can Respir J. 2003.10(6):320 - 6 .Conflict of Interest : .Summary for Patients .The full report is titled \" Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease : A Clinical Practice Guideline Update from the American College of Physicians , American College of Chest Physicians , American Thoracic Society , and European Respiratory Society .", "label": "", "metadata": {}, "score": "91.79676"}
{"text": "For example , a non - severe exacerbation costs between \u20ac 47 in Canada [ 12 ] against nearly \u20ac 1000 in Greece [ 11 ] .", "label": "", "metadata": {}, "score": "91.85187"}
{"text": "QVA149 2322 ( BLAZE ) .Data on file , Novartis Pharma AG .ClinicalTrials.gov identifier : NCT01490125 .QVA149 1301 ( ARISE ) .Data on file , Novartis Pharma AG .", "label": "", "metadata": {}, "score": "91.946175"}
{"text": "Claus Vogelmeier Klinik f\u00fcr Innere Medizin mit Schwerpunkt Pneumologie , Universit\u00e4tsklinikum Giessen und Marburg , Standort Marburg Baldingerstrasse , D 35043 Marburg , Germany Respir Med 102:1511 - 20 .", "label": "", "metadata": {}, "score": "92.01396"}
{"text": "Claus Vogelmeier Klinik f\u00fcr Innere Medizin mit Schwerpunkt Pneumologie , Universit\u00e4tsklinikum Giessen und Marburg , Standort Marburg Baldingerstrasse , D 35043 Marburg , Germany Respir Med 102:1511 - 20 .", "label": "", "metadata": {}, "score": "92.01396"}
{"text": "Corticosteroids ( inhaled ) .Adrenal suppression , anaphylactoid reactions , angioedema , behavioral disturbances ( children ) , bronchospasm , cataracts , Churg - Strauss syndrome , Cushingoid features , eosinophilia , glaucoma , growth suppression ( children ) , hyperglycemia , osteoporosis , vasculitis .", "label": "", "metadata": {}, "score": "92.29938"}
{"text": "No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Affiliated with .Abstract .Chronic obstructive pulmonary disease ( COPD ) is characterized by progressive airflow limitation and debilitating symptoms .", "label": "", "metadata": {}, "score": "92.35187"}
{"text": "Absence of evidence is not evidence of absence .However , based on currently available evidence , indirectly modelling a relatively large impact on mortality can be considered as a rather optimistic scenario .", "label": "", "metadata": {}, "score": "92.44184"}
{"text": "Financial Support : Financial support for the development of this guideline comes exclusively from the ACP operating budget .Potential Conflicts of Interest : Any financial and nonfinancial conflicts of interest of the group members were declared , discussed , and resolved .", "label": "", "metadata": {}, "score": "92.44245"}
{"text": "View Article PubMed .Cleemput I , Van Wilder P , Vrijens F , Huybrechts M , Ramaekers D : Guidelines for pharmaco - economic evaluations in Belgium .", "label": "", "metadata": {}, "score": "92.47972"}
{"text": "In combination with the non - negligible incremental costs , this results in an ICER of \u20ac 1 244 023 ( 95 % CI 328 571 - 4 712 704 ) per QALY gained .", "label": "", "metadata": {}, "score": "92.85578"}
{"text": "GIL C. GRIMES , MD , is an associate program director of the Scott and White Family Medicine Residency Program affiliated with Texas A&M University Health Science Center in Temple .", "label": "", "metadata": {}, "score": "92.87593"}
{"text": "Chest .Dewar M , Curry RW Jr. Chronic obstructive pulmonary disease : diagnostic considerations .Am Fam Physician .Copyright \u00a9 2007 by the American Academy of Family Physicians .", "label": "", "metadata": {}, "score": "92.947586"}
{"text": "Bartolome Celli Brigham and Women s Hospital and St Elizabeth s Medical Center , Boston , MA 02115 , USA Am J Respir Crit Care Med 180:948 - 55 .", "label": "", "metadata": {}, "score": "93.07652"}
{"text": "From an economic point of view , a revision of reimbursement modalities ( e.g. with a lower price ) would be justified and would entail a more efficient use of resources .", "label": "", "metadata": {}, "score": "93.19011"}
{"text": "1000 Latin hypercube simulations were generated in MicroSoft Excel using the @Risk ( Palisade Corporation ) add - in program .Following the Belgian pharmacoeconomic guidelines , the central estimate of the ICER results directly from the probabilistic sensitivity analysis as the mean of the simulated ICERs .", "label": "", "metadata": {}, "score": "93.26877"}
{"text": "The members reached agreement and resolved any disagreements through facilitated discussion .The final recommendations were approved by unanimous vote .The key questions and scope for the guideline were developed with input from the joint guideline panel .", "label": "", "metadata": {}, "score": "93.64416"}
{"text": "Nicholas J Gross Stritch Loyola School of Medicine , Voluntary Attending Physician , Hines VA Hospital , Chicago , Hines , IL 60141 , USA Eur J Pharmacol 533:36 - 9 .", "label": "", "metadata": {}, "score": "93.740875"}
{"text": "PubMed View Article .Cooper C : Airflow obstruction and exercise .Respir Med 2009 , 103 : 325 - 34 .PubMed View Article .", "label": "", "metadata": {}, "score": "93.76694"}
{"text": "He received his medical degree from the University of Texas Southwestern Medical School and completed the Scott and White Family Medicine Residency Program .Reprints are not available from the authors .", "label": "", "metadata": {}, "score": "94.1634"}
{"text": "Bad taste in the mouth , cough , throat irritation , tremor , URTI symptoms .Anaphylaxis , angioedema , arrhythmias , asthma exacerbation , bronchospasm ( paradoxical ) , death ( asthma - related ) , hypertension , laryngospasm .", "label": "", "metadata": {}, "score": "94.19293"}
{"text": "Contributors All authors made substantial contributions to conception and design of the study .MJ and CW acquired the data and conducted the analysis .All authors contributed substantially to data interpretation .", "label": "", "metadata": {}, "score": "94.392395"}
{"text": "Stony Brook University School of medicine , Stony Brook , New York , 11794 - 8036 .Conflict of Interest : None Declared .The authors of the new revision of the COPD clinical guidelines should be congratulated for the integrity of their efforts .", "label": "", "metadata": {}, "score": "94.733"}
{"text": "Cost to the patient will be higher , depending on prescription filling fee .Anaphylaxis , angioedema , bronchospasm ( paradoxical ) , glaucoma ( narrow - angle ) , hypersensitivity reaction , laryngospasm .", "label": "", "metadata": {}, "score": "95.19246"}
{"text": "Boehringer Ingelheim granted the authors permission to publish this study .The authors are solely responsible for the design , analysis , interpretation and conclusions of the study .", "label": "", "metadata": {}, "score": "95.28374"}
{"text": "Frank Buhling Institute of Immunology , Otto von Guericke University Magdeburg , Magdeburg , Leipziger Str 44 , 39120 Magdeburg , Germany Respir Med 101:2386 - 94 .", "label": "", "metadata": {}, "score": "95.385475"}
{"text": "Shawn D Aaron The Ottawa Health Research Institute and University of Ottawa , Ottawa , Ontario , Canada Ann Intern Med 146:545 - 55 .Treatment of moderate or severe chronic obstructive pulmonary disease ( COPD ) with combinations of inhaled corticosteroids , long - acting beta - agonists , and long - acting anticholinergic bronchodilators is common but unstudied ... .", "label": "", "metadata": {}, "score": "95.51757"}
{"text": "Respiratory medicine 2002 , 96 : 944 - 949 .View Article PubMed .Qual Life Res 2000 , 9 : 521 - 527 .View Article PubMed .", "label": "", "metadata": {}, "score": "95.540245"}
{"text": "Todd A Lee Center for Management of Complex Chronic Care , Edward Hines Jr VA Hospital , Hines , Illinois , USA Arch Intern Med 169:1403 - 10 .", "label": "", "metadata": {}, "score": "95.81056"}
{"text": "Daryl Freeman Department of General Practice and Primary Care , University of Aberdeen , Aberdeen , UK Respir Res 8:45 .In primary care , which is the most common setting for COPD management , many patients may have milder disease , and also may take a broad range of concomitant medication ... .", "label": "", "metadata": {}, "score": "96.50545"}
{"text": "Mario Cazzola Antonio Cardarelli Hospital , Department of Respiratory Medicine , Unit of Pneumology and Allergology , Naples , Italy Respir Med 99:524 - 8 .", "label": "", "metadata": {}, "score": "96.64134"}
{"text": "Jianmiao Wang Department of Respiratory Diseases , Tongji Hospital , Key Lab of Pulmonary Diseases of Health Ministry , Tongji Medical College , Huazhong University of Science and Technology , Wuhan , China Respirology 16:350 - 8 .", "label": "", "metadata": {}, "score": "96.76262"}
{"text": "The total economic costs of COPD in the United States were estimated to be $ 49.9 billion in 2010 , and the total direct cost of medical care is approximately $ 29.5 billion per year ( 4 ) .", "label": "", "metadata": {}, "score": "97.28085"}
{"text": "MAN performed the economic evaluation .All authors read and approved the final manuscript .Authors ' Affiliations .Academic Centre for Primary Care , KULeuven .", "label": "", "metadata": {}, "score": "97.65297"}
{"text": "Premature discontinuation during the UPLIFT study .Marc Decramer Respiratory Division , University Hospital , University of Leuven , Herestraat 49 , Leuven , Belgium Respir Med 105:1523 - 30 .", "label": "", "metadata": {}, "score": "97.97865"}
{"text": "Price negotiations could be started in a revision procedure of the reimbursement modalities .These resources could then be invested more efficiently .With current pressure on budgets , these efficiency considerations should not be neglected in resource allocation decisions .", "label": "", "metadata": {}, "score": "98.38719"}
{"text": "Anaphylaxis , angioedema , arrhythmias , asthma exacerbation , bronchospasm ( paradoxical ) , death ( asthma - related ) , hypertension , laryngospasm .Bronchitis , headache , nasal congestion , nervousness , palpitations , pharyngitis , rash , rhinitis , tachycardia , throat irritation , tracheitis , tremor , urticaria .", "label": "", "metadata": {}, "score": "98.56998"}
{"text": "( Not peer reviewed ) .Authors : No more than 5 Text : Word Limit 400 ( excludes references ) , 5 references , no figures or tables .", "label": "", "metadata": {}, "score": "98.612076"}
{"text": "Amir Hasani Department of Medical Physics , Royal Free Hampstead NHS Trust and Royal Free and University College Medical School , London , UK Chest 125:1726 - 34 .", "label": "", "metadata": {}, "score": "98.6311"}
{"text": "Ultra - LABA ' is a term already in use to describe the class of once - daily LABAs in development [ 6 , 113 ] .", "label": "", "metadata": {}, "score": "98.70232"}
{"text": "Authors ' Affiliations .Division of Pulmonary and Critical Care Medicine , David Geffen School of Medicine , UCLA .Department of Respiratory Diseases , University of Modena & Reggio Emilia .", "label": "", "metadata": {}, "score": "99.40459"}
{"text": "No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services .", "label": "", "metadata": {}, "score": "99.57123"}
{"text": "The IMA claims database contains the detailed registration of all ambulatory and in hospital health care use reimbursed by the Belgian compulsory health insurance .The TCT MCD - HBD database contains the detailed registration of both reimbursements and ICD9-CM codes of all Belgian in hospital health care use .", "label": "", "metadata": {}, "score": "99.75325"}
{"text": "Thorax 2003 , 58 : 589 - 593 .View Article PubMed .Neyt M : Measuring Quality of Life for Certain Events versus Pre - Specified Points in Time .", "label": "", "metadata": {}, "score": "100.11213"}
{"text": "Clinical Slide Sets .Terms of Use .The In the Clinic \u00ae slide sets are owned and copyrighted by the American College of Physicians ( ACP ) .", "label": "", "metadata": {}, "score": "100.69388"}
{"text": "The first five studies ( ILLUMINATE , SHINE , BRIGHT , ENLIGHTEN , SPARK ) have already completed in 2012 with three additional studies ( BLAZE , ARISE , BEACON ) expected to complete by the end of the year .", "label": "", "metadata": {}, "score": "101.34202"}
{"text": "Chronic obstructive pulmonary disease ( COPD ) is a progressive disease characterized by increasing airflow limitation and respiratory symptoms , often associated with chronic comorbidities , leading to a significant burden for the patient .", "label": "", "metadata": {}, "score": "101.44885"}
{"text": "17 - 20 This side effect was considered mild and typically resolved during the course of therapy .Additional side effects included constipation , blurred vision , glaucoma , increased heart rate , and urinary retention .", "label": "", "metadata": {}, "score": "101.85675"}
{"text": "None declared .Clinical Practice Guidelines on the diagnosis and management of COPD .Posted on August 8 , 2011 .Robert P. Young .Schools of Biological Science and Health Sciences , University of Auckland , New Zealand .", "label": "", "metadata": {}, "score": "102.071625"}
{"text": "JOHN L. MANNING , MD , is the program director of the Scott and White Family Medicine Residency Program .He received his medical degree from the University of Texas Medical Branch , Galveston , and completed the Scott and White Family Medicine Residency Program .", "label": "", "metadata": {}, "score": "102.225876"}
{"text": "E D Bateman Division of Pulmonology , Department of Medicine , University of Cape Town , Mowbray , Cape Town , South Africa Respir Med 104:1460 - 72 .", "label": "", "metadata": {}, "score": "102.81352"}
{"text": "PubMed View Article .Copyright .\u00a9 Tashkin and Fabbri .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "102.82425"}
{"text": "Cigarette smoking is the principal cause , accounting for 80 % of COPD deaths 23 .About Novartis Pharmaceuticals Canada Inc.Novartis Pharmaceuticals Canada Inc. , a leader in the healthcare field , is committed to the discovery , development and marketing of innovative products to improve the well - being of all Canadians .", "label": "", "metadata": {}, "score": "102.83827"}
{"text": "Definitive evidence for this approach may not have been present in the literature reviewed but surely the possibility should be recognized in guiding physicians .Norman H Edelman MD Stony Brook University School of medicine Stony Brook , New York , 11794 - 8036 .", "label": "", "metadata": {}, "score": "103.03162"}
{"text": "Competing interests .Authors ' contributions .Both authors contributed to the concept for the manuscript and critically reviewed and revised the initial and subsequent versions of the manuscript .", "label": "", "metadata": {}, "score": "103.357895"}
{"text": "A person viewing it online may make one printout of the material and may use that printout only for his or her personal , non - commercial reference .", "label": "", "metadata": {}, "score": "103.62961"}
{"text": "Ann Intern Med .PubMed .Badgett RG , Tanaka DJ , Hunt DK , Jelley MJ , Feinberg LE , Steiner JF . et al .", "label": "", "metadata": {}, "score": "104.11132"}
{"text": "Ann Intern Med .PubMed .Badgett RG , Tanaka DJ , Hunt DK , Jelley MJ , Feinberg LE , Steiner JF . et al .", "label": "", "metadata": {}, "score": "104.11132"}
{"text": "Evidence also indicates that LAMAs with a 24-hour duration of action have additional benefits in comparison with shorter acting SAMAs [ 106 ] .", "label": "", "metadata": {}, "score": "104.28122"}
{"text": "Unauthorized use of the In the Clinic slide sets will constitute copyright infringement .Article Sections .Chronic obstructive pulmonary disease ( COPD ) is a common problem among patients presenting to primary care .", "label": "", "metadata": {}, "score": "104.42969"}
{"text": "Dr. Denberg : Harvard Vanguard Medical Associates / Atrius Health , 275 Grove Street , Auburndale , MA 02466 .Dr. Schu\u0308nemann : Departments of Clinical Epidemiology and Biostatistics and Medicine , McMaster University , 1200 Main Street West , Room 2C10B , Hamilton , Ontario L8N 3Z5 , Canada .", "label": "", "metadata": {}, "score": "104.878494"}
{"text": "Because pulse oximetry has essentially supplanted arterial blood gases as a measure of oxygenation in nonhospitalized patients , it is reasonable to use oxygen saturation measured by pulse oximetry ( Sp o 2 ) as a surrogate for Pa o 2 .", "label": "", "metadata": {}, "score": "104.88319"}
{"text": "Anyone can submit a comment any time after publication , but only those submitted within 4 weeks of an article 's publication will be considered for print publication .", "label": "", "metadata": {}, "score": "105.01207"}
{"text": "J B Oostenbrink Erasmus Medical Centre , Institute for Medical Technology Assessment , Erasmus University , Rotterdam , The Netherlands Eur Respir J 23:241 - 9 .", "label": "", "metadata": {}, "score": "105.22458"}
{"text": "One pack of cigarettes per day for one year .History of exacerbation in the past year .Gender .Both .Ages .41 Years and older .", "label": "", "metadata": {}, "score": "107.14662"}
{"text": "Letters .CME Activities are only available to ACP members and Individual Annals subscribers .If you are a member or a subscriber please sign in .", "label": "", "metadata": {}, "score": "108.29349"}
{"text": "Eric Bateman Division of Pulmonology , Department of Medicine , University of Cape Town , Cape Town , South Africa Int J Chron Obstruct Pulmon Dis 5:197 - 208 .", "label": "", "metadata": {}, "score": "108.824"}
{"text": "Most end points were defined using medical codes from the Read Clinical Classification Version 2 , May 2006 .Mortality was identified from a combination of READ codes , registration status , additional health data codes and enrolment dates .", "label": "", "metadata": {}, "score": "109.168274"}
{"text": "Competing interests .The study was not externally funded .The authors declare that they have no competing interests .Authors ' contributions .All authors participated in the concept and design of the study .", "label": "", "metadata": {}, "score": "110.031166"}
{"text": "Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .October 2003 .Primary Completion Date .October 2003 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "110.601974"}
{"text": "The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not - for - profit educational activities .", "label": "", "metadata": {}, "score": "110.90892"}
{"text": "Comments .Please read the other comments before posting .Contributors must reveal any conflict of interest .Comments are moderated and will appear on the site at the discretion of The American College of Physicians editorial staff .", "label": "", "metadata": {}, "score": "111.827385"}
{"text": "Copyright .\u00a9 Neyt et al .2010 .This article is published under license to BioMed Central Ltd. Copyright in the material you requested is held by American College Of Physicians ( unless otherwise noted ) .", "label": "", "metadata": {}, "score": "112.39582"}
{"text": "D Singh Medicines Evaluation Unit , University Hospital of South Manchester , University of Manchester , Manchester M33 3TR , UK Thorax 63:592 - 8 .", "label": "", "metadata": {}, "score": "112.535736"}
{"text": "National Heart Lung and Blood Institute .Morbidity and Mortality : 2009 Chart Book on Cardiovascular , Lung , and Blood Diseases .Bethesda , MD : National Heart , Lung , and Blood Institute ; 2009 .", "label": "", "metadata": {}, "score": "114.65628"}
{"text": "National Heart Lung and Blood Institute .Morbidity and Mortality : 2009 Chart Book on Cardiovascular , Lung , and Blood Diseases .Bethesda , MD : National Heart , Lung , and Blood Institute ; 2009 .", "label": "", "metadata": {}, "score": "114.65628"}
{"text": "Dr. Criner : Temple University , 745 Parkinson Pavilion , 3401 North Broad Street , Philadelphia , PA 19140 .Dr. van der Molen : Department of General Practice , University Medical Center Groningen , University of Groningen , PO Box 196 , 9700 AD Groningen , the Netherlands .", "label": "", "metadata": {}, "score": "116.578255"}
{"text": "Sonal Singh Department of Medicine , One Medical Center Blvd , Wake Forest University School of Medicine , Winston Salem , NC 27157 , USA JAMA 300:1439 - 50 .", "label": "", "metadata": {}, "score": "117.345215"}
{"text": "About Sosei .Sosei is an international biopharmaceutical company anchored in Japan with a global reach .It practises a reduced risk business model by acquiring compounds from , and bringing compounds into , Japan through exploitation of its unique position within global markets .", "label": "", "metadata": {}, "score": "117.70157"}
{"text": "Thorax .Decramer M , Rutten - van Molken M , Dekhuijzen PN , Troosters T , van Herwaarden C , Pellegrino R , et al .", "label": "", "metadata": {}, "score": "119.54958"}
{"text": "41 42 This is especially important when increases in risk are small or studies were not large enough to detect such risks as statistically significant .", "label": "", "metadata": {}, "score": "122.921524"}
{"text": "Yaa Hui Dong Graduate Institute of Epidemiology and Preventive Medicine , College of Public Health , National Taiwan University , Taipei , Taiwan Thorax 68:48 - 56 .", "label": "", "metadata": {}, "score": "130.9472"}
{"text": "Yaa Hui Dong Graduate Institute of Epidemiology and Preventive Medicine , College of Public Health , National Taiwan University , Taipei , Taiwan Thorax 68:48 - 56 .", "label": "", "metadata": {}, "score": "130.9472"}
